<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.science.org/doi/10.1126/scitranslmed.abi5735');</script>

        <script> var body_html = '<body > <div > <div > <div > <div > <div > <div > <div > <div > <div > <div > <span >Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header > <div ><div ><div ><div ><div ><div ><div ><a ><div >science</div></a></div></div><div ><div ><a ><div >science advances</div></a></div></div><div ><div ><a ><div >science immunology</div></a></div></div><div ><div ><a ><div >science robotics</div></a></div></div><div ><div ><a ><div >science signaling</div></a></div></div><div ><div ><a ><div >science translational medicine</div></a></div></div><div ><div ><a ><div >science partner journals</div></a></div></div></div></div></div></div></div> <div > <div > <div > <div > <div ><div ><div ><label >Searching:</label><div ><div ><div >AnywhereScienceScience AdvancesScience Immunology<a >Science Robotics</a><a >Science Signaling</a><a >Science Translational Medicine</a></div></div></div></div><div > <a ><u>Advanced Search</u></a> </div></div></div> </div> </div> </div> <div > <div > <div > <h6 >Trending Terms:</h6> <ul > <li > <a >covid-19</a> </li> <li > <a >climate</a> </li> <li > <a >science policy</a> </li> <li > <a >genome editing</a> </li> <li > <a >batteries</a> </li> </ul> </div> </div> </div> </div> </header><div ><div ><div > <div > <div > <ul > <li > <a >Current Issue</a> </li> <li > <a >First release papers</a> </li> <li > <a >Archive</a> </li> <li > <div > <a >About</a> <div > <a >About Science Translational Medicine</a> <a >Mission Scope</a> <a >Editors and Advisory Boards</a> <a >Editorial Policies</a> <a >Information for Authors</a> <a >Information for Reviewers</a> <a >Journal Metrics</a> <a >Staff</a> <a >Contact Us</a> <a >Subscribe</a> <a >Free Sample Articles</a> </div> </div> </li> </ul> </div> <div > <ul > <li > <a >Submit manuscript</a> </li> <li > <div > <a >More</a> </div> </li> </ul> </div> </div> <a >GET OUR E-ALERTS</a> </div></div></div> <main > <div ><div ><div ><div ><div > <div ><a >Home</a><a >Science Translational Medicine</a><a >First Release</a>A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</div><div >Back To First Release</div> </div> <article ><section ><header><div ><div ><div ><div >OPEN ACCESS</div><div >Research Article</div><div >CORONAVIRUS</div></div><div ><div > <div >Share on</div> </div></div></div><h1 >A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</h1><div >M. Gordon Joyce [email protected], Hannah A. D. King, Ines Elakhal-Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, Caroline Subra, … Show All … , Rita E. Chen, Paul V. Thomas, Wei-Hung Chen, Rajeshwer S. Sankhala, Agnes Hajduczki, Elizabeth J. Martinez, Caroline E. Peterson, William C. Chang, Misook Choe, Clayton Smith, Parker J. Lee, Jarrett A. Headley, Mekdi G. Taddese, Hanne A. Elyard, Anthony Cook, Alexander Anderson, Kathryn McGuckin Wuertz, Ming Dong, Isabella Swafford, James Brett Case, Jeffrey R. Currier, Kerri G. Lal, Sebastian Molnar, Manoj S. Nair, Vincent Dussupt, Sharon P. Daye, Xiankun Zeng, Erica K. Barkei, Hilary M. Staples, Kendra Alfson, Ricardo Carrion, Shelly J. Krebs, Dominic Paquin-Proulx, Nicos Karasavva, Victoria R. Polonis, Linda L. Jagodzinski, Mihret F. Amare, Sandhya Vasan, Paul T. Scott, Yaoxing Huang, David D. Ho, Natalia de Val, Michael S. Diamond, Mark G. Lewis, Mangala Rao, Gary R. Matyas, Gregory D. Gromowski, Sheila A. Peel, Nelson L. Michael, Diane L. Bolton, and Kayvon Modjarrad [email protected] Show Fewer</div><div >Science Translational Medicine • 16 Dec 2021 • First Release • DOI: 10.1126/scitranslmed.abi5735</div><div ><div > <div > <a ><div ><div ><h6>PREVIOUS ARTICLE</h6><div>Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity</div></div></div>Previous</a><a ><div ><div ><h6>NEXT ARTICLE</h6><div>Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals</div></div></div>Next</a> </div> </div></div></div></header><div ><div ><section ><h2 >Abstract</h2><div >The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019 (COVID-19). We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50 μg) SpFN vaccine, given twice 28 days apart, induced a Th1-biased CD4 T cell helper response and elicited neutralizing antibodies against SARS-CoV-2 wild-type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates following high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates supports the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.</div></section></div></div></section><section ><div ><section ><h2>INTRODUCTION</h2><div >The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reached a milestone with the emergency use authorization, approval, and increasing availability of efficacious vaccines (<a ><i>1</i></a>). Successes in rapid coronavirus vaccine development, however, have been tempered by the rise of viral variants of concern (VOCs) (<a ><i>2</i></a>). The accelerating frequency with which variants are emerging raises the specter that host selective pressures may drive the evolution of mutants to escape vaccine-elicited immunity (<a ><i>3</i></a>). This concern, coupled with stringent cold-chain requirements for product stability and high unit costs for some vaccine platforms (<a ><i>4</i></a>), justifies the continued development of cost-effective, thermo-stable vaccines that match currently authorized and approved vaccines in safety and efficacy, and are also effective against a wide range of circulating variants and evolving strains, as well as species that may arise from zoonotic reservoirs in the future.</div><div >Self-assembling protein nanoparticle vaccines offer the advantage of multivalent antigen presentation, a property previously shown to augment immunogenicity over monovalent immunogens (<a ><i>5</i></a>–<a ><i>7</i></a>). Ferritin is a naturally occurring, ubiquitous, iron-carrying protein that self-oligomerizes into a 24-unit spherical particle (<a ><i>8</i></a>). The three-fold axis symmetry of the resulting polymer makes it conducive to conjugation and antigen display of trimeric glycoproteins, such as SARS-CoV-2 spike protein. Ferritin has been evaluated as a vaccine platform for several pathogens (<a ><i>9</i></a>–<a ><i>11</i></a>), most notably influenza, for which it has demonstrated immune potency and breadth (<a ><i>12</i></a>, <a ><i>13</i></a>). As such, ferritin vaccines have advanced to phase 1 clinical trials as a strategy to target multiple influenza strains (<a ><i>14</i></a>, <a ><i>15</i></a>).</div><div >The prefusion-stabilized form of the spike protein is the basis for most major SARS-CoV-2 vaccine candidates (<a ><i>16</i></a>, <a ><i>17</i></a>). Although a correlate of protection from COVID-19 has not been conclusively defined, there is mounting evidence that neutralizing, and some fraction of non-neutralizing, antibodies against spike protein are necessary, if not sufficient, to confer protective immunity (<a ><i>18</i></a>, <a ><i>19</i></a>). The most potent neutralizing antibodies are directed against the spike protein receptor-binding domain (RBD), which mediates attachment to the primary host cell receptor, angiotensin converting enzyme (ACE2). Our prior assessment of a SARS-CoV-2 spike protein ferritin nanoparticle (SpFN) vaccine candidate, co-formulated with a liposomal adjuvant, has demonstrated potent immunogenicity and protection against SARS-CoV-2 infection in mouse models (<a ><i>20</i></a>). These data have provided a basis for evaluating SpFN immunogenicity and efficacy against viral replication and pathology in the airways and lungs of nonhuman primates (NHP), a standard model for preclinical evaluation of SARS-CoV-2 vaccines (<a ><i>21</i></a>).</div></section><section ><h2>RESULTS</h2><section ><h3>A SARS-CoV-2 nanoparticle vaccine was designed and administered to NHPs.</h3><div >The spike ferritin nanoparticle (SpFN) vaccine was designed as a ferritin-fusion recombinant protein for expression as a nanoparticle, and has been described in detail previously (<a ><i>20</i></a>). Briefly, the spike protein sequence was derived from the Wuhan-Hu-1 genome sequence (GenBank accession number: MN908947.3). The spike protein ectodomain was modified to introduce two proline residues (K986P, V987P) and removal of the furin cleavage site (RRAS to GSAS), as previously described (<a ><i>16</i></a>). To stabilize spike protein trimer formation on the ferritin molecule, the heptad repeat between stem hinge 1 and 2 region (residues 1140 – 1161) was mutated to increase the coiled coil interactions. An adjuvant, Army Liposome Formulation containing QS21 (ALFQ), was mixed with the SpFN vaccine at room temperature and administered to animals within four hours of mixing. Briefly, ALFQ is a liposome formulation comprising saturated phospholipids, dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG); cholesterol, and two adjuvants, synthetic monophosphoryl lipid A (3D- PHAD) (200 μg/dose) and QS-21 (100 μg/dose) in a molar ratio of 9:1:12.2:0.114:0.044 (<a ><i>22</i></a>). QS-21 is a triterpenoid glycoside saponin derived from the bark of the <i>Quillaja saponaria</i> (soap bark) tree, found in Chile. QS-21 binds irreversibly to cholesterol in the liposomes and abrogates the toxicity seen with free QS-21 (<a ><i>23</i></a>).</div><div >In this study, 32 male and female specific-pathogen-free, research-naïve, Chinese-origin rhesus macaques (age 3 to 7 years) were distributed on the basis of age, weight and sex into 4 cohorts of 8 animals (table S1). Animals were vaccinated intramuscularly with either 50 or 5 μg of SpFN formulated with ALFQ or 1 ml of phosphate buffered saline (PBS) in the anterior proximal quadriceps muscle. Animals were vaccinated on alternating sides with each dose in the series. Immunizations were administered twice, 4 weeks apart, or once, 4 weeks prior to challenge (fig. S1). Animals were challenged with 1x10<sup>6</sup> 50% tissue culture infective dose (TCID<sub>50</sub>) of SARS-CoV-2 (SARS-Related Coronavirus 2, Isolate USA-WA1/2020) administered simultaneously by the intratracheal (1.0 ml) and intranasal (0.5 ml per nostril) routes.</div></section><section ><h3>SpFN vaccination elicits neutralizing antibody responses in NHPs.</h3><div >We measured longitudinal antibody responses in animals, after each vaccination and after viral challenge. Total binding to SARS-CoV-2 prefusion stabilized spike protein (S-2P) (<a ><i>16</i></a>) increased from baseline to an area under the curve (AUC) of 679,213 and 1,646,288 at 4 weeks after two vaccinations with 5 and 50 μg of SpFN, respectively (Fig. 1A). Vaccination with a single 50 μg dose resulted in a 4-week AUC of 621,605. Binding responses were unchanged in vaccinated groups after viral challenge; in contrast, unvaccinated controls had a 200-fold rise (Fig. 1A). Neutralization was tested using spike protein pseudotyped human immunodeficiency virus (HIV). Two-doses of 5 μg or 50 μg SpFN elicited reciprocal 50% inhibitory dilution (ID<sub>50</sub>) pseudovirus neutralizing antibody geometric mean titers (GMT) of 22,405 and 52,773, respectively, two weeks after second vaccination, and plateaued at 12,171 and 22,527, two weeks later (<a >Fig. 1B</a>). Administration of a single dose of 50 μg SpFN elicited a peak GMT of 4,063. Authentic virus neutralization activity mirrored group differences seen in the pseudovirus assay, but at slightly lower values (<a >Fig. 1C</a>).</div><div >We performed functional assessments of binding antibody responses by measuring the ability of serum samples to inhibit binding of RBD to the ACE2 receptor. Binding inhibition in the 5 μg and 50 μg vaccinated animals exceeded that among unvaccinated controls by a factor of 224 and 998, respectively (<a >Fig. 1D</a>). ACE2 competition in the single 50 μg dose group was 291 times higher than controls. We compared neutralizing antibody responses elicited by the vaccine against a panel of convalescent plasma samples with the same pseudovirus neutralization assay. We found that two doses of either SpFN dose elicited neutralizing activity that was an order of magnitude higher than that of the convalescent serum samples (p&lt;0.01, <a >Fig. 1E</a>).</div><div >We used orthogonal approaches to assess binding antibody specificities to the spike S1 subunit domains. RBD and S-2P binding recapitulated results of the ACE2 binding inhibition assay (fig. S2). Serum binding to the N-terminal domain (NTD), which may be a marker of additional protection through both neutralizing activity and non-neutralizing effector functions (<a ><i>24</i></a>), were 500-fold higher compared to baseline, across vaccine groups (fig. S3). We assessed the strength of RBD binding by biolayer interferometry, finding an increasing antibody on-rate association response throughout follow-up (fig. S4). Given the potential importance of auxiliary antibody functions for protection (<a ><i>25</i></a>, <a ><i>26</i></a>), we assessed a suite of Fc-mediated antibody effector functions, including opsonization, antibody-dependent complement deposition (ADCD), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP) and trogocytosis (a measure of antigen transfer) (<a ><i>27</i></a>). All activity peaked at week 6 and was highest in the two-dose 50 μg SpFN group (fig. S5).</div></section><section ><h3>SpFN vaccination elicits spike protein-specific T cell responses in NHPs.</h3><div >Helper CD4 T cell (Th) responses are important for respiratory virus vaccine development, given the theoretical concern and precedent for vaccine-associated enhanced respiratory disease and its association with a Th2-biased response (<a ><i>28</i></a>). We focused our assessment of cell-mediated immunity on canonical cytokines expressed by Th1 (interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-2) and Th2 (IL-4, IL-13) CD4 T cells. Robust Th1 responses were observed 4 weeks after second vaccination in all vaccinated groups, except one animal in the 50 μg single-dose group (<a >Fig. 2A</a>). Th1 responses were polyfunctional and variable but consistently high at week 8, ranging from 0.2% to 17%. Th2 and CD8 T cell responses were minimal or undetectable (<a >Fig. 2B</a>, fig. S6).</div><div >We interrogated key indicators of helper responses that support humoral immunity, such as IL-21, a cytokine secreted by follicular helper CD4 T cells (Tfh) that regulate the evolution of memory B cells (<a ><i>29</i></a>). Five of eight animals dosed twice with 50 μg of SpFN had detectable IL-21 responses, as did seven of eight animals given 5 μg of the vaccine (<a >Fig. 2C</a>). We also examined expression of CD40 ligand (CD40L), a broad T cell activation marker, expressed on the surfaces of CD4 T cells that promotes B cell maturation through antibody isotype switching (<a ><i>29</i></a>). All but one animal receiving two-doses of SpFN had detectable CD40L responses (<a >Fig. 2D</a>), indicating an engaged memory response.</div></section><section ><h3>SpFN vaccination reduces viral load after respiratory SARS-CoV-2 challenge.</h3><div >Rhesus macaques generally exhibit mild disease that does not fully recapitulate the severe pneumonia observed in many people with COVID-19 (<a ><i>21</i></a>). Protective efficacy, therefore, was assessed virologically and pathologically. The primary virologic endpoint was based on the measurement of subgenomic mRNA (sgmRNA) for the envelope (E) gene region of the virus, an indicator of viral replication, in the upper (nasopharyngeal (NP) swabs, saliva) and lower airways (bronchoalveolar lavage (BAL) fluid). sgmRNA concentrations (log<sub>10</sub> copies/ml) of vaccinated animals were compared to controls. On the second day after simultaneous respiratory mucosal challenge by the intratracheal and intranasal routes, sgmRNA concentrations in the BAL fluid of control animals peaked at a mean of 10<sup>6</sup> copies/ml (<a >Fig. 3A</a>). In contrast, none of the eight animals that received two doses of 50 μg SpFN had detectable sgmRNA at day 2. By day 4 sgmRNA was undetectable in the BAL fluid of all animals of the 5 μg vaccine group and all but one animal that received single dose SpFN.</div><div >Whereas sgmRNA concentrations reached a mean of 10<sup>7</sup> copies/ml in the NP swabs of control animals at day two after challenge, sgmRNA was undetectable in five of eight animals that received two doses of 50 μg SpFN (<a >Fig. 3B</a>). All animals in this group had undetectable virus from day four onward, whereas virus persisted in the control animals through day 10. Five of eight controls had high concentrations of sgmRNA in saliva on day two post-challenge, whereas virus was undetectable in all animals of the two-dose 50 μg SpFN group (<a >Fig. 3C</a>). Total viral load in the BAL fluid, NP swabs and saliva were similar to those observed for sgmRNA (fig. S7).</div></section><section ><h3>SpFN vaccination provides protection from lung pathology after SARS-CoV-2 challenge.</h3><div >One section of lung tissue from each lung lobe (six sections per animal) was fixed and stained at one-to-two weeks after virus challenge and evaluated under light microscopy and by immunohistochemistry. Unvaccinated control animals developed histopathologic evidence of multifocal, moderate interstitial pneumonia at 7 days after challenge (<a >Fig. 4A</a>). The pneumonia was characterized by type II pneumocyte hyperplasia, alveolar septal thickening, edema and necrotic debris, pulmonary macrophage infiltration and vasculitis of smaller caliber blood vessels. None of the vaccinated animals, however, had evidence of interstitial pneumonia (<a >Fig. 4B to D</a>). Immunohistochemistry revealed viral antigen in alveolar pneumocytes and pulmonary macrophages in at least one lung section of every control animal (<a >Fig. 4E</a>). In contrast, no viral antigen was detected in any of the lung sections taken from vaccinated animals (<a >Fig. 4F to H</a>).</div></section><section ><h3>SpFN elicits broadly neutralizing antibodies that bind to variants of concern.</h3><div >We assessed the serum antibody responses elicited by the SpFN vaccine against four circulating SARS-CoV-2 VOCs: B.1.1.7 (alpha variant), B.1.351 (beta variant), P.1 (gamma variant) and B.1.617.2 (delta variant). Serum binding assessment by biolayer interferometry to the first three variant forms of SARS-CoV-2 RBD showed no change in binding to B.1.1.7 (N501Y mutation) or B.1.351 (K417N, E484K, N501Y mutations) in the two-dose 50 μg SpFN group (fig. S8). Serum binding assessment by biolayer interferometry to these same variant forms of SARS-CoV-2 RBD showed no change in binding to B.1.1.7 (N501Y mutation), but a 25% reduction in binding to B.1.351 (K417N, E484K, N501Y mutations) in the two-dose 50 μg SpFN group (fig. S8). We next assessed the serum neutralizing activity elicited by the SpFN vaccine against all four VOCs, including B.1.617.2 (δ variant). Serum samples from all vaccinated NHPs elicited potent neutralizing activity against all variants in two orthogonal virus neutralization assays. Neutralization capacity of the authentic B.1.1.7 virus variant was high across all vaccine groups (<a >Fig. 5A to C</a>) and was significantly (p=0.02) higher than neutralization of wild-type WA-1 in the two-dose 50 μg group (<a >Fig. 5A</a>). Neutralizing activity against the authentic B.1.351, P.1 and B.1.617.2 virus variants, however, was diminished slightly (<a >Fig. 5A to C</a>), except in the two-dose 50 μg group (<a >Fig. 5A</a>). Neutralizing activity against the B.1.1.7 in an orthogonal pseudovirus assay revealed equivalent ID<sub>50</sub> GMTs to the WA-1 wild-type pseudovirus (<a >Fig. 5D to F</a>). Reductions in neutralizing activity against the B.1.351 pseudovirus, however, were slightly more pronounced in the pseudovirus assay as compared to the authentic virus assay. For example, the reciprocal ID<sub>50</sub> GMT dropped five-fold in the two-dose 50 μg group, but remained high at a value 10,209 (<a >Fig. 5D</a>). The absolute neutralizing antibody titers were generally elevated after two doses of vaccine, irrespective of the virus variant against which they were measured (<a >Fig. 5G</a>).</div><div >We expanded the assessment of the immunogenicity breadth to the interrogation of neutralizing and non-neutralizing antibody and cellular immune responses against SARS-CoV-1. Binding of vaccinee serum samples to SARS-CoV-1 RBD, as measured by biolayer interferometry, was absent in controls but was relatively potent in vaccinated animals, binding at half the strength of that observed to SARS-CoV-2 RBD (<a >Fig. 6A</a>, fig. S3, S4). Antibody-dependent cellular phagocytotic activity also increased in all vaccine groups, reaching a score that was 100-fold higher than baseline or compared to unvaccinated controls when measured two-weeks after last 50 μg SpFN vaccination (<a >Fig. 6B</a>). Two vaccinations with high-dose SpFN also yielded plaque reduction neutralizing activity against authentic SARS-CoV-1 with a reciprocal ID<sub>50</sub> GMT of 390 that was significantly increased above background (p=0.01, <a >Fig. 6C</a>). An orthogonal pseudovirus neutralization assay exhibited some background activity in PBS controls. We minimized this background by analyzing neutralization activity at a 90% inhibitory dilution (ID<sub>90</sub>) and found that two doses of 50 μg SpFN induced a SARS-CoV-1 neutralizing antibody titer that was 6-fold higher (GMT 667) than controls (<a >Fig. 6D</a>). CD4 T cell responses to SARS-CoV-1 spike protein peptides, though lower in absolute percentage than against SARS-CoV-2, were still robust and Th1-biased (<a >Fig. 6E and F</a>). The CD8 T cell response, in contrast, was minimal (fig. S9). Overall, the immune response elicited by SpFN against SARS-CoV-1, though lower in magnitude, recapitulated the quality of response against SARS-CoV-2.</div></section></section><section ><h2>DISCUSSION</h2><div >The recent success in the rapid development of safe and efficacious SARS-CoV-2 vaccines has been tempered by the emergence of virus variants to which vaccine-induced immunity has shown diminished potency or efficacy (<a ><i>30</i></a>–<a ><i>33</i></a>). Thus, there remains a need for next-generation vaccines that target the broadening antigenic diversity of SARS-CoV-2 and related coronaviruses. The major vaccines that have progressed to human efficacy trials and have been granted either approval or emergency use authorization all present the SARS-CoV-2 spike protein that is based on the genetic sequence of the Wuhan-Hu-1 isolate. All of these vaccines have demonstrated protective efficacy in NHPs against respiratory mucosal challenge with the closely matched USA-WA1/2020 (<a ><i>25</i></a>, <a ><i>34</i></a>–<a ><i>38</i></a>). These earlier animal studies, however, did not evaluate the neutralization capacity of serum against other coronavirus species. In the current study we demonstrate that an adjuvanted recombinant nanoparticle vaccine, SpFN, elicited high titers of that antibodies neutralized SARS-CoV-2 and rapidly protected against SARS-CoV-2 infection. We also found that, compared to wild type virus, SpFN elicited serum virus neutralizing activity that was either higher or equivalent against four major VOCs (B.1.1.7, B.1.351, P.1, B.1.617.2) in an authentic virus neutralization assay and equivalent or mildly diminished against two VOCs in a pseudovirus neutralization assay (B.1.1.7, B.1.351). Finally, SpFN induced robust neutralizing activity against SARS-CoV-1, a separate species that has 26% and 36% sequence divergence in the spike protein and S1 subunit, respectively (<a ><i>39</i></a>), which is important for protection in animal models (<a ><i>40</i></a>, <a ><i>41</i></a>).</div><div >SARS-CoV-2 vaccine efficacy studies in NHPs generally compare elicited antibody responses to those from patients who have recovered from COVID-19. We found neutralizing activity in the two-dose 50 μg SpFN group to be ten-fold higher than that in recovering patients. The lack of standardization across convalescent serum panels and absence of head-to-head comparisons of candidate vaccines makes it difficult to compare immunogenicity profiles. Direct comparisons come with a qualification that immunogenicity output assays have been in the process of harmonization. Bearing this caveat in mind, we found that SARS-CoV-2 antibody responses in animals vaccinated with high-dose SpFN were robust when set in the context of the entire vaccine landscape, to include genetic vaccines (<a ><i>34</i></a>, <a ><i>38</i></a>), recombinant virus vector vaccines (<a ><i>25</i></a>, <a ><i>37</i></a>), and adjuvanted protein subunit vaccines (<a ><i>35</i></a>). Although direct quantitative comparisons of NHP vaccine studies can be difficult to interpret, we have made attempts to mitigate differences in assay outputs by analyzing specimens with orthogonal assays harmonized to consensus platforms. Specifically, the pseudovirus neutralization assay we developed for our immunogenicity assessments demonstrated equivalence to platforms used for the assessment of other major vaccines through participation in the SARS-CoV-2 Neutralizing Assay Concordance Survey 1 coordinated by the External Quality Assurance Program Oversight Laboratory/Virology Quality Assurance Program at the Duke Human Vaccine Institute (<a ><i>42</i></a>).</div><div >Potent neutralizing antibody responses may offer advantages for both vaccine efficacy and durability. Thus far, neutralizing activity has been predictive of efficacy in human trials, as vaccines that generate lower antibody titers have diminished efficacy (<a ><i>43</i></a>). An open question remains, however, regarding the length of immunity conferred by SARS-CoV-2 vaccines. Among viral infections for which neutralizing antibodies are the primary correlate of protection, peak titers have been shown to be predictive of durability and may serve as one of several indicators of length of vaccine-elicited protective immunity (<a ><i>44</i></a>–<a ><i>46</i></a>). As such, SpFN may offer some measure of a durable immune response; though this will require empirical confirmation.</div><div >Overall, SpFN vaccination induced serum cross-neutralizing antibody responses. Additionally, we found serum binding to mutated SARS-CoV-2 RBD was either unaffected or mildly reduced. We also found serum binding to mutated SARS-CoV-2 RBD was either unaffected or mildly diminished. Other reports of nanoparticle vaccine approaches presenting RBD also have shown a breadth of neutralizing antibody responses against multiple sarbecoviruses (<a ><i>47</i></a>–<a ><i>49</i></a>). Similar to other studies, SpFN vaccination induces comprehensive binding and neutralizing antibody responses and a balanced cellular immune response against SARS-CoV-1. Although background neutralizing activity was high in one assay, neutralizing potency against SARS-CoV-1 was confirmed in an orthogonal virus neutralization assay. Still, we plan to test purified IgG from vaccine serum in both assays to control for the background activity at baseline and in controls.</div><div >We hypothesize that the breadth of immune response elicited by the SpFN vaccine may be the result of several factors. First, the quantity of the polyclonal antibody response may surpass a threshold that overcomes resistance to neutralization of antigenically distinct virus variants. Second, repetitive, ordered display of antigen on a self-assembling nanoparticle has been shown to drive an expanded germinal center reaction with resultant increases in B cell receptor mutation, affinity maturation and plasma cell differentiation (<a ><i>5</i></a>–<a ><i>7</i></a>). Lastly, the adjuvant, ALFQ, may drive some of the breadth through CD4 T cell activation (<a ><i>50</i></a>, <a ><i>51</i></a>), especially given the high Th1 response elicited by the co-formulation. ALFQ, as compared to aluminum hydroxide (Alhydrogel), previously has demonstrated superior immunogenicity when administered with SpFN to C57BL/6 and BALB/c mice (<a ><i>20</i></a>). As NHPs are a more predictive model with respect to adjuvant performance in humans, we are now conducting a follow-on adjuvant comparison study in NHPs to evaluate the impact of ALFQ on immunogenicity potency and breadth. Additionally, as NHPs do not exhibit the same degree of fidelity as Syrian golden hamsters in terms of developing severe COVID-19 disease (<a ><i>21</i></a>), we have also found SpFN to protect against VOCs in challenge experiments in the latter model (<a ><i>52</i></a>).</div><div >The interpretation of the results from this study is limited by several factors. First, we were able evaluate efficacy our vaccine candidate only against challenge with the Wuhan-Hu-1 strain of SARS-CoV-2. This is because VOCs were only beginning to emerge and circulate when this study was conceived and initiated. Our assessment of breadth of the immune response was, instead, evaluated by serum neutralizing activity against a panel of SARS-CoV-2 VOCs as well as SARS-CoV-1. Second, we cannot define, from the design and outputs of this study, the relative contributions of the immunogen and adjuvant of our vaccine formulation to the potency and breadth of immune response observed. Finally, we have yet to understand the role and repertoire of the humoral and cellular immune responses elicited by this SpFN. We are carrying out follow on studies examine the mechanisms of immunity conferred by our vaccine candidate.</div><div >The collective immune response elicited by SpFN translated into a robust and rapid reduction in replicating virus in the upper and lower airways of animals and resultant prevention of pulmonary pathology. It is notable that SpFN protected against a potent viral challenge, as replicating virus concentrations detected in the upper and lower airways of unvaccinated controls reached a mean of 10<sup>6</sup> to 10<sup>7</sup> copies/ml. Despite this higher challenge, SpFN still protected lower airway viral burden and disease as early as within one day of virus inoculation. The rapid elimination of replicating virus in the upper airways also lends evidence for potential near-sterilizing immunity, which again may have implications for preventing viral transmission. Altogether, these findings support the further development of SpFN, which has now moved to human evaluation in a phase 1 clinical trial (<a ><i>53</i></a>).</div></section><section ><h2>MATERIALS AND METHODS</h2><div ><b>Study design.</b> Thirty-two male and female specific-pathogen-free, research-naïve Chinese-origin rhesus macaques (age 3 to 7 years) were distributed—on the basis of age, weight, and sex—into 4 cohorts of 8 animals (table S1). Sample sizes were set based animal availability and prior experience with other nonhuman primate vaccination/challenge studies. Animals were assigned to groups without a specific randomization scheme; however, no outliers were skewed to any one group (table S1). Animals were vaccinated intramuscularly with either 50 or 5 μg of SpFN, formulated with ALFQ, or 1 ml of PBS in the anterior proximal quadriceps muscle, on alternating sides with each dose in the series. Immunizations were administered twice, 4 weeks apart, or once, 4 weeks prior to challenge. Animals were challenged with virus stock obtained through Biodefense and Emerging Infections Research Resources Repository Resources (BEI Resources), National Institute of Allergy and Infectious Diseases, National Institutes of Health: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-53780 (Lot# 70038893). Virus was stored at -80°C prior to use, thawed by hand and placed immediately on wet ice. Stock was diluted to 5x10<sup>5</sup> TCID<sub>50</sub> per ml in PBS and vortexed gently for 5 s prior to inoculation by combined intratracheal (1 mL) and intranasal routes (0.5 mL per nostril).</div><div >All procedures were carried out in accordance with institutional, local, state and national guidelines and laws governing animal research included in the Animal Welfare Act. Animal protocols and procedures were reviewed and approved by the Animal Care and Use Committee of both the US Army Medical Research and Development Command (USAMRDC, protocol 11355007.03) Animal Care and Use Review Office as well as the Institutional Animal Care and Use Committee of Bioqual, Inc. (protocol number 20-092), where nonhuman primates were housed for the duration of the study. USAMRDC and Bioqual, Inc. are both accredited by the Association for Assessment and Accreditation of Laboratory Animal Care and are in compliance with the Animal Welfare Act and Public Health Service Policy on Humane Care and Use of Laboratory Animals.</div><div ><b>Vaccine and adjuvant design and production.</b> The spike ferritin nanoparticle (SpFN) vaccine immunogen was produced by linking <i>Helicobacter pylori</i> ferritin to the C-terminal region of the pre-fusion stabilized ectodomain (residues 12-1158) of the SARS-CoV-2 spike protein in a genetic fusion. The immunogen was expressed, purified, and characterized as previously described (<a ><i>20</i></a>). Briefly, SpFN was derived from the Wuhan-Hu-1 strain genome sequence (GenBank MN9089473), synthesized by Genscript Inc, and subcloned into a modified cytomegalovirus promoter (CMVR) expression vector. Expi293F cells (Thermo Fisher Scientific) were transiently transfected with SpFN plasmid DNA using ExpiFectamine 293 transfection reagent (Thermo Fisher Scientific). Cells were grown in polycarbonate baffled shaker flasks at 34°C and 8% CO<sub>2</sub> at 120 revolutions per minute (rpm). Cells were harvested 5 days post-transfection by centrifugation at 3,500 × g for 30 min. Culture supernatants were filtered with a 0.22-μm filter and stored at 4°C prior to purification using GNA lectin affinity chromatography. Briefly, 25 mL GNA-lectin resin (VectorLabs) was used to purify SpFN from 1L of expression supernatant. GNA resin was equilibrated with 10 column volumes (CV) of PBS (pH 7.4) followed by supernatant loading twice at 4°C. Unbound protein was removed by washing with 20 CV of PBS buffer. Bound protein was eluted with 250mM methyl-α-D mannopyranoside in PBS buffer (pH 7.4). SpFN was further purified by size-exclusion chromatography using a 16/60 Superdex-200 purification column. Purification purity for all the proteins was assessed by SDS-PAGE. Endotoxin concentrations for SpFN was assessed (Endosafe nexgen-PTS, Charles River Laboratories) and 5% v/v glycerol was added prior to filter-sterilization with a 0.22-μm filter, flash-freezing in liquid nitrogen and storage at -80°C. SpFN antigenicity was assessed by Octet Biolayer Interferometry with a set of antibodies that included CR3022 (<a ><i>20</i></a>) and SR1-SR5 (potent neutralizing antibodies targeting the ACE2 binding site of the RBD; kindly provided by S. Rajan, P.M. McTamney, and M.T. Esser of Astra Zeneca). Size and consistency of the SpFN immunogen was determined by negative-stain electron microscopy. These measurements ensured lot-to-lot consistency of the SpFN immunogen.</div><div >The adjuvant, Army Liposomal Formulation with QS21 (ALFQ), was prepared as previously described (<a ><i>54</i></a>). Briefly, ALFQ is a unilamellar liposome that contains saturated phospholipids, cholesterol, monophosphoryl lipid A and the saponin, QS-21. It is comprised of dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), cholesterol (Chol), and synthetic monophosphoryl lipid A (3D-PHAD) (Avanti Polar Lipids) and QS-21 (Desert King). DMPC and Chol were dissolved in chloroform and DMPG and 3D-PHAD were dissolved in chloroform:methanol at a ratio of 9:1. The lipids were mixed in a molar ratio of 9:1:12.2:0.114 (DMPC:DMPG:Chol:3D-PHAD) and the solvent was removed by rotary evaporation. 3D-PHAD and QS-21 doses were 200 and 100 μg, respectively. The lipids were suspended in Sorenson's PBS, pH 6.2, microfluidized to form small unilamellar vesicles (SUV) and filtered. QS-21 was solubilized in Sorenson's PBS, pH 6.2, filtered and added to the SUV to form ALFQ. The final lipid ratio was 9:1:12.2:0.114:0.044 (DMPC:DMPG:Chol:3D-PHAD:QS-21).</div><div >Immunogen was diluted in Dulbecco’s PBS (Lot#723188, Quality Biological) to 0.1 mg/ml or 0.01 mg/ml and mixed 1:1 with 2X ALFQ liposomes on a tilted slow-speed roller at room temperature for 10 min, followed by incubation at 4°C for 50 min. All reagents were equilibrated to room temperature before use and immunizations were performed within 4 hours of vaccine formulation. Each vaccine comprised a 1.0 ml solution of SpFN formulated with ALFQ.</div><div ><b>Convalescent Plasma Samples.</b> A panel of 41 human convalescent-phase plasma samples were obtained from BEI Resources Repository (n=30), StemExpress (n=7) and a Walter Reed Army Institute of Research institutional review board-approved leukapheresis protocol (#1386H) (n=4) for which written informed consent was provided by participants. Samples were collected from males (n=20) and females (n=21) ranging in age from 31 to 71 years. Individuals donated plasma specimens approximately four-to-eight weeks after laboratory-confirmed SARS-CoV-2 infection and had histories of asymptomatic-to-mild-to-moderate clinical presentation.</div><div ><b>Binding antibody measurements.</b> SARS-CoV-2-specific binding IgG antibody responses were measured using MULTI-SPOT 96-well plates from Meso Scale Discovery (MSD). Multiplex wells were coated with spike (S), RBD and nucleocapsid (N) antigens at a concentration of 200-400 ng/ml and bovine serum antigen, which served as a negative control. Four-plex MULTISPOT plates were blocked with MSD Blocker A buffer for 1 hour at room temperature, shaking at 700 rpm. Plates were washed with buffer before the addition of reference standard and calibrator controls. Serum samples were diluted at 1:1,000 to 1:100,000 in diluent 100 buffer (provided with manufacturer kit), then added to each of four wells. Plates were incubated with shaking at 700 rpm for two hours at room temperature and then washed. MSD SULFO-TAG anti-IgG antibody was added to each well. Plates were incubated for 1 hour at room temperature with shaking at 700 rpm and washed, then MSD GOLD Read buffer B was added to each well. Plates were read by the MESO SECTOR SQ 120 Reader. IgG concentration was calculated using DISCOVERY WORKBENCH MSD Software and reported as arbitrary units (AU)/ml.</div><div >The ability of SARS-CoV-2 spike-specific binding antibodies to inhibit spike protein or RBD binding to the ACE2 receptor was also measured using MULTI-SPOT 96-well plates (MSD). Antigen-coated plates were blocked and washed as described above. Assay calibrator and samples were diluted at 1:25 to 1:1,000 in MSD Diluent buffer, then added to the wells. Plates were incubated for 1 hour at room temperature, shaking at 700 rpm. ACE2 protein conjugated with MSD SULFO-TAG was added and plates were incubated for 1 hour at room temperature, shaking at 700rpm. Plates were washed and read as described above. AU/ml concentration of inhibitory antibodies was calculated with DISCOVERY WORKBENCH MSD Software.</div><div >Binding antibody measurements by octet biolayer interferometry were made on biosensors of the Octet FortéBio Red96 instrument (Sartorius) that were hydrated in PBS prior to use. All assay steps were performed at 30°C with agitation set at 1,000 rpm. Baseline equilibration of the anti-His-tag biosensors (HIS1K biosensors with a conjugated Penta-His antibody (Sartorius) was carried out with PBS for 15 s, prior to SARS-CoV2-RBD (30 μg/ml diluted in PBS) loading for 120 s. After dipping in assay buffer (15 s in PBS), biosensors were dipped in the serum samples (100-fold dilution) for 180 s. Binding response (nm) at 180 s was recorded for each sample.</div><div ><b>SARS-CoV-1 and SARS-CoV-2 Pseudovirus Neutralization</b>. The spike protein expression plasmid sequence for SARS-CoV-2 was codon optimized and modified to remove an 18 amino acid endoplasmic reticulum retention signal in the cytoplasmic tail to improve spike protein incorporation into pseudovirions (PSV) and thereby enhance infectivity. SARS-CoV-2 PSV were produced by co-transfection of HEK293T/17 cells with a SARS-CoV-2 spike protein-expressing plasmid (pcDNA3.4), derived from the Wuhan-Hu-1 genome sequence (GenBank accession number: MN908947.3) and an HIV-1 (pNL4-3.Luc.R-E-, NIH HIV Reagent Program, Catalog number 3418). Infectivity and neutralization titers were determined using ACE2-expressing HEK293 target cells (Integral Molecular) in a semi-automated assay format using robotic liquid handling (Biomek NXp Beckman Coulter). Virions pseudotyped with the vesicular stomatitis virus (VSV) G protein were used as a non-specific control. Serum samples were diluted 1:40 in growth medium (10% fetal bovine serum, 2.5% HEPES, 0.5% Gentamicin, 0.1% Puromycin in Dulbecco’s Modified Eagle Medium); then 25 μl/well was added, in triplicate, to a white 96-well plate. An equal volume of diluted SARS-CoV-2 PSV was added to each well and plates were incubated for 1 hour at 37°C. Target cells were added to each well (40,000 cells/ well) and plates were incubated for an additional 48 hours. Relative light units (RLU) were measured with the EnVision Multimode Plate Reader (Perkin Elmer) using the Bright-Glo Luciferase Assay System (Promega). Neutralization dose–response curves were fitted by nonlinear regression using the LabKey Server, as previously described (<a ><i>55</i></a>). Final titers are reported as the reciprocal of the dilution of serum necessary to achieve 50% (ID<sub>50</sub>) and 90% neutralization (ID<sub>90</sub>). Assay equivalency was established by participation in the SARS-CoV-2 Neutralizing Assay Concordance Survey (SNACS) run by the Virology Quality Assurance Program and External Quality Assurance Program Oversite Laboratory (EQAPOL) at the Duke Human Vaccine Institute, sponsored through programs supported by the National Institute of Allergy and Infectious Diseases, Division of AIDS.</div><div ><b>Authentic SARS-CoV-2 wild-type neutralization assay.</b> Authentic virus neutralization was measured using SARS-CoV-2 (2019-nCoV/USA_WA1/2020) that was obtained from the Centers for Disease Control and Prevention and passaged once in Vero CCL81 cells (American Type Culture Collection (ATCC)). Rhesus serum samples were serially diluted and incubated with 100 focus-forming units (FFU) of SARS-CoV-2 for 1 hour at 37°C. Serum-virus mixtures were added to Vero E6 cells in 96-well plates and incubated for 1 hour at 37°C. Cells were overlaid with 1% (w/v) methylcellulose in Minimal Essential Media (Sigma-Aldrich). After 30 hours, cells were fixed with 4% paraformaldehyde in PBS for 20 min at room temperature then washed and stained overnight at 4°C with 1 μg/ml of antibody CR3022 in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin. Cells were subsequently stained with horseradish peroxidase (HRP)-conjugated goat anti-human IgG for 2 hours at room temperature. SARS-CoV-2-infected cell foci were visualized with TrueBlue peroxidase substrate (KPL) and quantified using ImmunoSpot microanalyzer (Cellular Technologies). Neutralization curves were generated with Prism software (GraphPad Prism 8.0).</div><div ><b>Authentic SARS-CoV-2 variant and SARS-CoV-1 neutralization assay.</b> The SARS-CoV-2 viruses USA-WA1/2020 (WA1), USA/CA_CDC_5574/2020 (B1.1.7), hCoV-19/South Africa/KRISP-EC-K005321/2020 (B.1.351), hCoV-19/Japan/TY7-503/2021, hCoV-19/USA/PHC658/2021 (B.1.617.2) were obtained from BEI Resources (NIAID, NIH) and propagated for one passage using Vero clone E6 cells. Virus infectious titer was determined by an end-point dilution and cytopathic effect (CPE) assay on Vero-E6 cells as described previously (<a ><i>56</i></a>, <a ><i>57</i></a>). An end-point dilution microplate neutralization assay was performed to measure the neutralization activity of NHP serum samples. In brief, serum samples were heat inactivated and subjected to successive three-fold dilutions starting from 1:50. Triplicates of each dilution were incubated with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 in Eagle’s Minimal Essential Medium (EMEM) with 7.5% inactivated fetal calf serum (FCS) for 1 hour at 37°C. Post incubation, the virus-antibody mixture was transferred onto a monolayer of Vero-E6 cells grown overnight. The cells were incubated with the mixture for about 70 hours. CPE of viral infection was visually scored for each well in a blinded fashion by two independent observers. The results were then reported as percentage of neutralization at a given sample dilution. A SARS-CoV-1 authentic plaque reduction virus neutralization assay was performed similarly to previously described (<a ><i>58</i></a>), with the following modifications. The starting dilution of serum was 1:5 and about 100 plaque-forming units of virus were used for virus and serum incubation. The overlay used after virus adsorption was Dulbecco's Modified Eagle Medium (Gibco) containing 2% FBS and 20% methylcellulose. Plates were then incubated for 5 days, and post crystal violet staining the washing step utilized water.​ Plaques were graded as follows: approximately 25 plaques/25% monolayer damage (MD; -/+); approximately 50 plaques/50% MD) (+); approximately 75 plaques/75% MD (++); approximately 100 plaques/100% MD (+++). All negative control wells were solid monolayers.</div><div ><b>Antibody-Dependent Neutrophil Phagocytosis (ADNP).</b> Biotinylated SARS-CoV-2 prefusion stabilized S trimer was incubated with yellow-green streptavidin-fluorescent beads (Molecular Probes) for 2 hours at 37°C. Ten μl of a 100-fold dilution of beads and protein was incubated for 2 hours at 37°C with 100μl of 8,100-fold diluted plasma samples before addition of effector cells (50,000 cells/well). Fresh human peripheral blood mononuclear cells were used as effector cells after red blood cell lysis with ACK lysing buffer (Thermo Fisher Scientific). After 1 hour, incubation at 37°C, the cells were washed, surface stained, fixed with 4% formaldehyde solution (Tousimis) and fluorescence was evaluated on an LSRII flow cytometer (BD Biosciences). Antibodies used for flow cytometry included anti-human CD3 Alexa Fluor 700 (clone UCHT1) and anti-human CD14 Allophycocyanin Cynanine Dye 7 (APC-Cy7) (clone MϕP9) from BD Biosciences, as well as anti-human CD66b Pacific Blue (clone G10F5) from BioLegend. A phagocytic score was calculated by multiplying the percentage of bead-positive neutrophils (side scatter high, CD3<sup>-</sup>CD14<sup>-</sup>CD66<sup>+</sup>) by the geometric mean of the fluorescence intensity of bead-positive cells; and dividing by 10,000.</div><div ><b>Antibody-Dependent Cellular Phagocytosis (ADCP).</b> ADCP was measured as previously described. Briefly, biotinylated SARS-CoV-1 or SARS-CoV-2 prefusion-stabilized spike protein trimer was incubated with red streptavidin-fluorescent beads (Molecular Probes) for 2 hour at 37°C. Ten μl of a 100-fold dilution of beads–protein was incubated for 2 hours at 37°C with 100μl of 8,100-fold (SARS-CoV-2) or 900-fold (SARS-CoV-1) diluted plasma samples before addition of THP-1 cells (20,000 cells per well; Millipore Sigma). After a 19 hour incubation at 37°C, the cells were fixed with 2% formaldehyde solution (Tousimis) and fluorescence was evaluated on an LSRII flow cytometer (BD Biosciences). The phagocytic score was calculated by multiplying the percentage of bead-positive cells by the geometric mean of the fluorescence intensity of bead-positive cells, and dividing by 10,000.</div><div ><b>Antibody-Dependent Complement Deposition (ADCD).</b> SARS-CoV-2 spike protein-expressing expi293F cells were generated by transfection with linearized plasmid (pcDNA3.1) encoding codon-optimized full-length SARS-CoV-2 spike protein matching the amino acid sequence of the IL-CDC-IL1/2020 isolate (GenBank ACC# MN988713). Stable transfectants were single-cell sorted and selected to obtain a high spike surface-expressing clone (293F-spike-S2A). ADCD was adapted from methods previously described (<a ><i>59</i></a>). Briefly, SARS-CoV-2 spike protein-expressing expi293F cells were incubated with 10-fold diluted, heat-inactivated (56°C for 30 min) plasma samples for 30 min at 37°C. Cells were washed twice and resuspended in R10 media. During this time, lyophilized guinea pig complement (CL4051, Cedarlane) was reconstituted in 1 ml cold water and centrifuged for 5 min at 4°C to remove aggregates. Cells were washed with PBS and resuspended in 200 μl of guinea pig complement, which was prepared at a 1:50 dilution in Gelatin Veronal Buffer with Ca<sup>2+</sup> and Mg<sup>2+</sup> (IBB-300x, Boston BioProducts). After incubation at 37°C for 20 min, cells were washed in PBS 15mM EDTA (Thermo Fisher Scientific) and stained with an anti-Guinea Pig Complement C3 FITC (polyclonal, Thermo Fisher Scientific). Cells were then fixed with 4% formaldehyde solution and fluorescence was evaluated on a LSRII flow cytometer (BD Biosciences).</div><div ><b>Opsonization.</b> SARS-CoV-2 spike protein-expressing expi293F cells were generated by transfection with linearized plasmid (pcDNA3.1) encoding codon-optimized full-length SARS-CoV-2 spike protein matching the amino acid sequence of the IL-CDC-IL1/2020 isolate (GenBank ACC# MN988713). Stable transfectants were single-cell sorted and selected to obtain a high Spike surface-expressing clone (293F-Spike-S2A). SARS-CoV-2 spike protein-expressing cells were incubated with 200-fold diluted plasma samples for 30 min at 37°C. Cells were washed twice and stained with anti-human IgG phycoerythrin (PE), anti-human IgM Alexa Fluor 647, and anti-human IgA FITC (Southern Biotech). Cells were then fixed with 4% formaldehyde solution and fluorescence was evaluated on an LSRII flow cytometer (BD Biosciences).</div><div ><b>Trogocytosis.</b> Trogocytosis was measured using a previously described assay (<a ><i>27</i></a>). Briefly, SARS-CoV-2 spike expressing expi293F cells were stained with PKH26 (Sigma-Aldrich). Cells were then washed with and resuspended in R10 media. Cells were then incubated with 200-fold diluted plasma samples for 30 min at 37°C. Effector peripheral blood mononuclear cells were next added to the R10 media at an effector to target (E:T) cell ratio of 50:1 and then incubated for 5 hours at 37°C. After the incubation, cells were washed, stained with live/dead aqua fixable cell stain (Life Technologies) and CD14 APC-Cy7 (clone MϕP9) for 15 min at room temperature, washed again, and fixed with 4% formaldehyde (Tousimis) for 15 min at room temperature. Fluorescence was evaluated on a LSRII flow cytometer (BD Biosciences). Trogocytosis was evaluated by measuring the PKH26 mean fluorescence intensity of the live CD14<sup>+</sup> cells.</div><div ><b>Intracellular Cytokine Staining.</b> Cryopreserved peripheral blood mononuclear cells were thawed and rested for 6 hours in R10 with 50 U/mL Benzonase Nuclease (Sigma Aldrich). They were then stimulated for 12 hours with two pools of peptides spanning the spike protein of either SARS-CoV-2 or SARS-CoV-1 (1 μg/mL, JPT, PM-WCPV-S and PM-CVHSA-S respectively) in the presence of Brefeldin A (0.65 μL/mL, GolgiPlug, BD Biosciences Cytofix/Cytoperm Kit, Cat. 555028), co-stimulatory antibodies anti-CD28 (BD Biosciences Cat. 555725 1 μg/mL) and anti-CD49d (BD Biosciences Cat. 555501; 1 μg/mL), and CD107a (H4A3, BD Biosciences Cat. 561348, Lot 9143920 and 253441). Following stimulation, cells were stained serially with LIVE/DEAD Fixable Blue Dead Cell Stain in PBS for 20 min at room temperature (Thermo Fisher Scientific #L23105) and a cocktail of fluorescently-labeled antibodies (BD Biosciences unless otherwise indicated) to cell surface markers CD4-PE-Cy5.5 (S3.5, Thermo Fisher #MHCD0418, Lot 2118390, 1:80), CD8 BV570 (RPA-T8, BioLegend #301038, Lot B281322, 1:160), CD45RA BUV395 (5H9, #552888, Lot 154382 and 259854, 1:160), CD28 BUV737 (CD28.2, #612815, Lot 0113886, 1:20), CCR7 BV650 (GO43H7, # 353234, Lot B297645, 1:20) and HLA-DR BV480 (G46-6, # 566113, Lot 0055314, 1:640) in 4% fetal bovine serum in PBS for 20 min at room temperature. Intracellular cytokine staining was performed following fixation and permeabilization per manufacturer’s instructions (BD Cytofix/Cytoperm, BD Biosciences) with CD3 APC-Cy7 (SP34-2, #557757, Lot 6140803, 1:1,282), CD154 PE-Cy7 (24-31, BioLegend # 310842, Lot B264810 and B313191, 1:40), IFN-γ Alexa Fluor 700 (B27, # 506516, Lot B187646 and B290145, 1:1,282), TNF-α FITC (MAb11, # 554512, Lot 15360, 1:160), IL-2 BV750 (MQ1-17H12, BioLegend #566361, Lot 0042313, 1:160), IL-4 BB700 (MP4-25D2, Lot 0133487 and 0308726, 1:320), MIP-1b PE (D21-1351, # 550078, Lot 9298609, 1:160), CD69 Electron coupled dye (ECD, phycoerythrin-Texas Red conjugate) (TP1.55.3, Beckman Coulter Life Sciences # 6607110, Lot 7620070 and 7620076, 1:80), IL-21 Alexa Fluor 647 (3A3-N2.1, # 560493, Lot 9199272, 1:20), IL-13 BV421 (JES10-5A2, # 563580, Lot 9322765, 210147 and 169570, 1:20) and IL-17A BV605 (BL168, BioLegend #512326, B289357, 1:20). Sample staining was measured on a FACSymphony A5 SORP (Becton Dickenson) and data analyzed using FlowJo v.9.9 software (Tree Star, Inc.). The gating strategy is shown in fig. S10. CD4 and CD8 T cell subsets were pre-gated on memory markers prior to assessing cytokine expression as follows: single-positive or double-negative for CD45RA and CD28. Boolean combinations of cells expressing one or more cytokines were used to assess the total spike protein-specific response of memory CD4 or CD8 T cells. Responses from the two-peptide pools spanning SARS-CoV-2 spike protein or SARS-CoV-1 were summed. Display of multicomponent distributions were performed with SPICE v6.0 (NIH).</div><div ><b>Total and Sub-Genomic Messenger (sgm) RNA Quantification.</b> Real time quantitative polymerase chain reaction (RT-qPCR) was carried out for subgenomic messenger RNA (sgmRNA) and viral load RNA quantification from NP swab, BAL fluid and saliva samples. Primers targeted the envelope (E) gene of SARS-CoV-2 (table S2). RNA was extracted from 200 μl of NP swab media or BAL specimens using the EZ1 DSP Virus kit (Qiagen) on the EZ1 Advanced XL instrument (Qiagen). Briefly, samples were lysed in 200 μl of ATL buffer (Qiagen) and transferred to the Qiagen EZ1 for extraction. Bacteriophage MS2 (ATCC) was added to the RNA carrier and used as an extraction control to monitor efficiency of RNA extraction and amplification (<a ><i>60</i></a>). Purified RNA was eluted in 90 μl elution buffer (AVE). The RT-qPCR amplification reactions were performed in separate wells of a 96-well Fast plate for the 3 targets: sgmRNA, RNA viral load, and MS2 RNA using 10 μl of extracted material 0.72uM of primer and 0.2uM of probe and 1x TaqPath 1-Step RT-qPCR (A15299: Life Technologies, Thermo Fisher Scientific). Amplification cycling conditions were: 2 min at 25°C, 15 min at 50°C, 2 min at 95°C and 45 cycles of 3 s at 94°C and 30 s at 55°C with fluorescence read at 55°C. An RNA transcript for the SARS-CoV-2 E gene was used as a calibration standard. RNA copy values were extrapolated from the standard curve and multiplied by 45 to obtain RNA copies/ml. A negative control (PBS) and two positive controls (heat inactivated SARS-CoV-2, ATCC, VR-1986HK at 10<sup>6</sup> and 10<sup>3</sup> copies/ml), were extracted and used to assess performance of both assays.</div><div ><b>Histopathology.</b> Formalin fixed sections of lung tissue were evaluated by light microscopy and immunohistochemistry. Lungs were perfused with 10% neutral-buffered formalin. Lung sections were processed routinely into paraffin wax, then sectioned at 5 μm, and resulting slides were stained with hematoxylin and eosin. Immunohistochemistry (IHC) was performed using the Dako Envision system (Dako Agilent Pathology Solutions). Briefly, after deparaffinization, peroxidase blocking, and antigen retrieval, sections were covered with a mouse monoclonal anti-SARS-CoV nucleocapsid protein antibody (#40143-MM05, Sino Biological) at a dilution of 1:4000 and incubated at room temperature for forty-five minutes. They were rinsed, and the peroxidase-labeled polymer (secondary antibody) was applied for thirty minutes. Slides were rinsed and a brown chromogenic substrate 3,3′ Diaminobenzidine (DAB) solution (Dako Agilent Pathology Solutions) was applied for eight minutes. The substrate-chromogen solution was rinsed off the slides, and slides were counterstained with hematoxylin and rinsed. The sections were dehydrated, cleared with Xyless, and then cover slipped. Tissue section slides were evaluated by a board-certified veterinary anatomic pathologist who was blinded to study group allocations.</div><div ><b>Statistical analysis.</b> Raw, individual level data can be found in data file S1. Primary immunogenicity outputs of binding and neutralizing antibody titers as well as T cell responses were compared across vaccination groups using Kruskal-Wallis test. Non-parametric pairwise comparisons between groups were made using the post-hoc Dunn’s test. The same hierarchical analysis was applied to comparisons of sgmRNA concentrations in the NP swabs and BAL fluids of vaccinated versus control groups. Statistical significance was preset at an alpha level of 0.05. The correlation between dependent T cell responses was assessed by non-parametric Spearman correlation (r).</div></section><section ><h2>Acknowledgments</h2><div ><b>ACKNOWLEDGMENTS</b></div><div >We thank J. Lay, E. Zografos, J. Lynch, L. Mendez-Rivera, N. Jackson, B. Slike, U. Tran, S. Peters, J. Bolton, T. Robinson, E. Duncan, H. Siegfried, R.J. O’Connell, Z. Beck and C. Alving for technical support, assistance, and advice.</div><div ><b>Funding:</b> We acknowledge support from the U.S. Department of Defense, Defense Health Agency (Restoral FY20 to KM). This work was partially executed through a cooperative agreement between the U.S. Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.</div><div ><b>Author contributions:</b> K.M. and M.G.J designed the study. I.E.N, A.A., K.K.P., C.M.C., C.S., R.E.C, J.B.C., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., M.C., C.S., P.J.L., A.A., K.M.W., M.S.N., H.M.S., N.dV., M.D., I.S., J.R.C., K.G.L, V.D., S.M., K.A., R.C., S.J.K. D.P.P., N.K., V.R.P., Y.H., L.L.J., G.D.G. performed immunologic and virologic assays. H.A.E, A.C., M.G.L. led the clinical care of the animals. S.P.D., X.Z., E.K.D performed histopathology. K.M., M.G.J., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., and M.C. designed the immunogens. M.R., G.R.M., and A.A. designed and provided the adjuvant. M.G.J., H.A.D.K. J.A.H., S.P.D., M.F.A., S.V., P.T.S., D.D.H., M.S.D., M.G.L., M.R., G.D.G., S.A.P., N.L.M. D.L.B. and K.M. analyzed and interpreted the data. K.M. wrote the paper with assistance from all coauthors.</div><div ><b>Competing interests:</b> K.M. and M.G.J. are primary co-inventors on related vaccine patents (U.S. Provisional Application 62/986,522 filed March 6, 2020, and to U.S. Provisional Application 63/038,600 filed June 12, 2020). M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech, and Carnival Corporation. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. M.S.D. is on the Scientific Advisory Boards of Moderna and Immunome. The other authors declare no competing interests.</div><div ><b>Data and materials availability:</b> All data are available in the manuscript or the supplementary materials. The vaccine and adjuvant used in this study will be made available to the scientific community by contacting Kayvon Modjarrad and completion of a materials transfer agreement.</div><div >This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using this material.</div></section> </div></section><section ><div ><section ><h2>Supplementary Materials</h2><section ><h3>This PDF file includes:</h3><div ><div ><div>Figs. S1 to S10</div><div>Tables S1 and S2</div></div><div ><a >Download (511.86 KB)</a></div></div></section><section ><h3>Other Supplementary Material for this manuscript includes the following:</h3><div ><div ><div>Data file S1</div></div><div ><a >Download (290.07 KB)</a></div></div></section></section><section ><h2>References and Notes</h2><div ><div >1</div><div ><div ><div >M. S. Freedman, K. Ault, H. Bernstein, Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2021. MMWR Morb. Mortal. Wkly. Rep. <b>70</b>, 193–196 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >2</div><div ><div ><div >J. R. Mascola, B. S. Graham, A. S. Fauci, SARS-CoV-2 Viral Variants-Tackling a Moving Target. JAMA <b>325</b>, 1261–1262 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >3</div><div ><div ><div >D. Ho <i>et al</i>., Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. <i>Res Sq</i>, (2021).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >4</div><div ><div ><div >J. R. Ortiz, J. Robertson, J.-S. Hsu, S. L. Yu, A. J. Driscoll, S. R. Williams, W. H. Chen, M. C. Fitzpatrick, S. Sow, R. J. Biellik, K. M. Neuzil, The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. Vaccine <b>39</b>, 2165–2176 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >5</div><div ><div ><div >H. G. Kelly, H.-X. Tan, J. A. Juno, R. Esterbauer, Y. Ju, W. Jiang, V. C. Wimmer, B. C. Duckworth, J. R. Groom, F. Caruso, M. Kanekiyo, S. J. Kent, A. K. Wheatley, Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight <b>5</b>, e136653 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >6</div><div ><div ><div >Y. Kato, R. K. Abbott, B. L. Freeman, S. Haupt, B. Groschel, M. Silva, S. Menis, D. J. Irvine, W. R. Schief, S. Crotty, Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. Immunity <b>53</b>, 548–563.e8 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >7</div><div ><div ><div >R. Übelhart, E. Hug, M. P. Bach, T. Wossning, M. Dühren-von Minden, A. H. C. Horn, D. Tsiantoulas, K. Kometani, T. Kurosaki, C. J. Binder, H. Sticht, L. Nitschke, M. Reth, H. Jumaa, Responsiveness of B cells is regulated by the hinge region of IgD. Nat. Immunol. <b>16</b>, 534–543 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >8</div><div ><div ><div >J. M. Bradley, N. E. Le Brun, G. R. Moore, Ferritins: Furnishing proteins with iron. Eur. J. Biochem. <b>21</b>, 13–28 (2016).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >9</div><div ><div ><div >H. D. Kamp, K. A. Swanson, R. R. Wei, P. K. Dhal, R. Dharanipragada, A. Kern, B. Sharma, R. Sima, O. Hajdusek, L. T. Hu, C.-J. Wei, G. J. Nabel, Design of a broadly reactive Lyme disease vaccine. NPJ Vaccines <b>5</b>, 33 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >10</div><div ><div ><div >K. A. Swanson, J. N. Rainho-Tomko, Z. P. Williams, L. Lanza, M. Peredelchuk, M. Kishko, V. Pavot, J. Alamares-Sapuay, H. Adhikarla, S. Gupta, S. Chivukula, S. Gallichan, L. Zhang, N. Jackson, H. Yoon, D. Edwards, C.-J. Wei, G. J. Nabel, A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. <b>5</b>, eaba6466 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >11</div><div ><div ><div >M. Kanekiyo, W. Bu, M. G. Joyce, G. Meng, J. R. R. Whittle, U. Baxa, T. Yamamoto, S. Narpala, J.-P. Todd, S. S. Rao, A. B. McDermott, R. A. Koup, M. G. Rossmann, J. R. Mascola, B. S. Graham, J. I. Cohen, G. J. Nabel, Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell <b>162</b>, 1090–1100 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >12</div><div ><div ><div >M. Kanekiyo, C.-J. Wei, H. M. Yassine, P. M. McTamney, J. C. Boyington, J. R. R. Whittle, S. S. Rao, W.-P. Kong, L. Wang, G. J. Nabel, Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature <b>499</b>, 102–106 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >13</div><div ><div ><div >H. M. Yassine, J. C. Boyington, P. M. McTamney, C.-J. Wei, M. Kanekiyo, W.-P. Kong, J. R. Gallagher, L. Wang, Y. Zhang, M. G. Joyce, D. Lingwood, S. M. Moin, H. Andersen, Y. Okuno, S. S. Rao, A. K. Harris, P. D. Kwong, J. R. Mascola, G. J. Nabel, B. S. Graham, Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. <b>21</b>, 1065–1070 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >14</div><div ><div ><div ><a >https://clinicaltrials.gov/ct2/show/NCT03186781</a>. (2021).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >15</div><div ><div ><div ><a >https://clinicaltrials.gov/ct2/show/NCT03814720</a>. (2021).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >16</div><div ><div ><div >D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science <b>367</b>, 1260–1263 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >17</div><div ><div ><div >G. Dagotto, J. Yu, D. H. Barouch, Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe <b>28</b>, 364–370 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >18</div><div ><div ><div >T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. T. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science <b>369</b>, 956–963 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >19</div><div ><div ><div >T. Zohar, G. Alter, Dissecting antibody-mediated protection against SARS-CoV-2. Nat. Rev. Immunol. <b>20</b>, 392–394 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >20</div><div ><div ><div >M. G. Joyce et al., SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. bioRxiv, (2021).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >21</div><div ><div ><div >C. Muñoz-Fontela, W. E. Dowling, S. G. P. Funnell, P.-S. Gsell, A. X. Riveros-Balta, R. A. Albrecht, H. Andersen, R. S. Baric, M. W. Carroll, M. Cavaleri, C. Qin, I. Crozier, K. Dallmeier, L. de Waal, E. de Wit, L. Delang, E. Dohm, W. P. Duprex, D. Falzarano, C. L. Finch, M. B. Frieman, B. S. Graham, L. E. Gralinski, K. Guilfoyle, B. L. Haagmans, G. A. Hamilton, A. L. Hartman, S. Herfst, S. J. F. Kaptein, W. B. Klimstra, I. Knezevic, P. R. Krause, J. H. Kuhn, R. Le Grand, M. G. Lewis, W.-C. Liu, P. Maisonnasse, A. K. McElroy, V. Munster, N. Oreshkova, A. L. Rasmussen, J. Rocha-Pereira, B. Rockx, E. Rodríguez, T. F. Rogers, F. J. Salguero, M. Schotsaert, K. J. Stittelaar, H. J. Thibaut, C.-T. Tseng, J. Vergara-Alert, M. Beer, T. Brasel, J. F. W. Chan, A. García-Sastre, J. Neyts, S. Perlman, D. S. Reed, J. A. Richt, C. J. Roy, J. Segalés, S. S. Vasan, A. M. Henao-Restrepo, D. H. Barouch, Animal models for COVID-19. Nature <b>586</b>, 509–515 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >22</div><div ><div ><div >Z. Beck, G. R. Matyas, R. Jalah, M. Rao, V. R. Polonis, C. R. Alving, Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine <b>33</b>, 5578–5587 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >23</div><div ><div ><div >Z. Beck, G. R. Matyas, C. R. Alving, Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim. Biophys. Acta <b>1848</b>, 775–780 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >24</div><div ><div ><div >N. Suryadevara, S. Shrihari, P. Gilchuk, L. A. VanBlargan, E. Binshtein, S. J. Zost, R. S. Nargi, R. E. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. J. Doranz, R. E. Chen, P.-Y. Shi, R. H. Carnahan, L. B. Thackray, M. S. Diamond, J. E. Crowe Jr., Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell <b>184</b>, 2316–2331.e15 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >25</div><div ><div ><div >N. B. Mercado, R. Zahn, F. Wegmann, C. Loos, A. Chandrashekar, J. Yu, J. Liu, L. Peter, K. McMahan, L. H. Tostanoski, X. He, D. R. Martinez, L. Rutten, R. Bos, D. van Manen, J. Vellinga, J. Custers, J. P. Langedijk, T. Kwaks, M. J. G. Bakkers, D. Zuijdgeest, S. K. Rosendahl Huber, C. Atyeo, S. Fischinger, J. S. Burke, J. Feldman, B. M. Hauser, T. M. Caradonna, E. A. Bondzie, G. Dagotto, M. S. Gebre, E. Hoffman, C. Jacob-Dolan, M. Kirilova, Z. Li, Z. Lin, S. H. Mahrokhian, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. P. Nkolola, S. Patel, J. D. Ventura, K. Verrington, H. Wan, L. Pessaint, A. Van Ry, K. Blade, A. Strasbaugh, M. Cabus, R. Brown, A. Cook, S. Zouantchangadou, E. Teow, H. Andersen, M. G. Lewis, Y. Cai, B. Chen, A. G. Schmidt, R. K. Reeves, R. S. Baric, D. A. Lauffenburger, G. Alter, P. Stoffels, M. Mammen, J. Van Hoof, H. Schuitemaker, D. H. Barouch, Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature <b>586</b>, 583–588 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >26</div><div ><div ><div >J. Yu, L. H. Tostanoski, L. Peter, N. B. Mercado, K. McMahan, S. H. Mahrokhian, J. P. Nkolola, J. Liu, Z. Li, A. Chandrashekar, D. R. Martinez, C. Loos, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Slein, Y. Chen, A. Zuiani, F. J. N. Lelis, M. Travers, S. Habibi, L. Pessaint, A. Van Ry, K. Blade, R. Brown, A. Cook, B. Finneyfrock, A. Dodson, E. Teow, J. Velasco, R. Zahn, F. Wegmann, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, M. Kirilova, N. Kordana, Z. Lin, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. D. Ventura, H. Wan, Y. Cai, B. Chen, A. G. Schmidt, D. R. Wesemann, R. S. Baric, G. Alter, H. Andersen, M. G. Lewis, D. H. Barouch, DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science <b>369</b>, 806–811 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >27</div><div ><div ><div >A. Alrubayyi, A. Schuetz, K. G. Lal, S. Jongrakthaitae, K. M. Paolino, J. A. Ake, M. L. Robb, M. S. de Souza, N. L. Michael, D. Paquin-Proulx, M. A. Eller, A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. J. Immunol. Methods <b>462</b>, 74–82 (2018).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >28</div><div ><div ><div >B. F. Haynes, L. Corey, P. Fernandes, P. B. Gilbert, P. J. Hotez, S. Rao, M. R. Santos, H. Schuitemaker, M. Watson, A. Arvin, Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. <b>12</b>, eabe0948 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >29</div><div ><div ><div >J. S. Hale, R. Ahmed, Memory T follicular helper CD4 T cells. Front. Immunol. <b>6</b>, 16 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >30</div><div ><div ><div >Y. Liu, J. Liu, H. Xia, X. Zhang, C. R. Fontes-Garfias, K. A. Swanson, H. Cai, R. Sarkar, W. Chen, M. Cutler, D. Cooper, S. C. Weaver, A. Muik, U. Sahin, K. U. Jansen, X. Xie, P. R. Dormitzer, P.-Y. Shi, Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. <b>384</b>, 1466–1468 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >31</div><div ><div ><div >X. Shen, H. Tang, C. McDanal, K. Wagh, W. Fischer, J. Theiler, H. Yoon, D. Li, B. F. Haynes, K. O. Sanders, S. Gnanakaran, N. Hengartner, R. Pajon, G. Smith, G. M. Glenn, B. Korber, D. C. Montefiori, SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe <b>29</b>, 529–539.e3 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >32</div><div ><div ><div >M. Voysey, A. J. Pollard, ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors’ reply. Lancet <b>396</b>, 1486–1487 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >33</div><div ><div ><div >Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, M. Turroja, K. A. West, K. Gordon, K. G. Millard, V. Ramos, J. Da Silva, J. Xu, R. A. Colbert, R. Patel, J. Dizon, C. Unson-O’Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. J. Bjorkman, R. Casellas, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature <b>592</b>, 616–622 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >34</div><div ><div ><div >K. S. Corbett, B. Flynn, K. E. Foulds, J. R. Francica, S. Boyoglu-Barnum, A. P. Werner, B. Flach, S. O’Connell, K. W. Bock, M. Minai, B. M. Nagata, H. Andersen, D. R. Martinez, A. T. Noe, N. Douek, M. M. Donaldson, N. N. Nji, G. S. Alvarado, D. K. Edwards, D. R. Flebbe, E. Lamb, N. A. Doria-Rose, B. C. Lin, M. K. Louder, S. O’Dell, S. D. Schmidt, E. Phung, L. A. Chang, C. Yap, J. M. Todd, L. Pessaint, A. Van Ry, S. Browne, J. Greenhouse, T. Putman-Taylor, A. Strasbaugh, T.-A. Campbell, A. Cook, A. Dodson, K. Steingrebe, W. Shi, Y. Zhang, O. M. Abiona, L. Wang, A. Pegu, E. S. Yang, K. Leung, T. Zhou, I.-T. Teng, A. Widge, I. Gordon, L. Novik, R. A. Gillespie, R. J. Loomis, J. I. Moliva, G. Stewart-Jones, S. Himansu, W.-P. Kong, M. C. Nason, K. M. Morabito, T. J. Ruckwardt, J. E. Ledgerwood, M. R. Gaudinski, P. D. Kwong, J. R. Mascola, A. Carfi, M. G. Lewis, R. S. Baric, A. McDermott, I. N. Moore, N. J. Sullivan, M. Roederer, R. A. Seder, B. S. Graham, Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. <b>383</b>, 1544–1555 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >35</div><div ><div ><div >M. Guebre-Xabier, N. Patel, J.-H. Tian, B. Zhou, S. Maciejewski, K. Lam, A. D. Portnoff, M. J. Massare, M. B. Frieman, P. A. Piedra, L. Ellingsworth, G. Glenn, G. Smith, NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine <b>38</b>, 7892–7896 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >36</div><div ><div ><div >H. Wang, Y. Zhang, B. Huang, W. Deng, Y. Quan, W. Wang, W. Xu, Y. Zhao, N. Li, J. Zhang, H. Liang, L. Bao, Y. Xu, L. Ding, W. Zhou, H. Gao, J. Liu, P. Niu, L. Zhao, W. Zhen, H. Fu, S. Yu, Z. Zhang, G. Xu, C. Li, Z. Lou, M. Xu, C. Qin, G. Wu, G. F. Gao, W. Tan, X. Yang, Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell <b>182</b>, 713–721.e9 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >37</div><div ><div ><div >N. van Doremalen, T. Lambe, A. Spencer, S. Belij-Rammerstorfer, J. N. Purushotham, J. R. Port, V. A. Avanzato, T. Bushmaker, A. Flaxman, M. Ulaszewska, F. Feldmann, E. R. Allen, H. Sharpe, J. Schulz, M. Holbrook, A. Okumura, K. Meade-White, L. Pérez-Pérez, N. J. Edwards, D. Wright, C. Bissett, C. Gilbride, B. N. Williamson, R. Rosenke, D. Long, A. Ishwarbhai, R. Kailath, L. Rose, S. Morris, C. Powers, J. Lovaglio, P. W. Hanley, D. Scott, G. Saturday, E. de Wit, S. C. Gilbert, V. J. Munster, ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature <b>586</b>, 578–582 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >38</div><div ><div ><div >A. B. Vogel, I. Kanevsky, Y. Che, K. A. Swanson, A. Muik, M. Vormehr, L. M. Kranz, K. C. Walzer, S. Hein, A. Güler, J. Loschko, M. S. Maddur, A. Ota-Setlik, K. Tompkins, J. Cole, B. G. Lui, T. Ziegenhals, A. Plaschke, D. Eisel, S. C. Dany, S. Fesser, S. Erbar, F. Bates, D. Schneider, B. Jesionek, B. Sänger, A.-K. Wallisch, Y. Feuchter, H. Junginger, S. A. Krumm, A. P. Heinen, P. Adams-Quack, J. Schlereth, S. Schille, C. Kröner, R. de la Caridad Güimil Garcia, T. Hiller, L. Fischer, R. S. Sellers, S. Choudhary, O. Gonzalez, F. Vascotto, M. R. Gutman, J. A. Fontenot, S. Hall-Ursone, K. Brasky, M. C. Griffor, S. Han, A. A. H. Su, J. A. Lees, N. L. Nedoma, E. H. Mashalidis, P. V. Sahasrabudhe, C. Y. Tan, D. Pavliakova, G. Singh, C. Fontes-Garfias, M. Pride, I. L. Scully, T. Ciolino, J. Obregon, M. Gazi, R. Carrion Jr., K. J. Alfson, W. V. Kalina, D. Kaushal, P.-Y. Shi, T. Klamp, C. Rosenbaum, A. N. Kuhn, Ö. Türeci, P. R. Dormitzer, K. U. Jansen, U. Sahin, BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature <b>592</b>, 283–289 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >39</div><div ><div ><div >J. Verma, N. Subbarao, A comparative study of human betacoronavirus spike proteins: Structure, function and therapeutics. Arch. Virol. <b>166</b>, 697–714 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >40</div><div ><div ><div >J. Li, L. Ulitzky, E. Silberstein, D. R. Taylor, R. Viscidi, Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral Immunol. <b>26</b>, 126–132 (2013).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >41</div><div ><div ><div >R. L. Roper, K. E. Rehm, SARS vaccines: Where are we? Expert Rev. Vaccines <b>8</b>, 887–898 (2009).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >42</div><div ><div ><div >A. M. Sholukh, A. Fiore-Gartland, E. S. Ford, M. D. Miner, Y. J. Hou, L. V. Tse, H. Kaiser, H. Zhu, J. Lu, B. Madarampalli, A. Park, F. A. Lempp, R. St Germain, E. L. Bossard, J. J. Kee, K. Diem, A. B. Stuart, P. B. Rupert, C. Brock, M. Buerger, M. K. Doll, A. K. Randhawa, L. Stamatatos, R. K. Strong, C. McLaughlin, M. L. Huang, K. R. Jerome, R. S. Baric, D. Montefiori, L. Corey, Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. J. Clin. Microbiol. <b>59</b>, e0052721 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >43</div><div ><div ><div >M. Voysey, S. A. C. Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley, B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. M. Collins, R. Colin-Jones, C. L. Cutland, T. C. Darton, K. Dheda, C. J. A. Duncan, K. R. W. Emary, K. J. Ewer, L. Fairlie, S. N. Faust, S. Feng, D. M. Ferreira, A. Finn, A. L. Goodman, C. M. Green, C. A. Green, P. T. Heath, C. Hill, H. Hill, I. Hirsch, S. H. C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. M. Lawrie, A. Lelliott, V. Libri, P. J. Lillie, R. Mallory, A. V. A. Mendes, E. P. Milan, A. M. Minassian, A. McGregor, H. Morrison, Y. F. Mujadidi, A. Nana, P. J. O’Reilly, S. D. Padayachee, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy, S. Rhead, A. V. Schwarzbold, N. Singh, A. Smith, R. Song, M. D. Snape, E. Sprinz, R. K. Sutherland, R. Tarrant, E. C. Thomson, M. E. Török, M. Toshner, D. P. J. Turner, J. Vekemans, T. L. Villafana, M. E. E. Watson, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, A. J. Pollard; Oxford COVID Vaccine Trial Group, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet <b>397</b>, 99–111 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >44</div><div ><div ><div >J. E. Staples, A. D. T. Barrett, A. Wilder-Smith, J. Hombach, Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. NPJ Vaccines <b>5</b>, 54 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >45</div><div ><div ><div >S. N. Crooke, M. M. Riggenbach, I. G. Ovsyannikova, N. D. Warner, M.-H. Chen, L. Hao, J. P. Icenogle, G. A. Poland, R. B. Kennedy, Durability of humoral immune responses to rubella following MMR vaccination. Vaccine <b>38</b>, 8185–8193 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >46</div><div ><div ><div >H. Theeten, K. Van Herck, O. Van Der Meeren, P. Crasta, P. Van Damme, N. Hens, Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine <b>33</b>, 5723–5727 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >47</div><div ><div ><div >A. A. Cohen, P. N. P. Gnanapragasam, Y. E. Lee, P. R. Hoffman, S. Ou, L. M. Kakutani, J. R. Keeffe, H.-J. Wu, M. Howarth, A. P. West, C. O. Barnes, M. C. Nussenzweig, P. J. Bjorkman, Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science <b>371</b>, 735–741 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >48</div><div ><div ><div >A. E. Powell, K. Zhang, M. Sanyal, S. Tang, P. A. Weidenbacher, S. Li, T. D. Pham, J. E. Pak, W. Chiu, P. S. Kim, A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Cent. Sci. <b>7</b>, 183–199 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >49</div><div ><div ><div >K. O. Saunders, E. Lee, R. Parks, D. R. Martinez, D. Li, H. Chen, R. J. Edwards, S. Gobeil, M. Barr, K. Mansouri, S. M. Alam, L. L. Sutherland, F. Cai, A. M. Sanzone, M. Berry, K. Manne, K. W. Bock, M. Minai, B. M. Nagata, A. B. Kapingidza, M. Azoitei, L. V. Tse, T. D. Scobey, R. L. Spreng, R. W. Rountree, C. T. DeMarco, T. N. Denny, C. W. Woods, E. W. Petzold, J. Tang, T. H. Oguin 3rd, G. D. Sempowski, M. Gagne, D. C. Douek, M. A. Tomai, C. B. Fox, R. Seder, K. Wiehe, D. Weissman, N. Pardi, H. Golding, S. Khurana, P. Acharya, H. Andersen, M. G. Lewis, I. N. Moore, D. C. Montefiori, R. S. Baric, B. F. Haynes, Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature <b>594</b>, 553–559 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >50</div><div ><div ><div >C. J. Genito, Z. Beck, T. W. Phares, F. Kalle, K. J. Limbach, M. E. Stefaniak, N. B. Patterson, E. S. Bergmann-Leitner, N. C. Waters, G. R. Matyas, C. R. Alving, S. Dutta, Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine <b>35</b>, 3865–3874 (2017).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >51</div><div ><div ><div >A. Ramakrishnan, N. M. Schumack, C. L. Gariepy, H. Eggleston, G. Nunez, N. Espinoza, M. Nieto, R. Castillo, J. Rojas, A. J. McCoy, Z. Beck, G. R. Matyas, C. R. Alving, P. Guerry, F. Poly, R. M. Laird, Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21. MSphere <b>4</b> (2019).</div><div ><div><a >Crossref</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >52</div><div ><div ><div >K. M. Wuertz, E. K. Barkei, W.-H. Chen, E. J. Martinez, I. Lakhal-Naouar, L. L. Jagodzinski, D. Paquin-Proulx, G. D. Gromowski, I. Swafford, A. Ganesh, M. Dong, X. Zeng, P. V. Thomas, R. S. Sankhala, A. Hajduczki, C. E. Peterson, C. Kuklis, S. Soman, L. Wieczorek, M. Zemil, A. Anderson, J. Darden, H. Hernandez, H. Grove, V. Dussupt, H. Hack, R. de la Barrera, S. Zarling, J. F. Wood, J. W. Froude, M. Gagne, A. R. Henry, E. B. Mokhtari, P. Mudvari, S. J. Krebs, A. S. Pekosz, J. R. Currier, S. Kar, M. Porto, A. Winn, K. Radzyminski, M. G. Lewis, S. Vasan, M. Suthar, V. R. Polonis, G. R. Matyas, E. A. Boritz, D. C. Douek, R. A. Seder, S. P. Daye, M. Rao, S. A. Peel, M. G. Joyce, D. L. Bolton, N. L. Michael, K. Modjarrad, A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines <b>6</b>, 129 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >53</div><div ><div ><div >clinicaltrials.gov, (<a >https://clinicaltrials.gov/ct2/show/NCT04784767?term=paul+scottdraw=2rank=1</a>, 2021).</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >54</div><div ><div ><div >P. Singh, Z. Beck, G. R. Matyas, C. R. Alving, Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. J. Liposome Res. <b>29</b>, 247–250 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >55</div><div ><div ><div >E. K. Nelson, B. Piehler, J. Eckels, A. Rauch, M. Bellew, P. Hussey, S. Ramsay, C. Nathe, K. Lum, K. Krouse, D. Stearns, B. Connolly, T. Skillman, M. Igra, LabKey Server: An open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics <b>12</b>, 71 (2011).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >56</div><div ><div ><div >L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F.-W. Chan, V. Sahi, A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P. D. Kwong, J. G. Sodroski, M. T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D. D. Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature <b>584</b>, 450–456 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >57</div><div ><div ><div >P. Wang, L. Liu, M. S. Nair, M. T. Yin, Y. Luo, Q. Wang, T. Yuan, K. Mori, A. G. Solis, M. Yamashita, A. Garg, L. J. Purpura, J. C. Laracy, J. Yu, L. Joshua-Tor, J. Sodroski, Y. Huang, D. D. Ho, SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg. Microbes Infect. <b>9</b>, 2091–2093 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >58</div><div ><div ><div >K. T. Abe, Z. Li, R. Samson, P. Samavarchi-Tehrani, E. J. Valcourt, H. Wood, P. Budylowski, A. P. Dupuis 2nd, R. C. Girardin, B. Rathod, J. H. Wang, M. Barrios-Rodiles, K. Colwill, A. J. McGeer, S. Mubareka, J. L. Gommerman, Y. Durocher, M. Ostrowski, K. A. McDonough, M. A. Drebot, S. J. Drews, J. M. Rini, A.-C. Gingras, A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight <b>5</b>, e142362 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >59</div><div ><div ><div >S. Fischinger, J. K. Fallon, A. R. Michell, T. Broge, T. J. Suscovich, H. Streeck, G. Alter, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods <b>473</b>, 112630 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >60</div><div ><div ><div >L. Ninove, A. Nougairede, C. Gazin, L. Thirion, I. Delogu, C. Zandotti, R. N. Charrel, X. De Lamballerie, RNA and DNA bacteriophages as molecular diagnosis controls in clinical virology: A comprehensive study of more than 45,000 routine PCR tests. PLOS ONE <b>6</b>, e16142 (2011).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div></section></div></section><div ><div ><header><h2>Information Authors</h2></header><section ><h3>Information</h3><section ><h4>Published In</h4><div > <div ><div >Science Translational Medicine</div><div >First Release</div></div></div></section><section ><h4>Copyright</h4><div >Copyright © 2021, American Association for the Advancement of Science.</div><div >https://creativecommons.org/licenses/by/4.0/ </div><div >This is an open-access article distributed under the terms of the <a >Creative Commons Attribution license</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></section><section ><h4>Submission history</h4><div><b >Received</b>: 17 March 2021</div><div><b >Accepted</b>: 8 December 2021</div></section><section ><h4>Permissions</h4><div>Request permissions for this article.</div><div><a >Request Permissions</a></div></section><section ><h4>Acknowledgments</h4><div ><b>ACKNOWLEDGMENTS</b></div><div >We thank J. Lay, E. Zografos, J. Lynch, L. Mendez-Rivera, N. Jackson, B. Slike, U. Tran, S. Peters, J. Bolton, T. Robinson, E. Duncan, H. Siegfried, R.J. O’Connell, Z. Beck and C. Alving for technical support, assistance, and advice.</div><div ><b>Funding:</b> We acknowledge support from the U.S. Department of Defense, Defense Health Agency (Restoral FY20 to KM). This work was partially executed through a cooperative agreement between the U.S. Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.</div><div ><b>Author contributions:</b> K.M. and M.G.J designed the study. I.E.N, A.A., K.K.P., C.M.C., C.S., R.E.C, J.B.C., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., M.C., C.S., P.J.L., A.A., K.M.W., M.S.N., H.M.S., N.dV., M.D., I.S., J.R.C., K.G.L, V.D., S.M., K.A., R.C., S.J.K. D.P.P., N.K., V.R.P., Y.H., L.L.J., G.D.G. performed immunologic and virologic assays. H.A.E, A.C., M.G.L. led the clinical care of the animals. S.P.D., X.Z., E.K.D performed histopathology. K.M., M.G.J., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., and M.C. designed the immunogens. M.R., G.R.M., and A.A. designed and provided the adjuvant. M.G.J., H.A.D.K. J.A.H., S.P.D., M.F.A., S.V., P.T.S., D.D.H., M.S.D., M.G.L., M.R., G.D.G., S.A.P., N.L.M. D.L.B. and K.M. analyzed and interpreted the data. K.M. wrote the paper with assistance from all coauthors.</div><div ><b>Competing interests:</b> K.M. and M.G.J. are primary co-inventors on related vaccine patents (U.S. Provisional Application 62/986,522 filed March 6, 2020, and to U.S. Provisional Application 63/038,600 filed June 12, 2020). M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech, and Carnival Corporation. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. M.S.D. is on the Scientific Advisory Boards of Moderna and Immunome. The other authors declare no competing interests.</div><div ><b>Data and materials availability:</b> All data are available in the manuscript or the supplementary materials. The vaccine and adjuvant used in this study will be made available to the scientific community by contacting Kayvon Modjarrad and completion of a materials transfer agreement.</div><div >This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using this material.</div></section></section><section ><h3>Authors</h3><section ><h4>Affiliations</h4><div ><div >M. Gordon Joyce<sup >*</sup> <a >[email protected]</a></div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Hannah A. D. King</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Ines Elakhal-Naouar</div><div ><div ><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Aslaa Ahmed</div><div ><div ><div >Viral Diseases Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Kristina K. Peachman</div><div ><div ><div >Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Camila Macedo Cincotta</div><div ><div ><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Caroline Subra</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Rita E. Chen</div><div ><div ><div >Department of Medicine, Washington University, St. Louis, MO 63130, USA.</div><div >Department of Pathology Immunology, Washington University, St. Louis, MO 63130, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Paul V. Thomas</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Wei-Hung Chen</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Rajeshwer S. Sankhala</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Agnes Hajduczki</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Elizabeth J. Martinez</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Caroline E. Peterson</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >William C. Chang</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Misook Choe</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Clayton Smith</div><div ><div ><div >Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Parker J. Lee</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jarrett A. Headley</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Mekdi G. Taddese</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Hanne A. Elyard</div><div ><div ><div >Bioqual, Rockville, MD 20850, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Anthony Cook</div><div ><div ><div >Bioqual, Rockville, MD 20850, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Alexander Anderson</div><div ><div ><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div><div >Oak Ridge Institute of Science and Education, Oak Ridge, TN 37830, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Kathryn McGuckin Wuertz</div><div ><div ><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Ming Dong</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Isabella Swafford</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >James Brett Case</div><div ><div ><div >Department of Medicine, Washington University, St. Louis, MO 63130, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Jeffrey R. Currier</div><div ><div ><div >Viral Diseases Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Kerri G. Lal</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Sebastian Molnar</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Manoj S. Nair</div><div ><div ><div >Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Vincent Dussupt</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Sharon P. Daye</div><div ><div ><div >Center for Infectious Diseases Research, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Xiankun Zeng</div><div ><div ><div >Division of Pathology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Erica K. Barkei</div><div ><div ><div >Veterinary Medicine Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Hilary M. Staples</div><div ><div ><div >Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio TX 78227, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Kendra Alfson</div><div ><div ><div >Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio TX 78227, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Ricardo Carrion</div><div ><div ><div >Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio TX 78227, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Shelly J. Krebs</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Dominic Paquin-Proulx</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Nicos Karasavva</div><div ><div ><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Victoria R. Polonis</div><div ><div ><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Linda L. Jagodzinski</div><div ><div ><div >Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Mihret F. Amare</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Sandhya Vasan</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Paul T. Scott</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Yaoxing Huang</div><div ><div ><div >Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >David D. Ho</div><div ><div ><div >Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Natalia de Val</div><div ><div ><div >Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Michael S. Diamond</div><div ><div ><div >Department of Medicine, Washington University, St. Louis, MO 63130, USA.</div><div >Department of Pathology Immunology, Washington University, St. Louis, MO 63130, USA.</div><div >Department of Molecular Microbiology, Washington University, St. Louis, MO 63130, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Mark G. Lewis</div><div ><div ><div >Bioqual, Rockville, MD 20850, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Mangala Rao</div><div ><div ><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Gary R. Matyas</div><div ><div ><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Gregory D. Gromowski</div><div ><div ><div >Viral Diseases Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Sheila A. Peel</div><div ><div ><div >Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Nelson L. Michael</div><div ><div ><div >Center for Infectious Diseases Research, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Diane L. Bolton</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div >Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div >US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div><div ><div >Kayvon Modjarrad<sup >*</sup> [email protected]</div><div ><div ><div >Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div></div><div >View all articles by this author</div></div></div></section><section ><h4>Funding Information</h4><div >U.S. Department of Defensehttp://dx.doi.org/10.13039/100000005: </div></section><section ><h4>Notes</h4><div >*Corresponding authors. Email: [email protected]; [email protected]</div></section></section></div><div ><header><h2>Metrics Citations</h2></header><section ><h3>Metrics</h3><section > <h5 > Article Usage </h5> </section><section > <h5 > Altmetrics </h5> </section></section><section ><h3>Citations</h3><section > <div > <h5 >Export citation</h5> <p>Select the format you want to export the citation of this publication.</p> </div> </section></section></div><div ><header><h2>View Options</h2></header><div ><h3>View options</h3><section ><h4>PDF format</h4><p>Download this article as a PDF file</p>Download PDF</section></div><div ><h3>Get Access</h3><section > <div ><h5>Log in to view the full text</h5> <p><a >AAAS Log in</a></p> <p>AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul > <li >Become a AAAS Member</li> <li ><a >Activate your Account</a></li> <li ><a >Purchase Access to Other Journals in the Science Family</a></li> <li><a >Account Help</a></li> </ul> <div > <div >Log in via OpenAthens. <div ><a >via OpenAthens</a></div> </div> <div >Log in via Shibboleth. <div ><a >via Shibboleth</a></div> </div> </div> </div> <div ><h4>More options</h4><p><a >Purchase digital access to this article</a></p><p >Download and print this article for your personal scholarly, research, and educational use.</p></div> </section></div></div><div ><header><h2>Media</h2></header><section ><h3>Figures</h3></section><section ><h3>Multimedia</h3></section></div><div ><header><h2>Tables</h2></header></div><div ><header><h2>Share</h2></header><h3>Share</h3><div ><section ><h4>Share article link</h4><div ><a >Copy Link</a><div ><p >Copied!</p><p >Copying failed.</p></div></div></section><section ><h4>Share on social media</h4><div >facebook<a >twitter</a><a >linkedin</a><a >email</a></div></section></div></div></div></article><section ><div ><div ><div ><div ><h3 >Submit a Response to This Article</h3></div></div></div></div> <div > <div > <h2 >(0)eLetters</h2> </div> <p >eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> <a >Log In to Submit a Response</a> <p >No eLetters have been published for this article yet.</p> </div> </section> <div ><a >View Full Text</a><a >Download PDF</a></div> </div></div></div></div><div ><div ><div ><div ><section><div ><h4 > Current Issue </h4><div ><div > <div ><div><article ><div ><div ><h3 ><a >Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics</a></h3><ul ><li >By<ul > <li >Jay-Hyun Jo</li> <li >Catriona P. Harkins</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia</h3><ul ><li >By<ul > <li >Qian Zhang</li> <li >Morgan E. Hresko</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma</h3><ul ><li >By<ul > <li >Paul-Joseph Aspuria</li> <li >Sandro Vivona</li> <li >et al.</li> </ul> </li></ul></div></div></article></div><div >Table of Contents</div></div> </div></div></div></section><section > <h4 >LATEST NEWS</h4> <div > <div ><div > <article > <div > <div > News<time >30 Dec 2021</time> </div> <div > Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article > <div > <div > ScienceInsider<time >29 Dec 2021</time> </div> <div > <a > Once a ‘crazy idea,’ patent-pooling nonprofit will help bring COVID-19 pills to world’s poor </a> </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > The natural world loses two of its biggest advocates </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > <a > What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article > <div > <div > ScienceInsider<time >25 Dec 2021</time> </div> <div > NASA’s Webb telescope takes flight—a Christmas gift to astronomers everywhere </div> </div> </article> <article > <div > <div > News<time >23 Dec 2021</time> </div> <div > <a > More than a virus: Science’s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, tag: body, level: 1" node_number="1"> <div class="valid" valid="valid" title="valid: True, node: 2, tag: div, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, tag: div, level: 3" node_number="3"> <div class="valid" valid="valid" title="valid: True, node: 4, tag: div, level: 4" node_number="4"> <div class="valid" valid="valid" title="valid: True, node: 5, tag: div, level: 5" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, tag: div, level: 6" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, tag: div, level: 7" node_number="7"> <div class="valid" valid="valid" title="valid: True, node: 8, tag: div, level: 8" node_number="8"> <div class="valid" valid="valid" title="valid: True, node: 9, tag: div, level: 9" node_number="9"> <div class="valid" valid="valid" title="valid: True, node: 10, tag: div, level: 10" node_number="10"> <div class="valid" valid="valid" title="valid: True, node: 11, tag: div, level: 11" node_number="11"> <span class="valid" valid="valid" title="valid: True, node: 12, tag: span, level: 12" node_number="12">Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header class="valid" valid="valid" title="valid: True, node: 13, tag: header, level: 5" node_number="13"> <div class="valid" valid="valid" title="valid: True, node: 14, tag: div, level: 6" node_number="14"><div class="valid" valid="valid" title="valid: True, node: 15, tag: div, level: 7" node_number="15"><div class="valid" valid="valid" title="valid: True, node: 16, tag: div, level: 8" node_number="16"><div class="valid" valid="valid" title="valid: True, node: 17, tag: div, level: 9" node_number="17"><div class="valid" valid="valid" title="valid: True, node: 18, tag: div, level: 10" node_number="18"><div class="valid" valid="valid" title="valid: True, node: 19, tag: div, level: 11" node_number="19"><div class="valid" valid="valid" title="valid: True, node: 20, tag: div, level: 12" node_number="20"><a class="valid" valid="valid" title="valid: True, node: 21, tag: a, level: 13" node_number="21"><div class="valid" valid="valid" title="valid: True, node: 22, tag: div, level: 14" node_number="22">science</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 23, tag: div, level: 11" node_number="23"><div class="valid" valid="valid" title="valid: True, node: 24, tag: div, level: 12" node_number="24"><a class="valid" valid="valid" title="valid: True, node: 25, tag: a, level: 13" node_number="25"><div class="valid" valid="valid" title="valid: True, node: 26, tag: div, level: 14" node_number="26">science advances</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 27, tag: div, level: 11" node_number="27"><div class="valid" valid="valid" title="valid: True, node: 28, tag: div, level: 12" node_number="28"><a class="valid" valid="valid" title="valid: True, node: 29, tag: a, level: 13" node_number="29"><div class="valid" valid="valid" title="valid: True, node: 30, tag: div, level: 14" node_number="30">science immunology</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 31, tag: div, level: 11" node_number="31"><div class="valid" valid="valid" title="valid: True, node: 32, tag: div, level: 12" node_number="32"><a class="valid" valid="valid" title="valid: True, node: 33, tag: a, level: 13" node_number="33"><div class="valid" valid="valid" title="valid: True, node: 34, tag: div, level: 14" node_number="34">science robotics</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 35, tag: div, level: 11" node_number="35"><div class="valid" valid="valid" title="valid: True, node: 36, tag: div, level: 12" node_number="36"><a class="valid" valid="valid" title="valid: True, node: 37, tag: a, level: 13" node_number="37"><div class="valid" valid="valid" title="valid: True, node: 38, tag: div, level: 14" node_number="38">science signaling</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 39, tag: div, level: 11" node_number="39"><div class="valid" valid="valid" title="valid: True, node: 40, tag: div, level: 12" node_number="40"><a class="valid" valid="valid" title="valid: True, node: 41, tag: a, level: 13" node_number="41"><div class="valid" valid="valid" title="valid: True, node: 42, tag: div, level: 14" node_number="42">science translational medicine</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 43, tag: div, level: 11" node_number="43"><div class="valid" valid="valid" title="valid: True, node: 44, tag: div, level: 12" node_number="44"><a class="valid" valid="valid" title="valid: True, node: 45, tag: a, level: 13" node_number="45"><div class="valid" valid="valid" title="valid: True, node: 46, tag: div, level: 14" node_number="46">science partner journals</div></a></div></div></div></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 47, tag: div, level: 6" node_number="47"> <div class="valid" valid="valid" title="valid: True, node: 48, tag: div, level: 7" node_number="48"> <div class="valid" valid="valid" title="valid: True, node: 49, tag: div, level: 8" node_number="49"> <div class="valid" valid="valid" title="valid: True, node: 50, tag: div, level: 9" node_number="50"> <div class="valid" valid="valid" title="valid: True, node: 51, tag: div, level: 10" node_number="51"><div class="valid" valid="valid" title="valid: True, node: 52, tag: div, level: 11" node_number="52"><div class="valid" valid="valid" title="valid: True, node: 53, tag: div, level: 12" node_number="53"><label class="valid" valid="valid" title="valid: True, node: 54, tag: label, level: 13" node_number="54">Searching:</label><div class="valid" valid="valid" title="valid: True, node: 55, tag: div, level: 13" node_number="55"><div class="valid" valid="valid" title="valid: True, node: 56, tag: div, level: 14" node_number="56"><div title="valid: False, node: 57, tag: div, level: 15" node_number="57">AnywhereScienceScience AdvancesScience Immunology<a title="valid: False, node: 58, tag: a, level: 16" node_number="58">Science Robotics</a><a title="valid: False, node: 59, tag: a, level: 16" node_number="59">Science Signaling</a><a title="valid: False, node: 60, tag: a, level: 16" node_number="60">Science Translational Medicine</a></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 61, tag: div, level: 12" node_number="61"> <a class="valid" valid="valid" title="valid: True, node: 62, tag: a, level: 13" node_number="62"><u class="valid" valid="valid" title="valid: True, node: 63, tag: u, level: 14" node_number="63">Advanced Search</u></a> </div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 64, tag: div, level: 7" node_number="64"> <div class="valid" valid="valid" title="valid: True, node: 65, tag: div, level: 8" node_number="65"> <div class="valid" valid="valid" title="valid: True, node: 66, tag: div, level: 9" node_number="66"> <h6 class="valid" valid="valid" title="valid: True, node: 67, tag: h6, level: 10" node_number="67">Trending Terms:</h6> <ul class="valid" valid="valid" title="valid: True, node: 68, tag: ul, level: 10" node_number="68"> <li class="valid" valid="valid" title="valid: True, node: 69, tag: li, level: 11" node_number="69"> <a class="valid" valid="valid" title="valid: True, node: 70, tag: a, level: 12" node_number="70">covid-19</a> </li> <li class="valid" valid="valid" title="valid: True, node: 71, tag: li, level: 11" node_number="71"> <a class="valid" valid="valid" title="valid: True, node: 72, tag: a, level: 12" node_number="72">climate</a> </li> <li class="valid" valid="valid" title="valid: True, node: 73, tag: li, level: 11" node_number="73"> <a class="valid" valid="valid" title="valid: True, node: 74, tag: a, level: 12" node_number="74">science policy</a> </li> <li class="valid" valid="valid" title="valid: True, node: 75, tag: li, level: 11" node_number="75"> <a class="valid" valid="valid" title="valid: True, node: 76, tag: a, level: 12" node_number="76">genome editing</a> </li> <li class="valid" valid="valid" title="valid: True, node: 77, tag: li, level: 11" node_number="77"> <a class="valid" valid="valid" title="valid: True, node: 78, tag: a, level: 12" node_number="78">batteries</a> </li> </ul> </div> </div> </div> </div> </header><div class="valid" valid="valid" title="valid: True, node: 79, tag: div, level: 5" node_number="79"><div class="valid" valid="valid" title="valid: True, node: 80, tag: div, level: 6" node_number="80"><div class="valid" valid="valid" title="valid: True, node: 81, tag: div, level: 7" node_number="81"> <div class="valid" valid="valid" title="valid: True, node: 82, tag: div, level: 8" node_number="82"> <div class="valid" valid="valid" title="valid: True, node: 83, tag: div, level: 9" node_number="83"> <ul class="valid" valid="valid" title="valid: True, node: 84, tag: ul, level: 10" node_number="84"> <li class="valid" valid="valid" title="valid: True, node: 85, tag: li, level: 11" node_number="85"> <a class="valid" valid="valid" title="valid: True, node: 86, tag: a, level: 12" node_number="86">Current Issue</a> </li> <li class="valid" valid="valid" title="valid: True, node: 87, tag: li, level: 11" node_number="87"> <a class="valid" valid="valid" title="valid: True, node: 88, tag: a, level: 12" node_number="88">First release papers</a> </li> <li class="valid" valid="valid" title="valid: True, node: 89, tag: li, level: 11" node_number="89"> <a class="valid" valid="valid" title="valid: True, node: 90, tag: a, level: 12" node_number="90">Archive</a> </li> <li class="valid" valid="valid" title="valid: True, node: 91, tag: li, level: 11" node_number="91"> <div class="valid" valid="valid" title="valid: True, node: 92, tag: div, level: 12" node_number="92"> <a class="valid" valid="valid" title="valid: True, node: 93, tag: a, level: 13" node_number="93">About</a> <div class="valid" valid="valid" title="valid: True, node: 94, tag: div, level: 13" node_number="94"> <a class="valid" valid="valid" title="valid: True, node: 95, tag: a, level: 14" node_number="95">About Science Translational Medicine</a> <a class="valid" valid="valid" title="valid: True, node: 96, tag: a, level: 14" node_number="96">Mission Scope</a> <a class="valid" valid="valid" title="valid: True, node: 97, tag: a, level: 14" node_number="97">Editors and Advisory Boards</a> <a class="valid" valid="valid" title="valid: True, node: 98, tag: a, level: 14" node_number="98">Editorial Policies</a> <a class="valid" valid="valid" title="valid: True, node: 99, tag: a, level: 14" node_number="99">Information for Authors</a> <a class="valid" valid="valid" title="valid: True, node: 100, tag: a, level: 14" node_number="100">Information for Reviewers</a> <a class="valid" valid="valid" title="valid: True, node: 101, tag: a, level: 14" node_number="101">Journal Metrics</a> <a class="valid" valid="valid" title="valid: True, node: 102, tag: a, level: 14" node_number="102">Staff</a> <a class="valid" valid="valid" title="valid: True, node: 103, tag: a, level: 14" node_number="103">Contact Us</a> <a class="valid" valid="valid" title="valid: True, node: 104, tag: a, level: 14" node_number="104">Subscribe</a> <a class="valid" valid="valid" title="valid: True, node: 105, tag: a, level: 14" node_number="105">Free Sample Articles</a> </div> </div> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 106, tag: div, level: 9" node_number="106"> <ul class="valid" valid="valid" title="valid: True, node: 107, tag: ul, level: 10" node_number="107"> <li class="valid" valid="valid" title="valid: True, node: 108, tag: li, level: 11" node_number="108"> <a class="valid" valid="valid" title="valid: True, node: 109, tag: a, level: 12" node_number="109">Submit manuscript</a> </li> <li class="valid" valid="valid" title="valid: True, node: 110, tag: li, level: 11" node_number="110"> <div class="valid" valid="valid" title="valid: True, node: 111, tag: div, level: 12" node_number="111"> <a class="valid" valid="valid" title="valid: True, node: 112, tag: a, level: 13" node_number="112">More</a> </div> </li> </ul> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 113, tag: a, level: 8" node_number="113">GET OUR E-ALERTS</a> </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 114, tag: main, level: 5" node_number="114"> <div class="valid" valid="valid" title="valid: True, node: 115, tag: div, level: 6" node_number="115"><div class="valid" valid="valid" title="valid: True, node: 116, tag: div, level: 7" node_number="116"><div class="valid" valid="valid" title="valid: True, node: 117, tag: div, level: 8" node_number="117"><div class="valid" valid="valid" title="valid: True, node: 118, tag: div, level: 9" node_number="118"><div class="valid" valid="valid" title="valid: True, node: 119, tag: div, level: 10" node_number="119"> <div class="valid" valid="valid" title="valid: True, node: 120, tag: div, level: 11" node_number="120"><a class="valid" valid="valid" title="valid: True, node: 121, tag: a, level: 12" node_number="121">Home</a><a class="valid" valid="valid" title="valid: True, node: 122, tag: a, level: 12" node_number="122">Science Translational Medicine</a><a class="valid" valid="valid" title="valid: True, node: 123, tag: a, level: 12" node_number="123">First Release</a>A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</div><div class="valid" valid="valid" title="valid: True, node: 124, tag: div, level: 11" node_number="124">Back To First Release</div> </div> <article class="valid" valid="valid" title="valid: True, node: 125, tag: article, level: 10" node_number="125"><section class="valid" valid="valid" title="valid: True, node: 126, tag: section, level: 11" node_number="126"><header class="valid" valid="valid" title="valid: True, node: 127, tag: header, level: 12" node_number="127"><div class="valid" valid="valid" title="valid: True, node: 128, tag: div, level: 13" node_number="128"><div class="valid" valid="valid" title="valid: True, node: 129, tag: div, level: 14" node_number="129"><div title="valid: False, node: 130, tag: div, level: 15" node_number="130"><div title="valid: False, node: 131, tag: div, level: 16" node_number="131">OPEN ACCESS</div><div title="valid: False, node: 132, tag: div, level: 16" node_number="132">Research Article</div><div title="valid: False, node: 133, tag: div, level: 16" node_number="133">CORONAVIRUS</div></div><div title="valid: False, node: 134, tag: div, level: 15" node_number="134"><div title="valid: False, node: 135, tag: div, level: 16" node_number="135"> <div title="valid: False, node: 136, tag: div, level: 17" node_number="136">Share on</div> </div></div></div><h1 class="valid" valid="valid" title="valid: True, node: 137, tag: h1, level: 14" node_number="137">A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates</h1><div class="valid" valid="valid" title="valid: True, node: 138, tag: div, level: 14" node_number="138">M. Gordon Joyce [email&#160;protected], Hannah A. D. King, Ines Elakhal-Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, Caroline Subra, &#8230; Show All &#8230; , Rita E. Chen, Paul V. Thomas, Wei-Hung Chen, Rajeshwer S. Sankhala, Agnes Hajduczki, Elizabeth J. Martinez, Caroline E. Peterson, William C. Chang, Misook Choe, Clayton Smith, Parker J. Lee, Jarrett A. Headley, Mekdi G. Taddese, Hanne A. Elyard, Anthony Cook, Alexander Anderson, Kathryn McGuckin Wuertz, Ming Dong, Isabella Swafford, James Brett Case, Jeffrey R. Currier, Kerri G. Lal, Sebastian Molnar, Manoj S. Nair, Vincent Dussupt, Sharon P. Daye, Xiankun Zeng, Erica K. Barkei, Hilary M. Staples, Kendra Alfson, Ricardo Carrion, Shelly J. Krebs, Dominic Paquin-Proulx, Nicos Karasavva, Victoria R. Polonis, Linda L. Jagodzinski, Mihret F. Amare, Sandhya Vasan, Paul T. Scott, Yaoxing Huang, David D. Ho, Natalia de Val, Michael S. Diamond, Mark G. Lewis, Mangala Rao, Gary R. Matyas, Gregory D. Gromowski, Sheila A. Peel, Nelson L. Michael, Diane L. Bolton, and Kayvon Modjarrad [email&#160;protected] Show Fewer</div><div class="valid" valid="valid" title="valid: True, node: 139, tag: div, level: 14" node_number="139">Science Translational Medicine &#8226; 16 Dec 2021 &#8226; First Release &#8226; DOI: 10.1126/scitranslmed.abi5735</div><div class="valid" valid="valid" title="valid: True, node: 140, tag: div, level: 14" node_number="140"><div title="valid: False, node: 141, tag: div, level: 15" node_number="141"> <div title="valid: False, node: 142, tag: div, level: 16" node_number="142"> <a title="valid: False, node: 143, tag: a, level: 17" node_number="143"><div title="valid: False, node: 144, tag: div, level: 18" node_number="144"><div title="valid: False, node: 145, tag: div, level: 19" node_number="145"><h6 title="valid: False, node: 146, tag: h6, level: 20" node_number="146">PREVIOUS ARTICLE</h6><div title="valid: False, node: 147, tag: div, level: 20" node_number="147">Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity</div></div></div>Previous</a><a title="valid: False, node: 148, tag: a, level: 17" node_number="148"><div title="valid: False, node: 149, tag: div, level: 18" node_number="149"><div title="valid: False, node: 150, tag: div, level: 19" node_number="150"><h6 title="valid: False, node: 151, tag: h6, level: 20" node_number="151">NEXT ARTICLE</h6><div title="valid: False, node: 152, tag: div, level: 20" node_number="152">Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals</div></div></div>Next</a> </div> </div></div></div></header><div class="valid" valid="valid" title="valid: True, node: 153, tag: div, level: 12" node_number="153"><div class="valid" valid="valid" title="valid: True, node: 154, tag: div, level: 13" node_number="154"><section class="valid" valid="valid" title="valid: True, node: 155, tag: section, level: 14" node_number="155"><h2 title="valid: False, node: 156, tag: h2, level: 15" node_number="156">Abstract</h2><div title="valid: False, node: 157, tag: div, level: 15" node_number="157">The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019 (COVID-19). We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50 &#956;g) SpFN vaccine, given twice 28 days apart, induced a Th1-biased CD4 T cell helper response and elicited neutralizing antibodies against SARS-CoV-2 wild-type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates following high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates supports the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.</div></section></div></div></section><section class="valid" valid="valid" title="valid: True, node: 158, tag: section, level: 11" node_number="158"><div class="valid" valid="valid" title="valid: True, node: 159, tag: div, level: 12" node_number="159"><section class="valid" valid="valid" title="valid: True, node: 160, tag: section, level: 13" node_number="160"><h2 class="valid" valid="valid" title="valid: True, node: 161, tag: h2, level: 14" node_number="161">INTRODUCTION</h2><div class="valid" valid="valid" title="valid: True, node: 162, tag: div, level: 14" node_number="162">The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reached a milestone with the emergency use authorization, approval, and increasing availability of efficacious vaccines (<a title="valid: False, node: 163, tag: a, level: 15" node_number="163"><i title="valid: False, node: 164, tag: i, level: 16" node_number="164">1</i></a>). Successes in rapid coronavirus vaccine development, however, have been tempered by the rise of viral variants of concern (VOCs) (<a title="valid: False, node: 165, tag: a, level: 15" node_number="165"><i title="valid: False, node: 166, tag: i, level: 16" node_number="166">2</i></a>). The accelerating frequency with which variants are emerging raises the specter that host selective pressures may drive the evolution of mutants to escape vaccine-elicited immunity (<a title="valid: False, node: 167, tag: a, level: 15" node_number="167"><i title="valid: False, node: 168, tag: i, level: 16" node_number="168">3</i></a>). This concern, coupled with stringent cold-chain requirements for product stability and high unit costs for some vaccine platforms (<a title="valid: False, node: 169, tag: a, level: 15" node_number="169"><i title="valid: False, node: 170, tag: i, level: 16" node_number="170">4</i></a>), justifies the continued development of cost-effective, thermo-stable vaccines that match currently authorized and approved vaccines in safety and efficacy, and are also effective against a wide range of circulating variants and evolving strains, as well as species that may arise from zoonotic reservoirs in the future.</div><div class="valid" valid="valid" title="valid: True, node: 171, tag: div, level: 14" node_number="171">Self-assembling protein nanoparticle vaccines offer the advantage of multivalent antigen presentation, a property previously shown to augment immunogenicity over monovalent immunogens (<a title="valid: False, node: 172, tag: a, level: 15" node_number="172"><i title="valid: False, node: 173, tag: i, level: 16" node_number="173">5</i></a>&#8211;<a title="valid: False, node: 174, tag: a, level: 15" node_number="174"><i title="valid: False, node: 175, tag: i, level: 16" node_number="175">7</i></a>). Ferritin is a naturally occurring, ubiquitous, iron-carrying protein that self-oligomerizes into a 24-unit spherical particle (<a title="valid: False, node: 176, tag: a, level: 15" node_number="176"><i title="valid: False, node: 177, tag: i, level: 16" node_number="177">8</i></a>). The three-fold axis symmetry of the resulting polymer makes it conducive to conjugation and antigen display of trimeric glycoproteins, such as SARS-CoV-2 spike protein. Ferritin has been evaluated as a vaccine platform for several pathogens (<a title="valid: False, node: 178, tag: a, level: 15" node_number="178"><i title="valid: False, node: 179, tag: i, level: 16" node_number="179">9</i></a>&#8211;<a title="valid: False, node: 180, tag: a, level: 15" node_number="180"><i title="valid: False, node: 181, tag: i, level: 16" node_number="181">11</i></a>), most notably influenza, for which it has demonstrated immune potency and breadth (<a title="valid: False, node: 182, tag: a, level: 15" node_number="182"><i title="valid: False, node: 183, tag: i, level: 16" node_number="183">12</i></a>, <a title="valid: False, node: 184, tag: a, level: 15" node_number="184"><i title="valid: False, node: 185, tag: i, level: 16" node_number="185">13</i></a>). As such, ferritin vaccines have advanced to phase 1 clinical trials as a strategy to target multiple influenza strains (<a title="valid: False, node: 186, tag: a, level: 15" node_number="186"><i title="valid: False, node: 187, tag: i, level: 16" node_number="187">14</i></a>, <a title="valid: False, node: 188, tag: a, level: 15" node_number="188"><i title="valid: False, node: 189, tag: i, level: 16" node_number="189">15</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 190, tag: div, level: 14" node_number="190">The prefusion-stabilized form of the spike protein is the basis for most major SARS-CoV-2 vaccine candidates (<a title="valid: False, node: 191, tag: a, level: 15" node_number="191"><i title="valid: False, node: 192, tag: i, level: 16" node_number="192">16</i></a>, <a title="valid: False, node: 193, tag: a, level: 15" node_number="193"><i title="valid: False, node: 194, tag: i, level: 16" node_number="194">17</i></a>). Although a correlate of protection from COVID-19 has not been conclusively defined, there is mounting evidence that neutralizing, and some fraction of non-neutralizing, antibodies against spike protein are necessary, if not sufficient, to confer protective immunity (<a title="valid: False, node: 195, tag: a, level: 15" node_number="195"><i title="valid: False, node: 196, tag: i, level: 16" node_number="196">18</i></a>, <a title="valid: False, node: 197, tag: a, level: 15" node_number="197"><i title="valid: False, node: 198, tag: i, level: 16" node_number="198">19</i></a>). The most potent neutralizing antibodies are directed against the spike protein receptor-binding domain (RBD), which mediates attachment to the primary host cell receptor, angiotensin converting enzyme (ACE2). Our prior assessment of a SARS-CoV-2 spike protein ferritin nanoparticle (SpFN) vaccine candidate, co-formulated with a liposomal adjuvant, has demonstrated potent immunogenicity and protection against SARS-CoV-2 infection in mouse models (<a title="valid: False, node: 199, tag: a, level: 15" node_number="199"><i title="valid: False, node: 200, tag: i, level: 16" node_number="200">20</i></a>). These data have provided a basis for evaluating SpFN immunogenicity and efficacy against viral replication and pathology in the airways and lungs of nonhuman primates (NHP), a standard model for preclinical evaluation of SARS-CoV-2 vaccines (<a title="valid: False, node: 201, tag: a, level: 15" node_number="201"><i title="valid: False, node: 202, tag: i, level: 16" node_number="202">21</i></a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 203, tag: section, level: 13" node_number="203"><h2 class="valid" valid="valid" title="valid: True, node: 204, tag: h2, level: 14" node_number="204">RESULTS</h2><section class="valid" valid="valid" title="valid: True, node: 205, tag: section, level: 14" node_number="205"><h3 title="valid: False, node: 206, tag: h3, level: 15" node_number="206">A SARS-CoV-2 nanoparticle vaccine was designed and administered to NHPs.</h3><div title="valid: False, node: 207, tag: div, level: 15" node_number="207">The spike ferritin nanoparticle (SpFN) vaccine was designed as a ferritin-fusion recombinant protein for expression as a nanoparticle, and has been described in detail previously (<a title="valid: False, node: 208, tag: a, level: 16" node_number="208"><i title="valid: False, node: 209, tag: i, level: 17" node_number="209">20</i></a>). Briefly, the spike protein sequence was derived from the Wuhan-Hu-1 genome sequence (GenBank accession number: MN908947.3). The spike protein ectodomain was modified to introduce two proline residues (K986P, V987P) and removal of the furin cleavage site (RRAS to GSAS), as previously described (<a title="valid: False, node: 210, tag: a, level: 16" node_number="210"><i title="valid: False, node: 211, tag: i, level: 17" node_number="211">16</i></a>). To stabilize spike protein trimer formation on the ferritin molecule, the heptad repeat between stem hinge 1 and 2 region (residues 1140 &#8211; 1161) was mutated to increase the coiled coil interactions. An adjuvant, Army Liposome Formulation containing QS21 (ALFQ), was mixed with the SpFN vaccine at room temperature and administered to animals within four hours of mixing. Briefly, ALFQ is a liposome formulation comprising saturated phospholipids, dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG); cholesterol, and two adjuvants, synthetic monophosphoryl lipid A (3D- PHAD) (200 &#956;g/dose) and QS-21 (100 &#956;g/dose) in a molar ratio of 9:1:12.2:0.114:0.044 (<a title="valid: False, node: 212, tag: a, level: 16" node_number="212"><i title="valid: False, node: 213, tag: i, level: 17" node_number="213">22</i></a>). QS-21 is a triterpenoid glycoside saponin derived from the bark of the <i title="valid: False, node: 214, tag: i, level: 16" node_number="214">Quillaja saponaria</i> (soap bark) tree, found in Chile. QS-21 binds irreversibly to cholesterol in the liposomes and abrogates the toxicity seen with free QS-21 (<a title="valid: False, node: 215, tag: a, level: 16" node_number="215"><i title="valid: False, node: 216, tag: i, level: 17" node_number="216">23</i></a>).</div><div title="valid: False, node: 217, tag: div, level: 15" node_number="217">In this study, 32 male and female specific-pathogen-free, research-na&#239;ve, Chinese-origin rhesus macaques (age 3 to 7 years) were distributed on the basis of age, weight and sex into 4 cohorts of 8 animals (table S1). Animals were vaccinated intramuscularly with either 50 or 5 &#956;g of SpFN formulated with ALFQ or 1 ml of phosphate buffered saline (PBS) in the anterior proximal quadriceps muscle. Animals were vaccinated on alternating sides with each dose in the series. Immunizations were administered twice, 4 weeks apart, or once, 4 weeks prior to challenge (fig. S1). Animals were challenged with 1x10<sup title="valid: False, node: 218, tag: sup, level: 16" node_number="218">6</sup> 50% tissue culture infective dose (TCID<sub title="valid: False, node: 219, tag: sub, level: 16" node_number="219">50</sub>) of SARS-CoV-2 (SARS-Related Coronavirus 2, Isolate USA-WA1/2020) administered simultaneously by the intratracheal (1.0 ml) and intranasal (0.5 ml per nostril) routes.</div></section><section class="valid" valid="valid" title="valid: True, node: 220, tag: section, level: 14" node_number="220"><h3 title="valid: False, node: 221, tag: h3, level: 15" node_number="221">SpFN vaccination elicits neutralizing antibody responses in NHPs.</h3><div title="valid: False, node: 222, tag: div, level: 15" node_number="222">We measured longitudinal antibody responses in animals, after each vaccination and after viral challenge. Total binding to SARS-CoV-2 prefusion stabilized spike protein (S-2P) (<a title="valid: False, node: 223, tag: a, level: 16" node_number="223"><i title="valid: False, node: 224, tag: i, level: 17" node_number="224">16</i></a>) increased from baseline to an area under the curve (AUC) of 679,213 and 1,646,288 at 4 weeks after two vaccinations with 5 and 50 &#956;g of SpFN, respectively (Fig. 1A). Vaccination with a single 50 &#956;g dose resulted in a 4-week AUC of 621,605. Binding responses were unchanged in vaccinated groups after viral challenge; in contrast, unvaccinated controls had a 200-fold rise (Fig. 1A). Neutralization was tested using spike protein pseudotyped human immunodeficiency virus (HIV). Two-doses of 5 &#956;g or 50 &#956;g SpFN elicited reciprocal 50% inhibitory dilution (ID<sub title="valid: False, node: 225, tag: sub, level: 16" node_number="225">50</sub>) pseudovirus neutralizing antibody geometric mean titers (GMT) of 22,405 and 52,773, respectively, two weeks after second vaccination, and plateaued at 12,171 and 22,527, two weeks later (<a title="valid: False, node: 226, tag: a, level: 16" node_number="226">Fig. 1B</a>). Administration of a single dose of 50 &#956;g SpFN elicited a peak GMT of 4,063. Authentic virus neutralization activity mirrored group differences seen in the pseudovirus assay, but at slightly lower values (<a title="valid: False, node: 227, tag: a, level: 16" node_number="227">Fig. 1C</a>).</div><div title="valid: False, node: 228, tag: div, level: 15" node_number="228">We performed functional assessments of binding antibody responses by measuring the ability of serum samples to inhibit binding of RBD to the ACE2 receptor. Binding inhibition in the 5 &#956;g and 50 &#956;g vaccinated animals exceeded that among unvaccinated controls by a factor of 224 and 998, respectively (<a title="valid: False, node: 229, tag: a, level: 16" node_number="229">Fig. 1D</a>). ACE2 competition in the single 50 &#956;g dose group was 291 times higher than controls. We compared neutralizing antibody responses elicited by the vaccine against a panel of convalescent plasma samples with the same pseudovirus neutralization assay. We found that two doses of either SpFN dose elicited neutralizing activity that was an order of magnitude higher than that of the convalescent serum samples (p&lt;0.01, <a title="valid: False, node: 230, tag: a, level: 16" node_number="230">Fig. 1E</a>).</div><div title="valid: False, node: 231, tag: div, level: 15" node_number="231">We used orthogonal approaches to assess binding antibody specificities to the spike S1 subunit domains. RBD and S-2P binding recapitulated results of the ACE2 binding inhibition assay (fig. S2). Serum binding to the N-terminal domain (NTD), which may be a marker of additional protection through both neutralizing activity and non-neutralizing effector functions (<a title="valid: False, node: 232, tag: a, level: 16" node_number="232"><i title="valid: False, node: 233, tag: i, level: 17" node_number="233">24</i></a>), were 500-fold higher compared to baseline, across vaccine groups (fig. S3). We assessed the strength of RBD binding by biolayer interferometry, finding an increasing antibody on-rate association response throughout follow-up (fig. S4). Given the potential importance of auxiliary antibody functions for protection (<a title="valid: False, node: 234, tag: a, level: 16" node_number="234"><i title="valid: False, node: 235, tag: i, level: 17" node_number="235">25</i></a>, <a title="valid: False, node: 236, tag: a, level: 16" node_number="236"><i title="valid: False, node: 237, tag: i, level: 17" node_number="237">26</i></a>), we assessed a suite of Fc-mediated antibody effector functions, including opsonization, antibody-dependent complement deposition (ADCD), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP) and trogocytosis (a measure of antigen transfer) (<a title="valid: False, node: 238, tag: a, level: 16" node_number="238"><i title="valid: False, node: 239, tag: i, level: 17" node_number="239">27</i></a>). All activity peaked at week 6 and was highest in the two-dose 50 &#956;g SpFN group (fig. S5).</div></section><section class="valid" valid="valid" title="valid: True, node: 240, tag: section, level: 14" node_number="240"><h3 title="valid: False, node: 241, tag: h3, level: 15" node_number="241">SpFN vaccination elicits spike protein-specific T cell responses in NHPs.</h3><div title="valid: False, node: 242, tag: div, level: 15" node_number="242">Helper CD4 T cell (Th) responses are important for respiratory virus vaccine development, given the theoretical concern and precedent for vaccine-associated enhanced respiratory disease and its association with a Th2-biased response (<a title="valid: False, node: 243, tag: a, level: 16" node_number="243"><i title="valid: False, node: 244, tag: i, level: 17" node_number="244">28</i></a>). We focused our assessment of cell-mediated immunity on canonical cytokines expressed by Th1 (interferon (IFN)-&#947;, tumor necrosis factor (TNF)-&#945;, interleukin (IL)-2) and Th2 (IL-4, IL-13) CD4 T cells. Robust Th1 responses were observed 4 weeks after second vaccination in all vaccinated groups, except one animal in the 50 &#956;g single-dose group (<a title="valid: False, node: 245, tag: a, level: 16" node_number="245">Fig. 2A</a>). Th1 responses were polyfunctional and variable but consistently high at week 8, ranging from 0.2% to 17%. Th2 and CD8 T cell responses were minimal or undetectable (<a title="valid: False, node: 246, tag: a, level: 16" node_number="246">Fig. 2B</a>, fig. S6).</div><div title="valid: False, node: 247, tag: div, level: 15" node_number="247">We interrogated key indicators of helper responses that support humoral immunity, such as IL-21, a cytokine secreted by follicular helper CD4 T cells (Tfh) that regulate the evolution of memory B cells (<a title="valid: False, node: 248, tag: a, level: 16" node_number="248"><i title="valid: False, node: 249, tag: i, level: 17" node_number="249">29</i></a>). Five of eight animals dosed twice with 50 &#956;g of SpFN had detectable IL-21 responses, as did seven of eight animals given 5 &#956;g of the vaccine (<a title="valid: False, node: 250, tag: a, level: 16" node_number="250">Fig. 2C</a>). We also examined expression of CD40 ligand (CD40L), a broad T cell activation marker, expressed on the surfaces of CD4 T cells that promotes B cell maturation through antibody isotype switching (<a title="valid: False, node: 251, tag: a, level: 16" node_number="251"><i title="valid: False, node: 252, tag: i, level: 17" node_number="252">29</i></a>). All but one animal receiving two-doses of SpFN had detectable CD40L responses (<a title="valid: False, node: 253, tag: a, level: 16" node_number="253">Fig. 2D</a>), indicating an engaged memory response.</div></section><section class="valid" valid="valid" title="valid: True, node: 254, tag: section, level: 14" node_number="254"><h3 title="valid: False, node: 255, tag: h3, level: 15" node_number="255">SpFN vaccination reduces viral load after respiratory SARS-CoV-2 challenge.</h3><div title="valid: False, node: 256, tag: div, level: 15" node_number="256">Rhesus macaques generally exhibit mild disease that does not fully recapitulate the severe pneumonia observed in many people with COVID-19 (<a title="valid: False, node: 257, tag: a, level: 16" node_number="257"><i title="valid: False, node: 258, tag: i, level: 17" node_number="258">21</i></a>). Protective efficacy, therefore, was assessed virologically and pathologically. The primary virologic endpoint was based on the measurement of subgenomic mRNA (sgmRNA) for the envelope (E) gene region of the virus, an indicator of viral replication, in the upper (nasopharyngeal (NP) swabs, saliva) and lower airways (bronchoalveolar lavage (BAL) fluid). sgmRNA concentrations (log<sub title="valid: False, node: 259, tag: sub, level: 16" node_number="259">10</sub> copies/ml) of vaccinated animals were compared to controls. On the second day after simultaneous respiratory mucosal challenge by the intratracheal and intranasal routes, sgmRNA concentrations in the BAL fluid of control animals peaked at a mean of 10<sup title="valid: False, node: 260, tag: sup, level: 16" node_number="260">6</sup> copies/ml (<a title="valid: False, node: 261, tag: a, level: 16" node_number="261">Fig. 3A</a>). In contrast, none of the eight animals that received two doses of 50 &#956;g SpFN had detectable sgmRNA at day 2. By day 4 sgmRNA was undetectable in the BAL fluid of all animals of the 5 &#956;g vaccine group and all but one animal that received single dose SpFN.</div><div title="valid: False, node: 262, tag: div, level: 15" node_number="262">Whereas sgmRNA concentrations reached a mean of 10<sup title="valid: False, node: 263, tag: sup, level: 16" node_number="263">7</sup> copies/ml in the NP swabs of control animals at day two after challenge, sgmRNA was undetectable in five of eight animals that received two doses of 50 &#956;g SpFN (<a title="valid: False, node: 264, tag: a, level: 16" node_number="264">Fig. 3B</a>). All animals in this group had undetectable virus from day four onward, whereas virus persisted in the control animals through day 10. Five of eight controls had high concentrations of sgmRNA in saliva on day two post-challenge, whereas virus was undetectable in all animals of the two-dose 50 &#956;g SpFN group (<a title="valid: False, node: 265, tag: a, level: 16" node_number="265">Fig. 3C</a>). Total viral load in the BAL fluid, NP swabs and saliva were similar to those observed for sgmRNA (fig. S7).</div></section><section class="valid" valid="valid" title="valid: True, node: 266, tag: section, level: 14" node_number="266"><h3 title="valid: False, node: 267, tag: h3, level: 15" node_number="267">SpFN vaccination provides protection from lung pathology after SARS-CoV-2 challenge.</h3><div title="valid: False, node: 268, tag: div, level: 15" node_number="268">One section of lung tissue from each lung lobe (six sections per animal) was fixed and stained at one-to-two weeks after virus challenge and evaluated under light microscopy and by immunohistochemistry. Unvaccinated control animals developed histopathologic evidence of multifocal, moderate interstitial pneumonia at 7 days after challenge (<a title="valid: False, node: 269, tag: a, level: 16" node_number="269">Fig. 4A</a>). The pneumonia was characterized by type II pneumocyte hyperplasia, alveolar septal thickening, edema and necrotic debris, pulmonary macrophage infiltration and vasculitis of smaller caliber blood vessels. None of the vaccinated animals, however, had evidence of interstitial pneumonia (<a title="valid: False, node: 270, tag: a, level: 16" node_number="270">Fig. 4B to D</a>). Immunohistochemistry revealed viral antigen in alveolar pneumocytes and pulmonary macrophages in at least one lung section of every control animal (<a title="valid: False, node: 271, tag: a, level: 16" node_number="271">Fig. 4E</a>). In contrast, no viral antigen was detected in any of the lung sections taken from vaccinated animals (<a title="valid: False, node: 272, tag: a, level: 16" node_number="272">Fig. 4F to H</a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 273, tag: section, level: 14" node_number="273"><h3 title="valid: False, node: 274, tag: h3, level: 15" node_number="274">SpFN elicits broadly neutralizing antibodies that bind to variants of concern.</h3><div title="valid: False, node: 275, tag: div, level: 15" node_number="275">We assessed the serum antibody responses elicited by the SpFN vaccine against four circulating SARS-CoV-2 VOCs: B.1.1.7 (alpha variant), B.1.351 (beta variant), P.1 (gamma variant) and B.1.617.2 (delta variant). Serum binding assessment by biolayer interferometry to the first three variant forms of SARS-CoV-2 RBD showed no change in binding to B.1.1.7 (N501Y mutation) or B.1.351 (K417N, E484K, N501Y mutations) in the two-dose 50 &#956;g SpFN group (fig. S8). Serum binding assessment by biolayer interferometry to these same variant forms of SARS-CoV-2 RBD showed no change in binding to B.1.1.7 (N501Y mutation), but a 25% reduction in binding to B.1.351 (K417N, E484K, N501Y mutations) in the two-dose 50 &#956;g SpFN group (fig. S8). We next assessed the serum neutralizing activity elicited by the SpFN vaccine against all four VOCs, including B.1.617.2 (&#948; variant). Serum samples from all vaccinated NHPs elicited potent neutralizing activity against all variants in two orthogonal virus neutralization assays. Neutralization capacity of the authentic B.1.1.7 virus variant was high across all vaccine groups (<a title="valid: False, node: 276, tag: a, level: 16" node_number="276">Fig. 5A to C</a>) and was significantly (p=0.02) higher than neutralization of wild-type WA-1 in the two-dose 50 &#956;g group (<a title="valid: False, node: 277, tag: a, level: 16" node_number="277">Fig. 5A</a>). Neutralizing activity against the authentic B.1.351, P.1 and B.1.617.2 virus variants, however, was diminished slightly (<a title="valid: False, node: 278, tag: a, level: 16" node_number="278">Fig. 5A to C</a>), except in the two-dose 50 &#956;g group (<a title="valid: False, node: 279, tag: a, level: 16" node_number="279">Fig. 5A</a>). Neutralizing activity against the B.1.1.7 in an orthogonal pseudovirus assay revealed equivalent ID<sub title="valid: False, node: 280, tag: sub, level: 16" node_number="280">50</sub> GMTs to the WA-1 wild-type pseudovirus (<a title="valid: False, node: 281, tag: a, level: 16" node_number="281">Fig. 5D to F</a>). Reductions in neutralizing activity against the B.1.351 pseudovirus, however, were slightly more pronounced in the pseudovirus assay as compared to the authentic virus assay. For example, the reciprocal ID<sub title="valid: False, node: 282, tag: sub, level: 16" node_number="282">50</sub> GMT dropped five-fold in the two-dose 50 &#956;g group, but remained high at a value 10,209 (<a title="valid: False, node: 283, tag: a, level: 16" node_number="283">Fig. 5D</a>). The absolute neutralizing antibody titers were generally elevated after two doses of vaccine, irrespective of the virus variant against which they were measured (<a title="valid: False, node: 284, tag: a, level: 16" node_number="284">Fig. 5G</a>).</div><div title="valid: False, node: 285, tag: div, level: 15" node_number="285">We expanded the assessment of the immunogenicity breadth to the interrogation of neutralizing and non-neutralizing antibody and cellular immune responses against SARS-CoV-1. Binding of vaccinee serum samples to SARS-CoV-1 RBD, as measured by biolayer interferometry, was absent in controls but was relatively potent in vaccinated animals, binding at half the strength of that observed to SARS-CoV-2 RBD (<a title="valid: False, node: 286, tag: a, level: 16" node_number="286">Fig. 6A</a>, fig. S3, S4). Antibody-dependent cellular phagocytotic activity also increased in all vaccine groups, reaching a score that was 100-fold higher than baseline or compared to unvaccinated controls when measured two-weeks after last 50 &#956;g SpFN vaccination (<a title="valid: False, node: 287, tag: a, level: 16" node_number="287">Fig. 6B</a>). Two vaccinations with high-dose SpFN also yielded plaque reduction neutralizing activity against authentic SARS-CoV-1 with a reciprocal ID<sub title="valid: False, node: 288, tag: sub, level: 16" node_number="288">50</sub> GMT of 390 that was significantly increased above background (p=0.01, <a title="valid: False, node: 289, tag: a, level: 16" node_number="289">Fig. 6C</a>). An orthogonal pseudovirus neutralization assay exhibited some background activity in PBS controls. We minimized this background by analyzing neutralization activity at a 90% inhibitory dilution (ID<sub title="valid: False, node: 290, tag: sub, level: 16" node_number="290">90</sub>) and found that two doses of 50 &#956;g SpFN induced a SARS-CoV-1 neutralizing antibody titer that was 6-fold higher (GMT 667) than controls (<a title="valid: False, node: 291, tag: a, level: 16" node_number="291">Fig. 6D</a>). CD4 T cell responses to SARS-CoV-1 spike protein peptides, though lower in absolute percentage than against SARS-CoV-2, were still robust and Th1-biased (<a title="valid: False, node: 292, tag: a, level: 16" node_number="292">Fig. 6E and F</a>). The CD8 T cell response, in contrast, was minimal (fig. S9). Overall, the immune response elicited by SpFN against SARS-CoV-1, though lower in magnitude, recapitulated the quality of response against SARS-CoV-2.</div></section></section><section class="valid" valid="valid" title="valid: True, node: 293, tag: section, level: 13" node_number="293"><h2 class="valid" valid="valid" title="valid: True, node: 294, tag: h2, level: 14" node_number="294">DISCUSSION</h2><div class="valid" valid="valid" title="valid: True, node: 295, tag: div, level: 14" node_number="295">The recent success in the rapid development of safe and efficacious SARS-CoV-2 vaccines has been tempered by the emergence of virus variants to which vaccine-induced immunity has shown diminished potency or efficacy (<a title="valid: False, node: 296, tag: a, level: 15" node_number="296"><i title="valid: False, node: 297, tag: i, level: 16" node_number="297">30</i></a>&#8211;<a title="valid: False, node: 298, tag: a, level: 15" node_number="298"><i title="valid: False, node: 299, tag: i, level: 16" node_number="299">33</i></a>). Thus, there remains a need for next-generation vaccines that target the broadening antigenic diversity of SARS-CoV-2 and related coronaviruses. The major vaccines that have progressed to human efficacy trials and have been granted either approval or emergency use authorization all present the SARS-CoV-2 spike protein that is based on the genetic sequence of the Wuhan-Hu-1 isolate. All of these vaccines have demonstrated protective efficacy in NHPs against respiratory mucosal challenge with the closely matched USA-WA1/2020 (<a title="valid: False, node: 300, tag: a, level: 15" node_number="300"><i title="valid: False, node: 301, tag: i, level: 16" node_number="301">25</i></a>, <a title="valid: False, node: 302, tag: a, level: 15" node_number="302"><i title="valid: False, node: 303, tag: i, level: 16" node_number="303">34</i></a>&#8211;<a title="valid: False, node: 304, tag: a, level: 15" node_number="304"><i title="valid: False, node: 305, tag: i, level: 16" node_number="305">38</i></a>). These earlier animal studies, however, did not evaluate the neutralization capacity of serum against other coronavirus species. In the current study we demonstrate that an adjuvanted recombinant nanoparticle vaccine, SpFN, elicited high titers of that antibodies neutralized SARS-CoV-2 and rapidly protected against SARS-CoV-2 infection. We also found that, compared to wild type virus, SpFN elicited serum virus neutralizing activity that was either higher or equivalent against four major VOCs (B.1.1.7, B.1.351, P.1, B.1.617.2) in an authentic virus neutralization assay and equivalent or mildly diminished against two VOCs in a pseudovirus neutralization assay (B.1.1.7, B.1.351). Finally, SpFN induced robust neutralizing activity against SARS-CoV-1, a separate species that has 26% and 36% sequence divergence in the spike protein and S1 subunit, respectively (<a title="valid: False, node: 306, tag: a, level: 15" node_number="306"><i title="valid: False, node: 307, tag: i, level: 16" node_number="307">39</i></a>), which is important for protection in animal models (<a title="valid: False, node: 308, tag: a, level: 15" node_number="308"><i title="valid: False, node: 309, tag: i, level: 16" node_number="309">40</i></a>, <a title="valid: False, node: 310, tag: a, level: 15" node_number="310"><i title="valid: False, node: 311, tag: i, level: 16" node_number="311">41</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 312, tag: div, level: 14" node_number="312">SARS-CoV-2 vaccine efficacy studies in NHPs generally compare elicited antibody responses to those from patients who have recovered from COVID-19. We found neutralizing activity in the two-dose 50 &#956;g SpFN group to be ten-fold higher than that in recovering patients. The lack of standardization across convalescent serum panels and absence of head-to-head comparisons of candidate vaccines makes it difficult to compare immunogenicity profiles. Direct comparisons come with a qualification that immunogenicity output assays have been in the process of harmonization. Bearing this caveat in mind, we found that SARS-CoV-2 antibody responses in animals vaccinated with high-dose SpFN were robust when set in the context of the entire vaccine landscape, to include genetic vaccines (<a title="valid: False, node: 313, tag: a, level: 15" node_number="313"><i title="valid: False, node: 314, tag: i, level: 16" node_number="314">34</i></a>, <a title="valid: False, node: 315, tag: a, level: 15" node_number="315"><i title="valid: False, node: 316, tag: i, level: 16" node_number="316">38</i></a>), recombinant virus vector vaccines (<a title="valid: False, node: 317, tag: a, level: 15" node_number="317"><i title="valid: False, node: 318, tag: i, level: 16" node_number="318">25</i></a>, <a title="valid: False, node: 319, tag: a, level: 15" node_number="319"><i title="valid: False, node: 320, tag: i, level: 16" node_number="320">37</i></a>), and adjuvanted protein subunit vaccines (<a title="valid: False, node: 321, tag: a, level: 15" node_number="321"><i title="valid: False, node: 322, tag: i, level: 16" node_number="322">35</i></a>). Although direct quantitative comparisons of NHP vaccine studies can be difficult to interpret, we have made attempts to mitigate differences in assay outputs by analyzing specimens with orthogonal assays harmonized to consensus platforms. Specifically, the pseudovirus neutralization assay we developed for our immunogenicity assessments demonstrated equivalence to platforms used for the assessment of other major vaccines through participation in the SARS-CoV-2 Neutralizing Assay Concordance Survey 1 coordinated by the External Quality Assurance Program Oversight Laboratory/Virology Quality Assurance Program at the Duke Human Vaccine Institute (<a title="valid: False, node: 323, tag: a, level: 15" node_number="323"><i title="valid: False, node: 324, tag: i, level: 16" node_number="324">42</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 325, tag: div, level: 14" node_number="325">Potent neutralizing antibody responses may offer advantages for both vaccine efficacy and durability. Thus far, neutralizing activity has been predictive of efficacy in human trials, as vaccines that generate lower antibody titers have diminished efficacy (<a title="valid: False, node: 326, tag: a, level: 15" node_number="326"><i title="valid: False, node: 327, tag: i, level: 16" node_number="327">43</i></a>). An open question remains, however, regarding the length of immunity conferred by SARS-CoV-2 vaccines. Among viral infections for which neutralizing antibodies are the primary correlate of protection, peak titers have been shown to be predictive of durability and may serve as one of several indicators of length of vaccine-elicited protective immunity (<a title="valid: False, node: 328, tag: a, level: 15" node_number="328"><i title="valid: False, node: 329, tag: i, level: 16" node_number="329">44</i></a>&#8211;<a title="valid: False, node: 330, tag: a, level: 15" node_number="330"><i title="valid: False, node: 331, tag: i, level: 16" node_number="331">46</i></a>). As such, SpFN may offer some measure of a durable immune response; though this will require empirical confirmation.</div><div class="valid" valid="valid" title="valid: True, node: 332, tag: div, level: 14" node_number="332">Overall, SpFN vaccination induced serum cross-neutralizing antibody responses. Additionally, we found serum binding to mutated SARS-CoV-2 RBD was either unaffected or mildly reduced. We also found serum binding to mutated SARS-CoV-2 RBD was either unaffected or mildly diminished. Other reports of nanoparticle vaccine approaches presenting RBD also have shown a breadth of neutralizing antibody responses against multiple sarbecoviruses (<a title="valid: False, node: 333, tag: a, level: 15" node_number="333"><i title="valid: False, node: 334, tag: i, level: 16" node_number="334">47</i></a>&#8211;<a title="valid: False, node: 335, tag: a, level: 15" node_number="335"><i title="valid: False, node: 336, tag: i, level: 16" node_number="336">49</i></a>). Similar to other studies, SpFN vaccination induces comprehensive binding and neutralizing antibody responses and a balanced cellular immune response against SARS-CoV-1. Although background neutralizing activity was high in one assay, neutralizing potency against SARS-CoV-1 was confirmed in an orthogonal virus neutralization assay. Still, we plan to test purified IgG from vaccine serum in both assays to control for the background activity at baseline and in controls.</div><div class="valid" valid="valid" title="valid: True, node: 337, tag: div, level: 14" node_number="337">We hypothesize that the breadth of immune response elicited by the SpFN vaccine may be the result of several factors. First, the quantity of the polyclonal antibody response may surpass a threshold that overcomes resistance to neutralization of antigenically distinct virus variants. Second, repetitive, ordered display of antigen on a self-assembling nanoparticle has been shown to drive an expanded germinal center reaction with resultant increases in B cell receptor mutation, affinity maturation and plasma cell differentiation (<a title="valid: False, node: 338, tag: a, level: 15" node_number="338"><i title="valid: False, node: 339, tag: i, level: 16" node_number="339">5</i></a>&#8211;<a title="valid: False, node: 340, tag: a, level: 15" node_number="340"><i title="valid: False, node: 341, tag: i, level: 16" node_number="341">7</i></a>). Lastly, the adjuvant, ALFQ, may drive some of the breadth through CD4 T cell activation (<a title="valid: False, node: 342, tag: a, level: 15" node_number="342"><i title="valid: False, node: 343, tag: i, level: 16" node_number="343">50</i></a>, <a title="valid: False, node: 344, tag: a, level: 15" node_number="344"><i title="valid: False, node: 345, tag: i, level: 16" node_number="345">51</i></a>), especially given the high Th1 response elicited by the co-formulation. ALFQ, as compared to aluminum hydroxide (Alhydrogel), previously has demonstrated superior immunogenicity when administered with SpFN to C57BL/6 and BALB/c mice (<a title="valid: False, node: 346, tag: a, level: 15" node_number="346"><i title="valid: False, node: 347, tag: i, level: 16" node_number="347">20</i></a>). As NHPs are a more predictive model with respect to adjuvant performance in humans, we are now conducting a follow-on adjuvant comparison study in NHPs to evaluate the impact of ALFQ on immunogenicity potency and breadth. Additionally, as NHPs do not exhibit the same degree of fidelity as Syrian golden hamsters in terms of developing severe COVID-19 disease (<a title="valid: False, node: 348, tag: a, level: 15" node_number="348"><i title="valid: False, node: 349, tag: i, level: 16" node_number="349">21</i></a>), we have also found SpFN to protect against VOCs in challenge experiments in the latter model (<a title="valid: False, node: 350, tag: a, level: 15" node_number="350"><i title="valid: False, node: 351, tag: i, level: 16" node_number="351">52</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 352, tag: div, level: 14" node_number="352">The interpretation of the results from this study is limited by several factors. First, we were able evaluate efficacy our vaccine candidate only against challenge with the Wuhan-Hu-1 strain of SARS-CoV-2. This is because VOCs were only beginning to emerge and circulate when this study was conceived and initiated. Our assessment of breadth of the immune response was, instead, evaluated by serum neutralizing activity against a panel of SARS-CoV-2 VOCs as well as SARS-CoV-1. Second, we cannot define, from the design and outputs of this study, the relative contributions of the immunogen and adjuvant of our vaccine formulation to the potency and breadth of immune response observed. Finally, we have yet to understand the role and repertoire of the humoral and cellular immune responses elicited by this SpFN. We are carrying out follow on studies examine the mechanisms of immunity conferred by our vaccine candidate.</div><div class="valid" valid="valid" title="valid: True, node: 353, tag: div, level: 14" node_number="353">The collective immune response elicited by SpFN translated into a robust and rapid reduction in replicating virus in the upper and lower airways of animals and resultant prevention of pulmonary pathology. It is notable that SpFN protected against a potent viral challenge, as replicating virus concentrations detected in the upper and lower airways of unvaccinated controls reached a mean of 10<sup title="valid: False, node: 354, tag: sup, level: 15" node_number="354">6</sup> to 10<sup title="valid: False, node: 355, tag: sup, level: 15" node_number="355">7</sup> copies/ml. Despite this higher challenge, SpFN still protected lower airway viral burden and disease as early as within one day of virus inoculation. The rapid elimination of replicating virus in the upper airways also lends evidence for potential near-sterilizing immunity, which again may have implications for preventing viral transmission. Altogether, these findings support the further development of SpFN, which has now moved to human evaluation in a phase 1 clinical trial (<a title="valid: False, node: 356, tag: a, level: 15" node_number="356"><i title="valid: False, node: 357, tag: i, level: 16" node_number="357">53</i></a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 358, tag: section, level: 13" node_number="358"><h2 class="valid" valid="valid" title="valid: True, node: 359, tag: h2, level: 14" node_number="359">MATERIALS AND METHODS</h2><div class="valid" valid="valid" title="valid: True, node: 360, tag: div, level: 14" node_number="360"><b title="valid: False, node: 361, tag: b, level: 15" node_number="361">Study design.</b> Thirty-two male and female specific-pathogen-free, research-na&#239;ve Chinese-origin rhesus macaques (age 3 to 7 years) were distributed&#8212;on the basis of age, weight, and sex&#8212;into 4 cohorts of 8 animals (table S1). Sample sizes were set based animal availability and prior experience with other nonhuman primate vaccination/challenge studies. Animals were assigned to groups without a specific randomization scheme; however, no outliers were skewed to any one group (table S1). Animals were vaccinated intramuscularly with either 50 or 5 &#956;g of SpFN, formulated with ALFQ, or 1 ml of PBS in the anterior proximal quadriceps muscle, on alternating sides with each dose in the series. Immunizations were administered twice, 4 weeks apart, or once, 4 weeks prior to challenge. Animals were challenged with virus stock obtained through Biodefense and Emerging Infections Research Resources Repository Resources (BEI Resources), National Institute of Allergy and Infectious Diseases, National Institutes of Health: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-53780 (Lot# 70038893). Virus was stored at -80&#176;C prior to use, thawed by hand and placed immediately on wet ice. Stock was diluted to 5x10<sup title="valid: False, node: 362, tag: sup, level: 15" node_number="362">5</sup> TCID<sub title="valid: False, node: 363, tag: sub, level: 15" node_number="363">50</sub> per ml in PBS and vortexed gently for 5 s prior to inoculation by combined intratracheal (1 mL) and intranasal routes (0.5 mL per nostril).</div><div class="valid" valid="valid" title="valid: True, node: 364, tag: div, level: 14" node_number="364">All procedures were carried out in accordance with institutional, local, state and national guidelines and laws governing animal research included in the Animal Welfare Act. Animal protocols and procedures were reviewed and approved by the Animal Care and Use Committee of both the US Army Medical Research and Development Command (USAMRDC, protocol 11355007.03) Animal Care and Use Review Office as well as the Institutional Animal Care and Use Committee of Bioqual, Inc. (protocol number 20-092), where nonhuman primates were housed for the duration of the study. USAMRDC and Bioqual, Inc. are both accredited by the Association for Assessment and Accreditation of Laboratory Animal Care and are in compliance with the Animal Welfare Act and Public Health Service Policy on Humane Care and Use of Laboratory Animals.</div><div class="valid" valid="valid" title="valid: True, node: 365, tag: div, level: 14" node_number="365"><b title="valid: False, node: 366, tag: b, level: 15" node_number="366">Vaccine and adjuvant design and production.</b> The spike ferritin nanoparticle (SpFN) vaccine immunogen was produced by linking <i title="valid: False, node: 367, tag: i, level: 15" node_number="367">Helicobacter pylori</i> ferritin to the C-terminal region of the pre-fusion stabilized ectodomain (residues 12-1158) of the SARS-CoV-2 spike protein in a genetic fusion. The immunogen was expressed, purified, and characterized as previously described (<a title="valid: False, node: 368, tag: a, level: 15" node_number="368"><i title="valid: False, node: 369, tag: i, level: 16" node_number="369">20</i></a>). Briefly, SpFN was derived from the Wuhan-Hu-1 strain genome sequence (GenBank MN9089473), synthesized by Genscript Inc, and subcloned into a modified cytomegalovirus promoter (CMVR) expression vector. Expi293F cells (Thermo Fisher Scientific) were transiently transfected with SpFN plasmid DNA using ExpiFectamine 293 transfection reagent (Thermo Fisher Scientific). Cells were grown in polycarbonate baffled shaker flasks at 34&#176;C and 8% CO<sub title="valid: False, node: 370, tag: sub, level: 15" node_number="370">2</sub> at 120 revolutions per minute (rpm). Cells were harvested 5 days post-transfection by centrifugation at 3,500 &#215; g for 30 min. Culture supernatants were filtered with a 0.22-&#956;m filter and stored at 4&#176;C prior to purification using GNA lectin affinity chromatography. Briefly, 25 mL GNA-lectin resin (VectorLabs) was used to purify SpFN from 1L of expression supernatant. GNA resin was equilibrated with 10 column volumes (CV) of PBS (pH 7.4) followed by supernatant loading twice at 4&#176;C. Unbound protein was removed by washing with 20 CV of PBS buffer. Bound protein was eluted with 250mM methyl-&#945;-D mannopyranoside in PBS buffer (pH 7.4). SpFN was further purified by size-exclusion chromatography using a 16/60 Superdex-200 purification column. Purification purity for all the proteins was assessed by SDS-PAGE. Endotoxin concentrations for SpFN was assessed (Endosafe nexgen-PTS, Charles River Laboratories) and 5% v/v glycerol was added prior to filter-sterilization with a 0.22-&#956;m filter, flash-freezing in liquid nitrogen and storage at -80&#176;C. SpFN antigenicity was assessed by Octet Biolayer Interferometry with a set of antibodies that included CR3022 (<a title="valid: False, node: 371, tag: a, level: 15" node_number="371"><i title="valid: False, node: 372, tag: i, level: 16" node_number="372">20</i></a>) and SR1-SR5 (potent neutralizing antibodies targeting the ACE2 binding site of the RBD; kindly provided by S. Rajan, P.M. McTamney, and M.T. Esser of Astra Zeneca). Size and consistency of the SpFN immunogen was determined by negative-stain electron microscopy. These measurements ensured lot-to-lot consistency of the SpFN immunogen.</div><div class="valid" valid="valid" title="valid: True, node: 373, tag: div, level: 14" node_number="373">The adjuvant, Army Liposomal Formulation with QS21 (ALFQ), was prepared as previously described (<a title="valid: False, node: 374, tag: a, level: 15" node_number="374"><i title="valid: False, node: 375, tag: i, level: 16" node_number="375">54</i></a>). Briefly, ALFQ is a unilamellar liposome that contains saturated phospholipids, cholesterol, monophosphoryl lipid A and the saponin, QS-21. It is comprised of dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), cholesterol (Chol), and synthetic monophosphoryl lipid A (3D-PHAD) (Avanti Polar Lipids) and QS-21 (Desert King). DMPC and Chol were dissolved in chloroform and DMPG and 3D-PHAD were dissolved in chloroform:methanol at a ratio of 9:1. The lipids were mixed in a molar ratio of 9:1:12.2:0.114 (DMPC:DMPG:Chol:3D-PHAD) and the solvent was removed by rotary evaporation. 3D-PHAD and QS-21 doses were 200 and 100 &#956;g, respectively. The lipids were suspended in Sorenson's PBS, pH 6.2, microfluidized to form small unilamellar vesicles (SUV) and filtered. QS-21 was solubilized in Sorenson's PBS, pH 6.2, filtered and added to the SUV to form ALFQ. The final lipid ratio was 9:1:12.2:0.114:0.044 (DMPC:DMPG:Chol:3D-PHAD:QS-21).</div><div class="valid" valid="valid" title="valid: True, node: 376, tag: div, level: 14" node_number="376">Immunogen was diluted in Dulbecco&#8217;s PBS (Lot#723188, Quality Biological) to 0.1 mg/ml or 0.01 mg/ml and mixed 1:1 with 2X ALFQ liposomes on a tilted slow-speed roller at room temperature for 10 min, followed by incubation at 4&#176;C for 50 min. All reagents were equilibrated to room temperature before use and immunizations were performed within 4 hours of vaccine formulation. Each vaccine comprised a 1.0 ml solution of SpFN formulated with ALFQ.</div><div class="valid" valid="valid" title="valid: True, node: 377, tag: div, level: 14" node_number="377"><b title="valid: False, node: 378, tag: b, level: 15" node_number="378">Convalescent Plasma Samples.</b> A panel of 41 human convalescent-phase plasma samples were obtained from BEI Resources Repository (n=30), StemExpress (n=7) and a Walter Reed Army Institute of Research institutional review board-approved leukapheresis protocol (#1386H) (n=4) for which written informed consent was provided by participants. Samples were collected from males (n=20) and females (n=21) ranging in age from 31 to 71 years. Individuals donated plasma specimens approximately four-to-eight weeks after laboratory-confirmed SARS-CoV-2 infection and had histories of asymptomatic-to-mild-to-moderate clinical presentation.</div><div class="valid" valid="valid" title="valid: True, node: 379, tag: div, level: 14" node_number="379"><b title="valid: False, node: 380, tag: b, level: 15" node_number="380">Binding antibody measurements.</b> SARS-CoV-2-specific binding IgG antibody responses were measured using MULTI-SPOT 96-well plates from Meso Scale Discovery (MSD). Multiplex wells were coated with spike (S), RBD and nucleocapsid (N) antigens at a concentration of 200-400 ng/ml and bovine serum antigen, which served as a negative control. Four-plex MULTISPOT plates were blocked with MSD Blocker A buffer for 1 hour at room temperature, shaking at 700 rpm. Plates were washed with buffer before the addition of reference standard and calibrator controls. Serum samples were diluted at 1:1,000 to 1:100,000 in diluent 100 buffer (provided with manufacturer kit), then added to each of four wells. Plates were incubated with shaking at 700 rpm for two hours at room temperature and then washed. MSD SULFO-TAG anti-IgG antibody was added to each well. Plates were incubated for 1 hour at room temperature with shaking at 700 rpm and washed, then MSD GOLD Read buffer B was added to each well. Plates were read by the MESO SECTOR SQ 120 Reader. IgG concentration was calculated using DISCOVERY WORKBENCH MSD Software and reported as arbitrary units (AU)/ml.</div><div class="valid" valid="valid" title="valid: True, node: 381, tag: div, level: 14" node_number="381">The ability of SARS-CoV-2 spike-specific binding antibodies to inhibit spike protein or RBD binding to the ACE2 receptor was also measured using MULTI-SPOT 96-well plates (MSD). Antigen-coated plates were blocked and washed as described above. Assay calibrator and samples were diluted at 1:25 to 1:1,000 in MSD Diluent buffer, then added to the wells. Plates were incubated for 1 hour at room temperature, shaking at 700 rpm. ACE2 protein conjugated with MSD SULFO-TAG was added and plates were incubated for 1 hour at room temperature, shaking at 700rpm. Plates were washed and read as described above. AU/ml concentration of inhibitory antibodies was calculated with DISCOVERY WORKBENCH MSD Software.</div><div class="valid" valid="valid" title="valid: True, node: 382, tag: div, level: 14" node_number="382">Binding antibody measurements by octet biolayer interferometry were made on biosensors of the Octet Fort&#233;Bio Red96 instrument (Sartorius) that were hydrated in PBS prior to use. All assay steps were performed at 30&#176;C with agitation set at 1,000&#8201;rpm. Baseline equilibration of the anti-His-tag biosensors (HIS1K biosensors with a conjugated Penta-His antibody (Sartorius) was carried out with PBS for 15 s, prior to SARS-CoV2-RBD (30 &#956;g/ml diluted in PBS) loading for 120 s. After dipping in assay buffer (15 s in PBS), biosensors were dipped in the serum samples (100-fold dilution) for 180 s. Binding response (nm) at 180 s was recorded for each sample.</div><div class="valid" valid="valid" title="valid: True, node: 383, tag: div, level: 14" node_number="383"><b title="valid: False, node: 384, tag: b, level: 15" node_number="384">SARS-CoV-1 and SARS-CoV-2 Pseudovirus Neutralization</b>. The spike protein expression plasmid sequence for SARS-CoV-2 was codon optimized and modified to remove an 18 amino acid endoplasmic reticulum retention signal in the cytoplasmic tail to improve spike protein incorporation into pseudovirions (PSV) and thereby enhance infectivity. SARS-CoV-2 PSV were produced by co-transfection of HEK293T/17 cells with a SARS-CoV-2 spike protein-expressing plasmid (pcDNA3.4), derived from the Wuhan-Hu-1 genome sequence (GenBank accession number: MN908947.3) and an HIV-1 (pNL4-3.Luc.R-E-, NIH HIV Reagent Program, Catalog number 3418). Infectivity and neutralization titers were determined using ACE2-expressing HEK293 target cells (Integral Molecular) in a semi-automated assay format using robotic liquid handling (Biomek NXp Beckman Coulter). Virions pseudotyped with the vesicular stomatitis virus (VSV) G protein were used as a non-specific control. Serum samples were diluted 1:40 in growth medium (10% fetal bovine serum, 2.5% HEPES, 0.5% Gentamicin, 0.1% Puromycin in Dulbecco&#8217;s Modified Eagle Medium); then 25 &#956;l/well was added, in triplicate, to a white 96-well plate. An equal volume of diluted SARS-CoV-2 PSV was added to each well and plates were incubated for 1 hour at 37&#176;C. Target cells were added to each well (40,000 cells/ well) and plates were incubated for an additional 48 hours. Relative light units (RLU) were measured with the EnVision Multimode Plate Reader (Perkin Elmer) using the Bright-Glo Luciferase Assay System (Promega). Neutralization dose&#8211;response curves were fitted by nonlinear regression using the LabKey Server, as previously described (<a title="valid: False, node: 385, tag: a, level: 15" node_number="385"><i title="valid: False, node: 386, tag: i, level: 16" node_number="386">55</i></a>). Final titers are reported as the reciprocal of the dilution of serum necessary to achieve 50% (ID<sub title="valid: False, node: 387, tag: sub, level: 15" node_number="387">50</sub>) and 90% neutralization (ID<sub title="valid: False, node: 388, tag: sub, level: 15" node_number="388">90</sub>). Assay equivalency was established by participation in the SARS-CoV-2 Neutralizing Assay Concordance Survey (SNACS) run by the Virology Quality Assurance Program and External Quality Assurance Program Oversite Laboratory (EQAPOL) at the Duke Human Vaccine Institute, sponsored through programs supported by the National Institute of Allergy and Infectious Diseases, Division of AIDS.</div><div class="valid" valid="valid" title="valid: True, node: 389, tag: div, level: 14" node_number="389"><b title="valid: False, node: 390, tag: b, level: 15" node_number="390">Authentic SARS-CoV-2 wild-type neutralization assay.</b> Authentic virus neutralization was measured using SARS-CoV-2 (2019-nCoV/USA_WA1/2020) that was obtained from the Centers for Disease Control and Prevention and passaged once in Vero CCL81 cells (American Type Culture Collection (ATCC)). Rhesus serum samples were serially diluted and incubated with 100 focus-forming units (FFU) of SARS-CoV-2 for 1 hour at 37&#176;C. Serum-virus mixtures were added to Vero E6 cells in 96-well plates and incubated for 1 hour at 37&#176;C. Cells were overlaid with 1% (w/v) methylcellulose in Minimal Essential Media (Sigma-Aldrich). After 30 hours, cells were fixed with 4% paraformaldehyde in PBS for 20 min at room temperature then washed and stained overnight at 4&#176;C with 1 &#956;g/ml of antibody CR3022 in PBS supplemented with 0.1% saponin and 0.1% bovine serum albumin. Cells were subsequently stained with horseradish peroxidase (HRP)-conjugated goat anti-human IgG for 2 hours at room temperature. SARS-CoV-2-infected cell foci were visualized with TrueBlue peroxidase substrate (KPL) and quantified using ImmunoSpot microanalyzer (Cellular Technologies). Neutralization curves were generated with Prism software (GraphPad Prism 8.0).</div><div class="valid" valid="valid" title="valid: True, node: 391, tag: div, level: 14" node_number="391"><b title="valid: False, node: 392, tag: b, level: 15" node_number="392">Authentic SARS-CoV-2 variant and SARS-CoV-1 neutralization assay.</b> The SARS-CoV-2 viruses USA-WA1/2020 (WA1), USA/CA_CDC_5574/2020 (B1.1.7), hCoV-19/South Africa/KRISP-EC-K005321/2020 (B.1.351), hCoV-19/Japan/TY7-503/2021, hCoV-19/USA/PHC658/2021 (B.1.617.2) were obtained from BEI Resources (NIAID, NIH) and propagated for one passage using Vero clone E6 cells. Virus infectious titer was determined by an end-point dilution and cytopathic effect (CPE) assay on Vero-E6 cells as described previously (<a title="valid: False, node: 393, tag: a, level: 15" node_number="393"><i title="valid: False, node: 394, tag: i, level: 16" node_number="394">56</i></a>, <a title="valid: False, node: 395, tag: a, level: 15" node_number="395"><i title="valid: False, node: 396, tag: i, level: 16" node_number="396">57</i></a>). An end-point dilution microplate neutralization assay was performed to measure the neutralization activity of NHP serum samples. In brief, serum samples were heat inactivated and subjected to successive three-fold dilutions starting from 1:50. Triplicates of each dilution were incubated with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 in Eagle&#8217;s Minimal Essential Medium (EMEM) with 7.5% inactivated fetal calf serum (FCS) for 1 hour at 37&#176;C. Post incubation, the virus-antibody mixture was transferred onto a monolayer of Vero-E6 cells grown overnight. The cells were incubated with the mixture for about 70 hours. CPE of viral infection was visually scored for each well in a blinded fashion by two independent observers. The results were then reported as percentage of neutralization at a given sample dilution. A SARS-CoV-1 authentic plaque reduction virus neutralization assay was performed similarly to previously described (<a title="valid: False, node: 397, tag: a, level: 15" node_number="397"><i title="valid: False, node: 398, tag: i, level: 16" node_number="398">58</i></a>), with the following modifications. The starting dilution of serum was 1:5 and about 100 plaque-forming units of virus were used for virus and serum incubation. The overlay used after virus adsorption was Dulbecco's Modified Eagle Medium (Gibco) containing 2% FBS and 20% methylcellulose. Plates were then incubated for 5 days, and post crystal violet staining the washing step utilized water.&#8203; Plaques were graded as follows: approximately 25 plaques/25% monolayer damage (MD; -/+); approximately 50 plaques/50% MD) (+); approximately 75 plaques/75% MD (++); approximately 100 plaques/100% MD (+++). All negative control wells were solid monolayers.</div><div class="valid" valid="valid" title="valid: True, node: 399, tag: div, level: 14" node_number="399"><b title="valid: False, node: 400, tag: b, level: 15" node_number="400">Antibody-Dependent Neutrophil Phagocytosis (ADNP).</b> Biotinylated SARS-CoV-2 prefusion stabilized S trimer was incubated with yellow-green streptavidin-fluorescent beads (Molecular Probes) for 2 hours at 37&#176;C. Ten &#956;l of a 100-fold dilution of beads and protein was incubated for 2 hours at 37&#176;C with 100&#956;l of 8,100-fold diluted plasma samples before addition of effector cells (50,000 cells/well). Fresh human peripheral blood mononuclear cells were used as effector cells after red blood cell lysis with ACK lysing buffer (Thermo Fisher Scientific). After 1 hour, incubation at 37&#176;C, the cells were washed, surface stained, fixed with 4% formaldehyde solution (Tousimis) and fluorescence was evaluated on an LSRII flow cytometer (BD Biosciences). Antibodies used for flow cytometry included anti-human CD3 Alexa Fluor 700 (clone UCHT1) and anti-human CD14 Allophycocyanin Cynanine Dye 7 (APC-Cy7) (clone M&#981;P9) from BD Biosciences, as well as anti-human CD66b Pacific Blue (clone G10F5) from BioLegend. A phagocytic score was calculated by multiplying the percentage of bead-positive neutrophils (side scatter high, CD3<sup title="valid: False, node: 401, tag: sup, level: 15" node_number="401">-</sup>CD14<sup title="valid: False, node: 402, tag: sup, level: 15" node_number="402">-</sup>CD66<sup title="valid: False, node: 403, tag: sup, level: 15" node_number="403">+</sup>) by the geometric mean of the fluorescence intensity of bead-positive cells; and dividing by 10,000.</div><div class="valid" valid="valid" title="valid: True, node: 404, tag: div, level: 14" node_number="404"><b title="valid: False, node: 405, tag: b, level: 15" node_number="405">Antibody-Dependent Cellular Phagocytosis (ADCP).</b> ADCP was measured as previously described. Briefly, biotinylated SARS-CoV-1 or SARS-CoV-2 prefusion-stabilized spike protein trimer was incubated with red streptavidin-fluorescent beads (Molecular Probes) for 2 hour at 37&#176;C. Ten &#956;l of a 100-fold dilution of beads&#8211;protein was incubated for 2 hours at 37&#176;C with 100&#956;l of 8,100-fold (SARS-CoV-2) or 900-fold (SARS-CoV-1) diluted plasma samples before addition of THP-1 cells (20,000 cells per well; Millipore Sigma). After a 19 hour incubation at 37&#176;C, the cells were fixed with 2% formaldehyde solution (Tousimis) and fluorescence was evaluated on an LSRII flow cytometer (BD Biosciences). The phagocytic score was calculated by multiplying the percentage of bead-positive cells by the geometric mean of the fluorescence intensity of bead-positive cells, and dividing by 10,000.</div><div class="valid" valid="valid" title="valid: True, node: 406, tag: div, level: 14" node_number="406"><b title="valid: False, node: 407, tag: b, level: 15" node_number="407">Antibody-Dependent Complement Deposition (ADCD).</b> SARS-CoV-2 spike protein-expressing expi293F cells were generated by transfection with linearized plasmid (pcDNA3.1) encoding codon-optimized full-length SARS-CoV-2 spike protein matching the amino acid sequence of the IL-CDC-IL1/2020 isolate (GenBank ACC# MN988713). Stable transfectants were single-cell sorted and selected to obtain a high spike surface-expressing clone (293F-spike-S2A). ADCD was adapted from methods previously described (<a title="valid: False, node: 408, tag: a, level: 15" node_number="408"><i title="valid: False, node: 409, tag: i, level: 16" node_number="409">59</i></a>). Briefly, SARS-CoV-2 spike protein-expressing expi293F cells were incubated with 10-fold diluted, heat-inactivated (56&#176;C for 30 min) plasma samples for 30 min at 37&#176;C. Cells were washed twice and resuspended in R10 media. During this time, lyophilized guinea pig complement (CL4051, Cedarlane) was reconstituted in 1 ml cold water and centrifuged for 5 min at 4&#176;C to remove aggregates. Cells were washed with PBS and resuspended in 200 &#956;l of guinea pig complement, which was prepared at a 1:50 dilution in Gelatin Veronal Buffer with Ca<sup title="valid: False, node: 410, tag: sup, level: 15" node_number="410">2+</sup> and Mg<sup title="valid: False, node: 411, tag: sup, level: 15" node_number="411">2+</sup> (IBB-300x, Boston BioProducts). After incubation at 37&#176;C for 20 min, cells were washed in PBS 15mM EDTA (Thermo Fisher Scientific) and stained with an anti-Guinea Pig Complement C3 FITC (polyclonal, Thermo Fisher Scientific). Cells were then fixed with 4% formaldehyde solution and fluorescence was evaluated on a LSRII flow cytometer (BD Biosciences).</div><div class="valid" valid="valid" title="valid: True, node: 412, tag: div, level: 14" node_number="412"><b title="valid: False, node: 413, tag: b, level: 15" node_number="413">Opsonization.</b> SARS-CoV-2 spike protein-expressing expi293F cells were generated by transfection with linearized plasmid (pcDNA3.1) encoding codon-optimized full-length SARS-CoV-2 spike protein matching the amino acid sequence of the IL-CDC-IL1/2020 isolate (GenBank ACC# MN988713). Stable transfectants were single-cell sorted and selected to obtain a high Spike surface-expressing clone (293F-Spike-S2A). SARS-CoV-2 spike protein-expressing cells were incubated with 200-fold diluted plasma samples for 30 min at 37&#176;C. Cells were washed twice and stained with anti-human IgG phycoerythrin (PE), anti-human IgM Alexa Fluor 647, and anti-human IgA FITC (Southern Biotech). Cells were then fixed with 4% formaldehyde solution and fluorescence was evaluated on an LSRII flow cytometer (BD Biosciences).</div><div class="valid" valid="valid" title="valid: True, node: 414, tag: div, level: 14" node_number="414"><b title="valid: False, node: 415, tag: b, level: 15" node_number="415">Trogocytosis.</b> Trogocytosis was measured using a previously described assay (<a title="valid: False, node: 416, tag: a, level: 15" node_number="416"><i title="valid: False, node: 417, tag: i, level: 16" node_number="417">27</i></a>). Briefly, SARS-CoV-2 spike expressing expi293F cells were stained with PKH26 (Sigma-Aldrich). Cells were then washed with and resuspended in R10 media. Cells were then incubated with 200-fold diluted plasma samples for 30 min at 37&#176;C. Effector peripheral blood mononuclear cells were next added to the R10 media at an effector to target (E:T) cell ratio of 50:1 and then incubated for 5 hours at 37&#176;C. After the incubation, cells were washed, stained with live/dead aqua fixable cell stain (Life Technologies) and CD14 APC-Cy7 (clone M&#981;P9) for 15 min at room temperature, washed again, and fixed with 4% formaldehyde (Tousimis) for 15 min at room temperature. Fluorescence was evaluated on a LSRII flow cytometer (BD Biosciences). Trogocytosis was evaluated by measuring the PKH26 mean fluorescence intensity of the live CD14<sup title="valid: False, node: 418, tag: sup, level: 15" node_number="418">+</sup> cells.</div><div class="valid" valid="valid" title="valid: True, node: 419, tag: div, level: 14" node_number="419"><b title="valid: False, node: 420, tag: b, level: 15" node_number="420">Intracellular Cytokine Staining.</b> Cryopreserved peripheral blood mononuclear cells were thawed and rested for 6 hours in R10 with 50 U/mL Benzonase Nuclease (Sigma Aldrich). They were then stimulated for 12 hours with two pools of peptides spanning the spike protein of either SARS-CoV-2 or SARS-CoV-1 (1 &#956;g/mL, JPT, PM-WCPV-S and PM-CVHSA-S respectively) in the presence of Brefeldin A (0.65 &#956;L/mL, GolgiPlug, BD Biosciences Cytofix/Cytoperm Kit, Cat. 555028), co-stimulatory antibodies anti-CD28 (BD Biosciences Cat. 555725 1 &#956;g/mL) and anti-CD49d (BD Biosciences Cat. 555501; 1 &#956;g/mL), and CD107a (H4A3, BD Biosciences Cat. 561348, Lot 9143920 and 253441). Following stimulation, cells were stained serially with LIVE/DEAD Fixable Blue Dead Cell Stain in PBS for 20 min at room temperature (Thermo Fisher Scientific #L23105) and a cocktail of fluorescently-labeled antibodies (BD Biosciences unless otherwise indicated) to cell surface markers CD4-PE-Cy5.5 (S3.5, Thermo Fisher #MHCD0418, Lot 2118390, 1:80), CD8 BV570 (RPA-T8, BioLegend #301038, Lot B281322, 1:160), CD45RA BUV395 (5H9, #552888, Lot 154382 and 259854, 1:160), CD28 BUV737 (CD28.2, #612815, Lot 0113886, 1:20), CCR7 BV650 (GO43H7, # 353234, Lot B297645, 1:20) and HLA-DR BV480 (G46-6, # 566113, Lot 0055314, 1:640) in 4% fetal bovine serum in PBS for 20 min at room temperature. Intracellular cytokine staining was performed following fixation and permeabilization per manufacturer&#8217;s instructions (BD Cytofix/Cytoperm, BD Biosciences) with CD3 APC-Cy7 (SP34-2, #557757, Lot 6140803, 1:1,282), CD154 PE-Cy7 (24-31, BioLegend # 310842, Lot B264810 and B313191, 1:40), IFN-&#947; Alexa Fluor 700 (B27, # 506516, Lot B187646 and B290145, 1:1,282), TNF-&#945; FITC (MAb11, # 554512, Lot 15360, 1:160), IL-2 BV750 (MQ1-17H12, BioLegend #566361, Lot 0042313, 1:160), IL-4 BB700 (MP4-25D2, Lot 0133487 and 0308726, 1:320), MIP-1b PE (D21-1351, # 550078, Lot 9298609, 1:160), CD69 Electron coupled dye (ECD, phycoerythrin-Texas Red conjugate) (TP1.55.3, Beckman Coulter Life Sciences # 6607110, Lot 7620070 and 7620076, 1:80), IL-21 Alexa Fluor 647 (3A3-N2.1, # 560493, Lot 9199272, 1:20), IL-13 BV421 (JES10-5A2, # 563580, Lot 9322765, 210147 and 169570, 1:20) and IL-17A BV605 (BL168, BioLegend #512326, B289357, 1:20). Sample staining was measured on a FACSymphony A5 SORP (Becton Dickenson) and data analyzed using FlowJo v.9.9 software (Tree Star, Inc.). The gating strategy is shown in fig. S10. CD4 and CD8 T cell subsets were pre-gated on memory markers prior to assessing cytokine expression as follows: single-positive or double-negative for CD45RA and CD28. Boolean combinations of cells expressing one or more cytokines were used to assess the total spike protein-specific response of memory CD4 or CD8 T cells. Responses from the two-peptide pools spanning SARS-CoV-2 spike protein or SARS-CoV-1 were summed. Display of multicomponent distributions were performed with SPICE v6.0 (NIH).</div><div class="valid" valid="valid" title="valid: True, node: 421, tag: div, level: 14" node_number="421"><b title="valid: False, node: 422, tag: b, level: 15" node_number="422">Total and Sub-Genomic Messenger (sgm) RNA Quantification.</b> Real time quantitative polymerase chain reaction (RT-qPCR) was carried out for subgenomic messenger RNA (sgmRNA) and viral load RNA quantification from NP swab, BAL fluid and saliva samples. Primers targeted the envelope (E) gene of SARS-CoV-2 (table S2). RNA was extracted from 200 &#956;l of NP swab media or BAL specimens using the EZ1 DSP Virus kit (Qiagen) on the EZ1 Advanced XL instrument (Qiagen). Briefly, samples were lysed in 200 &#956;l of ATL buffer (Qiagen) and transferred to the Qiagen EZ1 for extraction. Bacteriophage MS2 (ATCC) was added to the RNA carrier and used as an extraction control to monitor efficiency of RNA extraction and amplification (<a title="valid: False, node: 423, tag: a, level: 15" node_number="423"><i title="valid: False, node: 424, tag: i, level: 16" node_number="424">60</i></a>). Purified RNA was eluted in 90 &#956;l elution buffer (AVE). The RT-qPCR amplification reactions were performed in separate wells of a 96-well Fast plate for the 3 targets: sgmRNA, RNA viral load, and MS2 RNA using 10 &#956;l of extracted material 0.72uM of primer and 0.2uM of probe and 1x TaqPath 1-Step RT-qPCR (A15299: Life Technologies, Thermo Fisher Scientific). Amplification cycling conditions were: 2 min at 25&#176;C, 15 min at 50&#176;C, 2 min at 95&#176;C and 45 cycles of 3 s at 94&#176;C and 30 s at 55&#176;C with fluorescence read at 55&#176;C. An RNA transcript for the SARS-CoV-2 E gene was used as a calibration standard. RNA copy values were extrapolated from the standard curve and multiplied by 45 to obtain RNA copies/ml. A negative control (PBS) and two positive controls (heat inactivated SARS-CoV-2, ATCC, VR-1986HK at 10<sup title="valid: False, node: 425, tag: sup, level: 15" node_number="425">6</sup> and 10<sup title="valid: False, node: 426, tag: sup, level: 15" node_number="426">3</sup> copies/ml), were extracted and used to assess performance of both assays.</div><div class="valid" valid="valid" title="valid: True, node: 427, tag: div, level: 14" node_number="427"><b title="valid: False, node: 428, tag: b, level: 15" node_number="428">Histopathology.</b> Formalin fixed sections of lung tissue were evaluated by light microscopy and immunohistochemistry. Lungs were perfused with 10% neutral-buffered formalin. Lung sections were processed routinely into paraffin wax, then sectioned at 5 &#956;m, and resulting slides were stained with hematoxylin and eosin. Immunohistochemistry (IHC) was performed using the Dako Envision system (Dako Agilent Pathology Solutions). Briefly, after deparaffinization, peroxidase blocking, and antigen retrieval, sections were covered with a mouse monoclonal anti-SARS-CoV nucleocapsid protein antibody (#40143-MM05, Sino Biological) at a dilution of 1:4000 and incubated at room temperature for forty-five minutes. They were rinsed, and the peroxidase-labeled polymer (secondary antibody) was applied for thirty minutes. Slides were rinsed and a brown chromogenic substrate 3,3&#8242; Diaminobenzidine (DAB) solution (Dako Agilent Pathology Solutions) was applied for eight minutes. The substrate-chromogen solution was rinsed off the slides, and slides were counterstained with hematoxylin and rinsed. The sections were dehydrated, cleared with Xyless, and then cover slipped. Tissue section slides were evaluated by a board-certified veterinary anatomic pathologist who was blinded to study group allocations.</div><div class="valid" valid="valid" title="valid: True, node: 429, tag: div, level: 14" node_number="429"><b title="valid: False, node: 430, tag: b, level: 15" node_number="430">Statistical analysis.</b> Raw, individual level data can be found in data file S1. Primary immunogenicity outputs of binding and neutralizing antibody titers as well as T cell responses were compared across vaccination groups using Kruskal-Wallis test. Non-parametric pairwise comparisons between groups were made using the post-hoc Dunn&#8217;s test. The same hierarchical analysis was applied to comparisons of sgmRNA concentrations in the NP swabs and BAL fluids of vaccinated versus control groups. Statistical significance was preset at an alpha level of 0.05. The correlation between dependent T cell responses was assessed by non-parametric Spearman correlation (r).</div></section><section class="valid" valid="valid" title="valid: True, node: 431, tag: section, level: 13" node_number="431"><h2 class="valid" valid="valid" title="valid: True, node: 432, tag: h2, level: 14" node_number="432">Acknowledgments</h2><div class="valid" valid="valid" title="valid: True, node: 433, tag: div, level: 14" node_number="433"><b title="valid: False, node: 434, tag: b, level: 15" node_number="434">ACKNOWLEDGMENTS</b></div><div class="valid" valid="valid" title="valid: True, node: 435, tag: div, level: 14" node_number="435">We thank J. Lay, E. Zografos, J. Lynch, L. Mendez-Rivera, N. Jackson, B. Slike, U. Tran, S. Peters, J. Bolton, T. Robinson, E. Duncan, H. Siegfried, R.J. O&#8217;Connell, Z. Beck and C. Alving for technical support, assistance, and advice.</div><div class="valid" valid="valid" title="valid: True, node: 436, tag: div, level: 14" node_number="436"><b title="valid: False, node: 437, tag: b, level: 15" node_number="437">Funding:</b> We acknowledge support from the U.S. Department of Defense, Defense Health Agency (Restoral FY20 to KM). This work was partially executed through a cooperative agreement between the U.S. Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.</div><div class="valid" valid="valid" title="valid: True, node: 438, tag: div, level: 14" node_number="438"><b title="valid: False, node: 439, tag: b, level: 15" node_number="439">Author contributions:</b> K.M. and M.G.J designed the study. I.E.N, A.A., K.K.P., C.M.C., C.S., R.E.C, J.B.C., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., M.C., C.S., P.J.L., A.A., K.M.W., M.S.N., H.M.S., N.dV., M.D., I.S., J.R.C., K.G.L, V.D., S.M., K.A., R.C., S.J.K. D.P.P., N.K., V.R.P., Y.H., L.L.J., G.D.G. performed immunologic and virologic assays. H.A.E, A.C., M.G.L. led the clinical care of the animals. S.P.D., X.Z., E.K.D performed histopathology. K.M., M.G.J., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., and M.C. designed the immunogens. M.R., G.R.M., and A.A. designed and provided the adjuvant. M.G.J., H.A.D.K. J.A.H., S.P.D., M.F.A., S.V., P.T.S., D.D.H., M.S.D., M.G.L., M.R., G.D.G., S.A.P., N.L.M. D.L.B. and K.M. analyzed and interpreted the data. K.M. wrote the paper with assistance from all coauthors.</div><div class="valid" valid="valid" title="valid: True, node: 440, tag: div, level: 14" node_number="440"><b title="valid: False, node: 441, tag: b, level: 15" node_number="441">Competing interests:</b> K.M. and M.G.J. are primary co-inventors on related vaccine patents (U.S. Provisional Application 62/986,522 filed March 6, 2020, and to U.S. Provisional Application 63/038,600 filed June 12, 2020). M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech, and Carnival Corporation. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. M.S.D. is on the Scientific Advisory Boards of Moderna and Immunome. The other authors declare no competing interests.</div><div class="valid" valid="valid" title="valid: True, node: 442, tag: div, level: 14" node_number="442"><b title="valid: False, node: 443, tag: b, level: 15" node_number="443">Data and materials availability:</b> All data are available in the manuscript or the supplementary materials. The vaccine and adjuvant used in this study will be made available to the scientific community by contacting Kayvon Modjarrad and completion of a materials transfer agreement.</div><div class="valid" valid="valid" title="valid: True, node: 444, tag: div, level: 14" node_number="444">This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 445, tag: a, level: 15" node_number="445">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using this material.</div></section> </div></section><section class="valid" valid="valid" title="valid: True, node: 446, tag: section, level: 11" node_number="446"><div class="valid" valid="valid" title="valid: True, node: 447, tag: div, level: 12" node_number="447"><section class="valid" valid="valid" title="valid: True, node: 448, tag: section, level: 13" node_number="448"><h2 class="valid" valid="valid" title="valid: True, node: 449, tag: h2, level: 14" node_number="449">Supplementary Materials</h2><section class="valid" valid="valid" title="valid: True, node: 450, tag: section, level: 14" node_number="450"><h3 title="valid: False, node: 451, tag: h3, level: 15" node_number="451">This PDF file includes:</h3><div title="valid: False, node: 452, tag: div, level: 15" node_number="452"><div title="valid: False, node: 453, tag: div, level: 16" node_number="453"><div title="valid: False, node: 454, tag: div, level: 17" node_number="454">Figs. S1 to S10</div><div title="valid: False, node: 455, tag: div, level: 17" node_number="455">Tables S1 and S2</div></div><div title="valid: False, node: 456, tag: div, level: 16" node_number="456"><a title="valid: False, node: 457, tag: a, level: 17" node_number="457">Download (511.86 KB)</a></div></div></section><section class="valid" valid="valid" title="valid: True, node: 458, tag: section, level: 14" node_number="458"><h3 title="valid: False, node: 459, tag: h3, level: 15" node_number="459">Other Supplementary Material for this manuscript includes the following:</h3><div title="valid: False, node: 460, tag: div, level: 15" node_number="460"><div title="valid: False, node: 461, tag: div, level: 16" node_number="461"><div title="valid: False, node: 462, tag: div, level: 17" node_number="462">Data file S1</div></div><div title="valid: False, node: 463, tag: div, level: 16" node_number="463"><a title="valid: False, node: 464, tag: a, level: 17" node_number="464">Download (290.07 KB)</a></div></div></section></section><section class="valid" valid="valid" title="valid: True, node: 465, tag: section, level: 13" node_number="465"><h2 class="valid" valid="valid" title="valid: True, node: 466, tag: h2, level: 14" node_number="466">References and Notes</h2><div class="valid" valid="valid" title="valid: True, node: 467, tag: div, level: 14" node_number="467"><div title="valid: False, node: 468, tag: div, level: 15" node_number="468">1</div><div title="valid: False, node: 469, tag: div, level: 15" node_number="469"><div title="valid: False, node: 470, tag: div, level: 16" node_number="470"><div title="valid: False, node: 471, tag: div, level: 17" node_number="471">M. S. Freedman, K. Ault, H. Bernstein, Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2021. MMWR Morb. Mortal. Wkly. Rep. <b title="valid: False, node: 472, tag: b, level: 18" node_number="472">70</b>, 193&#8211;196 (2021).</div><div title="valid: False, node: 473, tag: div, level: 17" node_number="473"><div title="valid: False, node: 474, tag: div, level: 18" node_number="474"><a title="valid: False, node: 475, tag: a, level: 19" node_number="475">Crossref</a></div><div title="valid: False, node: 476, tag: div, level: 18" node_number="476"><a title="valid: False, node: 477, tag: a, level: 19" node_number="477">PubMed</a></div><div title="valid: False, node: 478, tag: div, level: 18" node_number="478"><a title="valid: False, node: 479, tag: a, level: 19" node_number="479">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 480, tag: div, level: 14" node_number="480"><div title="valid: False, node: 481, tag: div, level: 15" node_number="481">2</div><div title="valid: False, node: 482, tag: div, level: 15" node_number="482"><div title="valid: False, node: 483, tag: div, level: 16" node_number="483"><div title="valid: False, node: 484, tag: div, level: 17" node_number="484">J. R. Mascola, B. S. Graham, A. S. Fauci, SARS-CoV-2 Viral Variants-Tackling a Moving Target. JAMA <b title="valid: False, node: 485, tag: b, level: 18" node_number="485">325</b>, 1261&#8211;1262 (2021).</div><div title="valid: False, node: 486, tag: div, level: 17" node_number="486"><div title="valid: False, node: 487, tag: div, level: 18" node_number="487"><a title="valid: False, node: 488, tag: a, level: 19" node_number="488">Crossref</a></div><div title="valid: False, node: 489, tag: div, level: 18" node_number="489"><a title="valid: False, node: 490, tag: a, level: 19" node_number="490">PubMed</a></div><div title="valid: False, node: 491, tag: div, level: 18" node_number="491"><a title="valid: False, node: 492, tag: a, level: 19" node_number="492">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 493, tag: div, level: 14" node_number="493"><div title="valid: False, node: 494, tag: div, level: 15" node_number="494">3</div><div title="valid: False, node: 495, tag: div, level: 15" node_number="495"><div title="valid: False, node: 496, tag: div, level: 16" node_number="496"><div title="valid: False, node: 497, tag: div, level: 17" node_number="497">D. Ho <i title="valid: False, node: 498, tag: i, level: 18" node_number="498">et al</i>., Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. <i title="valid: False, node: 499, tag: i, level: 18" node_number="499">Res Sq</i>, (2021).</div><div title="valid: False, node: 500, tag: div, level: 17" node_number="500"><div title="valid: False, node: 501, tag: div, level: 18" node_number="501"><a title="valid: False, node: 502, tag: a, level: 19" node_number="502">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 503, tag: div, level: 14" node_number="503"><div title="valid: False, node: 504, tag: div, level: 15" node_number="504">4</div><div title="valid: False, node: 505, tag: div, level: 15" node_number="505"><div title="valid: False, node: 506, tag: div, level: 16" node_number="506"><div title="valid: False, node: 507, tag: div, level: 17" node_number="507">J. R. Ortiz, J. Robertson, J.-S. Hsu, S. L. Yu, A. J. Driscoll, S. R. Williams, W. H. Chen, M. C. Fitzpatrick, S. Sow, R. J. Biellik, K. M. Neuzil, The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. Vaccine <b title="valid: False, node: 508, tag: b, level: 18" node_number="508">39</b>, 2165&#8211;2176 (2021).</div><div title="valid: False, node: 509, tag: div, level: 17" node_number="509"><div title="valid: False, node: 510, tag: div, level: 18" node_number="510"><a title="valid: False, node: 511, tag: a, level: 19" node_number="511">Crossref</a></div><div title="valid: False, node: 512, tag: div, level: 18" node_number="512"><a title="valid: False, node: 513, tag: a, level: 19" node_number="513">PubMed</a></div><div title="valid: False, node: 514, tag: div, level: 18" node_number="514"><a title="valid: False, node: 515, tag: a, level: 19" node_number="515">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 516, tag: div, level: 14" node_number="516"><div title="valid: False, node: 517, tag: div, level: 15" node_number="517">5</div><div title="valid: False, node: 518, tag: div, level: 15" node_number="518"><div title="valid: False, node: 519, tag: div, level: 16" node_number="519"><div title="valid: False, node: 520, tag: div, level: 17" node_number="520">H. G. Kelly, H.-X. Tan, J. A. Juno, R. Esterbauer, Y. Ju, W. Jiang, V. C. Wimmer, B. C. Duckworth, J. R. Groom, F. Caruso, M. Kanekiyo, S. J. Kent, A. K. Wheatley, Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight <b title="valid: False, node: 521, tag: b, level: 18" node_number="521">5</b>, e136653 (2020).</div><div title="valid: False, node: 522, tag: div, level: 17" node_number="522"><div title="valid: False, node: 523, tag: div, level: 18" node_number="523"><a title="valid: False, node: 524, tag: a, level: 19" node_number="524">Crossref</a></div><div title="valid: False, node: 525, tag: div, level: 18" node_number="525"><a title="valid: False, node: 526, tag: a, level: 19" node_number="526">PubMed</a></div><div title="valid: False, node: 527, tag: div, level: 18" node_number="527"><a title="valid: False, node: 528, tag: a, level: 19" node_number="528">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 529, tag: div, level: 14" node_number="529"><div title="valid: False, node: 530, tag: div, level: 15" node_number="530">6</div><div title="valid: False, node: 531, tag: div, level: 15" node_number="531"><div title="valid: False, node: 532, tag: div, level: 16" node_number="532"><div title="valid: False, node: 533, tag: div, level: 17" node_number="533">Y. Kato, R. K. Abbott, B. L. Freeman, S. Haupt, B. Groschel, M. Silva, S. Menis, D. J. Irvine, W. R. Schief, S. Crotty, Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In&#160;Vivo. Immunity <b title="valid: False, node: 534, tag: b, level: 18" node_number="534">53</b>, 548&#8211;563.e8 (2020).</div><div title="valid: False, node: 535, tag: div, level: 17" node_number="535"><div title="valid: False, node: 536, tag: div, level: 18" node_number="536"><a title="valid: False, node: 537, tag: a, level: 19" node_number="537">Crossref</a></div><div title="valid: False, node: 538, tag: div, level: 18" node_number="538"><a title="valid: False, node: 539, tag: a, level: 19" node_number="539">PubMed</a></div><div title="valid: False, node: 540, tag: div, level: 18" node_number="540"><a title="valid: False, node: 541, tag: a, level: 19" node_number="541">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 542, tag: div, level: 14" node_number="542"><div title="valid: False, node: 543, tag: div, level: 15" node_number="543">7</div><div title="valid: False, node: 544, tag: div, level: 15" node_number="544"><div title="valid: False, node: 545, tag: div, level: 16" node_number="545"><div title="valid: False, node: 546, tag: div, level: 17" node_number="546">R. &#220;belhart, E. Hug, M. P. Bach, T. Wossning, M. D&#252;hren-von Minden, A. H. C. Horn, D. Tsiantoulas, K. Kometani, T. Kurosaki, C. J. Binder, H. Sticht, L. Nitschke, M. Reth, H. Jumaa, Responsiveness of B cells is regulated by the hinge region of IgD. Nat. Immunol. <b title="valid: False, node: 547, tag: b, level: 18" node_number="547">16</b>, 534&#8211;543 (2015).</div><div title="valid: False, node: 548, tag: div, level: 17" node_number="548"><div title="valid: False, node: 549, tag: div, level: 18" node_number="549"><a title="valid: False, node: 550, tag: a, level: 19" node_number="550">Crossref</a></div><div title="valid: False, node: 551, tag: div, level: 18" node_number="551"><a title="valid: False, node: 552, tag: a, level: 19" node_number="552">PubMed</a></div><div title="valid: False, node: 553, tag: div, level: 18" node_number="553"><a title="valid: False, node: 554, tag: a, level: 19" node_number="554">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 555, tag: div, level: 14" node_number="555"><div title="valid: False, node: 556, tag: div, level: 15" node_number="556">8</div><div title="valid: False, node: 557, tag: div, level: 15" node_number="557"><div title="valid: False, node: 558, tag: div, level: 16" node_number="558"><div title="valid: False, node: 559, tag: div, level: 17" node_number="559">J. M. Bradley, N. E. Le Brun, G. R. Moore, Ferritins: Furnishing proteins with iron. Eur. J. Biochem. <b title="valid: False, node: 560, tag: b, level: 18" node_number="560">21</b>, 13&#8211;28 (2016).</div><div title="valid: False, node: 561, tag: div, level: 17" node_number="561"><div title="valid: False, node: 562, tag: div, level: 18" node_number="562"><a title="valid: False, node: 563, tag: a, level: 19" node_number="563">Crossref</a></div><div title="valid: False, node: 564, tag: div, level: 18" node_number="564"><a title="valid: False, node: 565, tag: a, level: 19" node_number="565">PubMed</a></div><div title="valid: False, node: 566, tag: div, level: 18" node_number="566"><a title="valid: False, node: 567, tag: a, level: 19" node_number="567">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 568, tag: div, level: 14" node_number="568"><div title="valid: False, node: 569, tag: div, level: 15" node_number="569">9</div><div title="valid: False, node: 570, tag: div, level: 15" node_number="570"><div title="valid: False, node: 571, tag: div, level: 16" node_number="571"><div title="valid: False, node: 572, tag: div, level: 17" node_number="572">H. D. Kamp, K. A. Swanson, R. R. Wei, P. K. Dhal, R. Dharanipragada, A. Kern, B. Sharma, R. Sima, O. Hajdusek, L. T. Hu, C.-J. Wei, G. J. Nabel, Design of a broadly reactive Lyme disease vaccine. NPJ Vaccines <b title="valid: False, node: 573, tag: b, level: 18" node_number="573">5</b>, 33 (2020).</div><div title="valid: False, node: 574, tag: div, level: 17" node_number="574"><div title="valid: False, node: 575, tag: div, level: 18" node_number="575"><a title="valid: False, node: 576, tag: a, level: 19" node_number="576">Crossref</a></div><div title="valid: False, node: 577, tag: div, level: 18" node_number="577"><a title="valid: False, node: 578, tag: a, level: 19" node_number="578">PubMed</a></div><div title="valid: False, node: 579, tag: div, level: 18" node_number="579"><a title="valid: False, node: 580, tag: a, level: 19" node_number="580">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 581, tag: div, level: 14" node_number="581"><div title="valid: False, node: 582, tag: div, level: 15" node_number="582">10</div><div title="valid: False, node: 583, tag: div, level: 15" node_number="583"><div title="valid: False, node: 584, tag: div, level: 16" node_number="584"><div title="valid: False, node: 585, tag: div, level: 17" node_number="585">K. A. Swanson, J. N. Rainho-Tomko, Z. P. Williams, L. Lanza, M. Peredelchuk, M. Kishko, V. Pavot, J. Alamares-Sapuay, H. Adhikarla, S. Gupta, S. Chivukula, S. Gallichan, L. Zhang, N. Jackson, H. Yoon, D. Edwards, C.-J. Wei, G. J. Nabel, A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. <b title="valid: False, node: 586, tag: b, level: 18" node_number="586">5</b>, eaba6466 (2020).</div><div title="valid: False, node: 587, tag: div, level: 17" node_number="587"><div title="valid: False, node: 588, tag: div, level: 18" node_number="588"><a title="valid: False, node: 589, tag: a, level: 19" node_number="589">Crossref</a></div><div title="valid: False, node: 590, tag: div, level: 18" node_number="590"><a title="valid: False, node: 591, tag: a, level: 19" node_number="591">PubMed</a></div><div title="valid: False, node: 592, tag: div, level: 18" node_number="592"><a title="valid: False, node: 593, tag: a, level: 19" node_number="593">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 594, tag: div, level: 14" node_number="594"><div title="valid: False, node: 595, tag: div, level: 15" node_number="595">11</div><div title="valid: False, node: 596, tag: div, level: 15" node_number="596"><div title="valid: False, node: 597, tag: div, level: 16" node_number="597"><div title="valid: False, node: 598, tag: div, level: 17" node_number="598">M. Kanekiyo, W. Bu, M. G. Joyce, G. Meng, J. R. R. Whittle, U. Baxa, T. Yamamoto, S. Narpala, J.-P. Todd, S. S. Rao, A. B. McDermott, R. A. Koup, M. G. Rossmann, J. R. Mascola, B. S. Graham, J. I. Cohen, G. J. Nabel, Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell <b title="valid: False, node: 599, tag: b, level: 18" node_number="599">162</b>, 1090&#8211;1100 (2015).</div><div title="valid: False, node: 600, tag: div, level: 17" node_number="600"><div title="valid: False, node: 601, tag: div, level: 18" node_number="601"><a title="valid: False, node: 602, tag: a, level: 19" node_number="602">Crossref</a></div><div title="valid: False, node: 603, tag: div, level: 18" node_number="603"><a title="valid: False, node: 604, tag: a, level: 19" node_number="604">PubMed</a></div><div title="valid: False, node: 605, tag: div, level: 18" node_number="605"><a title="valid: False, node: 606, tag: a, level: 19" node_number="606">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 607, tag: div, level: 14" node_number="607"><div title="valid: False, node: 608, tag: div, level: 15" node_number="608">12</div><div title="valid: False, node: 609, tag: div, level: 15" node_number="609"><div title="valid: False, node: 610, tag: div, level: 16" node_number="610"><div title="valid: False, node: 611, tag: div, level: 17" node_number="611">M. Kanekiyo, C.-J. Wei, H. M. Yassine, P. M. McTamney, J. C. Boyington, J. R. R. Whittle, S. S. Rao, W.-P. Kong, L. Wang, G. J. Nabel, Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature <b title="valid: False, node: 612, tag: b, level: 18" node_number="612">499</b>, 102&#8211;106 (2013).</div><div title="valid: False, node: 613, tag: div, level: 17" node_number="613"><div title="valid: False, node: 614, tag: div, level: 18" node_number="614"><a title="valid: False, node: 615, tag: a, level: 19" node_number="615">Crossref</a></div><div title="valid: False, node: 616, tag: div, level: 18" node_number="616"><a title="valid: False, node: 617, tag: a, level: 19" node_number="617">PubMed</a></div><div title="valid: False, node: 618, tag: div, level: 18" node_number="618"><a title="valid: False, node: 619, tag: a, level: 19" node_number="619">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 620, tag: div, level: 14" node_number="620"><div title="valid: False, node: 621, tag: div, level: 15" node_number="621">13</div><div title="valid: False, node: 622, tag: div, level: 15" node_number="622"><div title="valid: False, node: 623, tag: div, level: 16" node_number="623"><div title="valid: False, node: 624, tag: div, level: 17" node_number="624">H. M. Yassine, J. C. Boyington, P. M. McTamney, C.-J. Wei, M. Kanekiyo, W.-P. Kong, J. R. Gallagher, L. Wang, Y. Zhang, M. G. Joyce, D. Lingwood, S. M. Moin, H. Andersen, Y. Okuno, S. S. Rao, A. K. Harris, P. D. Kwong, J. R. Mascola, G. J. Nabel, B. S. Graham, Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. <b title="valid: False, node: 625, tag: b, level: 18" node_number="625">21</b>, 1065&#8211;1070 (2015).</div><div title="valid: False, node: 626, tag: div, level: 17" node_number="626"><div title="valid: False, node: 627, tag: div, level: 18" node_number="627"><a title="valid: False, node: 628, tag: a, level: 19" node_number="628">Crossref</a></div><div title="valid: False, node: 629, tag: div, level: 18" node_number="629"><a title="valid: False, node: 630, tag: a, level: 19" node_number="630">PubMed</a></div><div title="valid: False, node: 631, tag: div, level: 18" node_number="631"><a title="valid: False, node: 632, tag: a, level: 19" node_number="632">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 633, tag: div, level: 14" node_number="633"><div title="valid: False, node: 634, tag: div, level: 15" node_number="634">14</div><div title="valid: False, node: 635, tag: div, level: 15" node_number="635"><div title="valid: False, node: 636, tag: div, level: 16" node_number="636"><div title="valid: False, node: 637, tag: div, level: 17" node_number="637"><a title="valid: False, node: 638, tag: a, level: 18" node_number="638">https://clinicaltrials.gov/ct2/show/NCT03186781</a>. (2021).</div><div title="valid: False, node: 639, tag: div, level: 17" node_number="639"><div title="valid: False, node: 640, tag: div, level: 18" node_number="640"><a title="valid: False, node: 641, tag: a, level: 19" node_number="641">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 642, tag: div, level: 14" node_number="642"><div title="valid: False, node: 643, tag: div, level: 15" node_number="643">15</div><div title="valid: False, node: 644, tag: div, level: 15" node_number="644"><div title="valid: False, node: 645, tag: div, level: 16" node_number="645"><div title="valid: False, node: 646, tag: div, level: 17" node_number="646"><a title="valid: False, node: 647, tag: a, level: 18" node_number="647">https://clinicaltrials.gov/ct2/show/NCT03814720</a>. (2021).</div><div title="valid: False, node: 648, tag: div, level: 17" node_number="648"><div title="valid: False, node: 649, tag: div, level: 18" node_number="649"><a title="valid: False, node: 650, tag: a, level: 19" node_number="650">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 651, tag: div, level: 14" node_number="651"><div title="valid: False, node: 652, tag: div, level: 15" node_number="652">16</div><div title="valid: False, node: 653, tag: div, level: 15" node_number="653"><div title="valid: False, node: 654, tag: div, level: 16" node_number="654"><div title="valid: False, node: 655, tag: div, level: 17" node_number="655">D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science <b title="valid: False, node: 656, tag: b, level: 18" node_number="656">367</b>, 1260&#8211;1263 (2020).</div><div title="valid: False, node: 657, tag: div, level: 17" node_number="657"><div title="valid: False, node: 658, tag: div, level: 18" node_number="658"><a title="valid: False, node: 659, tag: a, level: 19" node_number="659">Crossref</a></div><div title="valid: False, node: 660, tag: div, level: 18" node_number="660"><a title="valid: False, node: 661, tag: a, level: 19" node_number="661">PubMed</a></div><div title="valid: False, node: 662, tag: div, level: 18" node_number="662"><a title="valid: False, node: 663, tag: a, level: 19" node_number="663">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 664, tag: div, level: 14" node_number="664"><div title="valid: False, node: 665, tag: div, level: 15" node_number="665">17</div><div title="valid: False, node: 666, tag: div, level: 15" node_number="666"><div title="valid: False, node: 667, tag: div, level: 16" node_number="667"><div title="valid: False, node: 668, tag: div, level: 17" node_number="668">G. Dagotto, J. Yu, D. H. Barouch, Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe <b title="valid: False, node: 669, tag: b, level: 18" node_number="669">28</b>, 364&#8211;370 (2020).</div><div title="valid: False, node: 670, tag: div, level: 17" node_number="670"><div title="valid: False, node: 671, tag: div, level: 18" node_number="671"><a title="valid: False, node: 672, tag: a, level: 19" node_number="672">Crossref</a></div><div title="valid: False, node: 673, tag: div, level: 18" node_number="673"><a title="valid: False, node: 674, tag: a, level: 19" node_number="674">PubMed</a></div><div title="valid: False, node: 675, tag: div, level: 18" node_number="675"><a title="valid: False, node: 676, tag: a, level: 19" node_number="676">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 677, tag: div, level: 14" node_number="677"><div title="valid: False, node: 678, tag: div, level: 15" node_number="678">18</div><div title="valid: False, node: 679, tag: div, level: 15" node_number="679"><div title="valid: False, node: 680, tag: div, level: 16" node_number="680"><div title="valid: False, node: 681, tag: div, level: 17" node_number="681">T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. T. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science <b title="valid: False, node: 682, tag: b, level: 18" node_number="682">369</b>, 956&#8211;963 (2020).</div><div title="valid: False, node: 683, tag: div, level: 17" node_number="683"><div title="valid: False, node: 684, tag: div, level: 18" node_number="684"><a title="valid: False, node: 685, tag: a, level: 19" node_number="685">Crossref</a></div><div title="valid: False, node: 686, tag: div, level: 18" node_number="686"><a title="valid: False, node: 687, tag: a, level: 19" node_number="687">PubMed</a></div><div title="valid: False, node: 688, tag: div, level: 18" node_number="688"><a title="valid: False, node: 689, tag: a, level: 19" node_number="689">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 690, tag: div, level: 14" node_number="690"><div title="valid: False, node: 691, tag: div, level: 15" node_number="691">19</div><div title="valid: False, node: 692, tag: div, level: 15" node_number="692"><div title="valid: False, node: 693, tag: div, level: 16" node_number="693"><div title="valid: False, node: 694, tag: div, level: 17" node_number="694">T. Zohar, G. Alter, Dissecting antibody-mediated protection against SARS-CoV-2. Nat. Rev. Immunol. <b title="valid: False, node: 695, tag: b, level: 18" node_number="695">20</b>, 392&#8211;394 (2020).</div><div title="valid: False, node: 696, tag: div, level: 17" node_number="696"><div title="valid: False, node: 697, tag: div, level: 18" node_number="697"><a title="valid: False, node: 698, tag: a, level: 19" node_number="698">Crossref</a></div><div title="valid: False, node: 699, tag: div, level: 18" node_number="699"><a title="valid: False, node: 700, tag: a, level: 19" node_number="700">PubMed</a></div><div title="valid: False, node: 701, tag: div, level: 18" node_number="701"><a title="valid: False, node: 702, tag: a, level: 19" node_number="702">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 703, tag: div, level: 14" node_number="703"><div title="valid: False, node: 704, tag: div, level: 15" node_number="704">20</div><div title="valid: False, node: 705, tag: div, level: 15" node_number="705"><div title="valid: False, node: 706, tag: div, level: 16" node_number="706"><div title="valid: False, node: 707, tag: div, level: 17" node_number="707">M. G. Joyce et al., SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. bioRxiv, (2021).</div><div title="valid: False, node: 708, tag: div, level: 17" node_number="708"><div title="valid: False, node: 709, tag: div, level: 18" node_number="709"><a title="valid: False, node: 710, tag: a, level: 19" node_number="710">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 711, tag: div, level: 14" node_number="711"><div title="valid: False, node: 712, tag: div, level: 15" node_number="712">21</div><div title="valid: False, node: 713, tag: div, level: 15" node_number="713"><div title="valid: False, node: 714, tag: div, level: 16" node_number="714"><div title="valid: False, node: 715, tag: div, level: 17" node_number="715">C. Mu&#241;oz-Fontela, W. E. Dowling, S. G. P. Funnell, P.-S. Gsell, A. X. Riveros-Balta, R. A. Albrecht, H. Andersen, R. S. Baric, M. W. Carroll, M. Cavaleri, C. Qin, I. Crozier, K. Dallmeier, L. de Waal, E. de Wit, L. Delang, E. Dohm, W. P. Duprex, D. Falzarano, C. L. Finch, M. B. Frieman, B. S. Graham, L. E. Gralinski, K. Guilfoyle, B. L. Haagmans, G. A. Hamilton, A. L. Hartman, S. Herfst, S. J. F. Kaptein, W. B. Klimstra, I. Knezevic, P. R. Krause, J. H. Kuhn, R. Le Grand, M. G. Lewis, W.-C. Liu, P. Maisonnasse, A. K. McElroy, V. Munster, N. Oreshkova, A. L. Rasmussen, J. Rocha-Pereira, B. Rockx, E. Rodr&#237;guez, T. F. Rogers, F. J. Salguero, M. Schotsaert, K. J. Stittelaar, H. J. Thibaut, C.-T. Tseng, J. Vergara-Alert, M. Beer, T. Brasel, J. F. W. Chan, A. Garc&#237;a-Sastre, J. Neyts, S. Perlman, D. S. Reed, J. A. Richt, C. J. Roy, J. Segal&#233;s, S. S. Vasan, A. M. Henao-Restrepo, D. H. Barouch, Animal models for COVID-19. Nature <b title="valid: False, node: 716, tag: b, level: 18" node_number="716">586</b>, 509&#8211;515 (2020).</div><div title="valid: False, node: 717, tag: div, level: 17" node_number="717"><div title="valid: False, node: 718, tag: div, level: 18" node_number="718"><a title="valid: False, node: 719, tag: a, level: 19" node_number="719">Crossref</a></div><div title="valid: False, node: 720, tag: div, level: 18" node_number="720"><a title="valid: False, node: 721, tag: a, level: 19" node_number="721">PubMed</a></div><div title="valid: False, node: 722, tag: div, level: 18" node_number="722"><a title="valid: False, node: 723, tag: a, level: 19" node_number="723">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 724, tag: div, level: 14" node_number="724"><div title="valid: False, node: 725, tag: div, level: 15" node_number="725">22</div><div title="valid: False, node: 726, tag: div, level: 15" node_number="726"><div title="valid: False, node: 727, tag: div, level: 16" node_number="727"><div title="valid: False, node: 728, tag: div, level: 17" node_number="728">Z. Beck, G. R. Matyas, R. Jalah, M. Rao, V. R. Polonis, C. R. Alving, Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine <b title="valid: False, node: 729, tag: b, level: 18" node_number="729">33</b>, 5578&#8211;5587 (2015).</div><div title="valid: False, node: 730, tag: div, level: 17" node_number="730"><div title="valid: False, node: 731, tag: div, level: 18" node_number="731"><a title="valid: False, node: 732, tag: a, level: 19" node_number="732">Crossref</a></div><div title="valid: False, node: 733, tag: div, level: 18" node_number="733"><a title="valid: False, node: 734, tag: a, level: 19" node_number="734">PubMed</a></div><div title="valid: False, node: 735, tag: div, level: 18" node_number="735"><a title="valid: False, node: 736, tag: a, level: 19" node_number="736">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 737, tag: div, level: 14" node_number="737"><div title="valid: False, node: 738, tag: div, level: 15" node_number="738">23</div><div title="valid: False, node: 739, tag: div, level: 15" node_number="739"><div title="valid: False, node: 740, tag: div, level: 16" node_number="740"><div title="valid: False, node: 741, tag: div, level: 17" node_number="741">Z. Beck, G. R. Matyas, C. R. Alving, Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim. Biophys. Acta <b title="valid: False, node: 742, tag: b, level: 18" node_number="742">1848</b>, 775&#8211;780 (2015).</div><div title="valid: False, node: 743, tag: div, level: 17" node_number="743"><div title="valid: False, node: 744, tag: div, level: 18" node_number="744"><a title="valid: False, node: 745, tag: a, level: 19" node_number="745">Crossref</a></div><div title="valid: False, node: 746, tag: div, level: 18" node_number="746"><a title="valid: False, node: 747, tag: a, level: 19" node_number="747">PubMed</a></div><div title="valid: False, node: 748, tag: div, level: 18" node_number="748"><a title="valid: False, node: 749, tag: a, level: 19" node_number="749">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 750, tag: div, level: 14" node_number="750"><div title="valid: False, node: 751, tag: div, level: 15" node_number="751">24</div><div title="valid: False, node: 752, tag: div, level: 15" node_number="752"><div title="valid: False, node: 753, tag: div, level: 16" node_number="753"><div title="valid: False, node: 754, tag: div, level: 17" node_number="754">N. Suryadevara, S. Shrihari, P. Gilchuk, L. A. VanBlargan, E. Binshtein, S. J. Zost, R. S. Nargi, R. E. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. J. Doranz, R. E. Chen, P.-Y. Shi, R. H. Carnahan, L. B. Thackray, M. S. Diamond, J. E. Crowe Jr., Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell <b title="valid: False, node: 755, tag: b, level: 18" node_number="755">184</b>, 2316&#8211;2331.e15 (2021).</div><div title="valid: False, node: 756, tag: div, level: 17" node_number="756"><div title="valid: False, node: 757, tag: div, level: 18" node_number="757"><a title="valid: False, node: 758, tag: a, level: 19" node_number="758">Crossref</a></div><div title="valid: False, node: 759, tag: div, level: 18" node_number="759"><a title="valid: False, node: 760, tag: a, level: 19" node_number="760">PubMed</a></div><div title="valid: False, node: 761, tag: div, level: 18" node_number="761"><a title="valid: False, node: 762, tag: a, level: 19" node_number="762">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 763, tag: div, level: 14" node_number="763"><div title="valid: False, node: 764, tag: div, level: 15" node_number="764">25</div><div title="valid: False, node: 765, tag: div, level: 15" node_number="765"><div title="valid: False, node: 766, tag: div, level: 16" node_number="766"><div title="valid: False, node: 767, tag: div, level: 17" node_number="767">N. B. Mercado, R. Zahn, F. Wegmann, C. Loos, A. Chandrashekar, J. Yu, J. Liu, L. Peter, K. McMahan, L. H. Tostanoski, X. He, D. R. Martinez, L. Rutten, R. Bos, D. van Manen, J. Vellinga, J. Custers, J. P. Langedijk, T. Kwaks, M. J. G. Bakkers, D. Zuijdgeest, S. K. Rosendahl Huber, C. Atyeo, S. Fischinger, J. S. Burke, J. Feldman, B. M. Hauser, T. M. Caradonna, E. A. Bondzie, G. Dagotto, M. S. Gebre, E. Hoffman, C. Jacob-Dolan, M. Kirilova, Z. Li, Z. Lin, S. H. Mahrokhian, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. P. Nkolola, S. Patel, J. D. Ventura, K. Verrington, H. Wan, L. Pessaint, A. Van Ry, K. Blade, A. Strasbaugh, M. Cabus, R. Brown, A. Cook, S. Zouantchangadou, E. Teow, H. Andersen, M. G. Lewis, Y. Cai, B. Chen, A. G. Schmidt, R. K. Reeves, R. S. Baric, D. A. Lauffenburger, G. Alter, P. Stoffels, M. Mammen, J. Van Hoof, H. Schuitemaker, D. H. Barouch, Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature <b title="valid: False, node: 768, tag: b, level: 18" node_number="768">586</b>, 583&#8211;588 (2020).</div><div title="valid: False, node: 769, tag: div, level: 17" node_number="769"><div title="valid: False, node: 770, tag: div, level: 18" node_number="770"><a title="valid: False, node: 771, tag: a, level: 19" node_number="771">Crossref</a></div><div title="valid: False, node: 772, tag: div, level: 18" node_number="772"><a title="valid: False, node: 773, tag: a, level: 19" node_number="773">PubMed</a></div><div title="valid: False, node: 774, tag: div, level: 18" node_number="774"><a title="valid: False, node: 775, tag: a, level: 19" node_number="775">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 776, tag: div, level: 14" node_number="776"><div title="valid: False, node: 777, tag: div, level: 15" node_number="777">26</div><div title="valid: False, node: 778, tag: div, level: 15" node_number="778"><div title="valid: False, node: 779, tag: div, level: 16" node_number="779"><div title="valid: False, node: 780, tag: div, level: 17" node_number="780">J. Yu, L. H. Tostanoski, L. Peter, N. B. Mercado, K. McMahan, S. H. Mahrokhian, J. P. Nkolola, J. Liu, Z. Li, A. Chandrashekar, D. R. Martinez, C. Loos, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Slein, Y. Chen, A. Zuiani, F. J. N. Lelis, M. Travers, S. Habibi, L. Pessaint, A. Van Ry, K. Blade, R. Brown, A. Cook, B. Finneyfrock, A. Dodson, E. Teow, J. Velasco, R. Zahn, F. Wegmann, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, M. Kirilova, N. Kordana, Z. Lin, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. D. Ventura, H. Wan, Y. Cai, B. Chen, A. G. Schmidt, D. R. Wesemann, R. S. Baric, G. Alter, H. Andersen, M. G. Lewis, D. H. Barouch, DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science <b title="valid: False, node: 781, tag: b, level: 18" node_number="781">369</b>, 806&#8211;811 (2020).</div><div title="valid: False, node: 782, tag: div, level: 17" node_number="782"><div title="valid: False, node: 783, tag: div, level: 18" node_number="783"><a title="valid: False, node: 784, tag: a, level: 19" node_number="784">Crossref</a></div><div title="valid: False, node: 785, tag: div, level: 18" node_number="785"><a title="valid: False, node: 786, tag: a, level: 19" node_number="786">PubMed</a></div><div title="valid: False, node: 787, tag: div, level: 18" node_number="787"><a title="valid: False, node: 788, tag: a, level: 19" node_number="788">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 789, tag: div, level: 14" node_number="789"><div title="valid: False, node: 790, tag: div, level: 15" node_number="790">27</div><div title="valid: False, node: 791, tag: div, level: 15" node_number="791"><div title="valid: False, node: 792, tag: div, level: 16" node_number="792"><div title="valid: False, node: 793, tag: div, level: 17" node_number="793">A. Alrubayyi, A. Schuetz, K. G. Lal, S. Jongrakthaitae, K. M. Paolino, J. A. Ake, M. L. Robb, M. S. de Souza, N. L. Michael, D. Paquin-Proulx, M. A. Eller, A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. J. Immunol. Methods <b title="valid: False, node: 794, tag: b, level: 18" node_number="794">462</b>, 74&#8211;82 (2018).</div><div title="valid: False, node: 795, tag: div, level: 17" node_number="795"><div title="valid: False, node: 796, tag: div, level: 18" node_number="796"><a title="valid: False, node: 797, tag: a, level: 19" node_number="797">Crossref</a></div><div title="valid: False, node: 798, tag: div, level: 18" node_number="798"><a title="valid: False, node: 799, tag: a, level: 19" node_number="799">PubMed</a></div><div title="valid: False, node: 800, tag: div, level: 18" node_number="800"><a title="valid: False, node: 801, tag: a, level: 19" node_number="801">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 802, tag: div, level: 14" node_number="802"><div title="valid: False, node: 803, tag: div, level: 15" node_number="803">28</div><div title="valid: False, node: 804, tag: div, level: 15" node_number="804"><div title="valid: False, node: 805, tag: div, level: 16" node_number="805"><div title="valid: False, node: 806, tag: div, level: 17" node_number="806">B. F. Haynes, L. Corey, P. Fernandes, P. B. Gilbert, P. J. Hotez, S. Rao, M. R. Santos, H. Schuitemaker, M. Watson, A. Arvin, Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. <b title="valid: False, node: 807, tag: b, level: 18" node_number="807">12</b>, eabe0948 (2020).</div><div title="valid: False, node: 808, tag: div, level: 17" node_number="808"><div title="valid: False, node: 809, tag: div, level: 18" node_number="809"><a title="valid: False, node: 810, tag: a, level: 19" node_number="810">Crossref</a></div><div title="valid: False, node: 811, tag: div, level: 18" node_number="811"><a title="valid: False, node: 812, tag: a, level: 19" node_number="812">PubMed</a></div><div title="valid: False, node: 813, tag: div, level: 18" node_number="813"><a title="valid: False, node: 814, tag: a, level: 19" node_number="814">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 815, tag: div, level: 14" node_number="815"><div title="valid: False, node: 816, tag: div, level: 15" node_number="816">29</div><div title="valid: False, node: 817, tag: div, level: 15" node_number="817"><div title="valid: False, node: 818, tag: div, level: 16" node_number="818"><div title="valid: False, node: 819, tag: div, level: 17" node_number="819">J. S. Hale, R. Ahmed, Memory T follicular helper CD4 T cells. Front. Immunol. <b title="valid: False, node: 820, tag: b, level: 18" node_number="820">6</b>, 16 (2015).</div><div title="valid: False, node: 821, tag: div, level: 17" node_number="821"><div title="valid: False, node: 822, tag: div, level: 18" node_number="822"><a title="valid: False, node: 823, tag: a, level: 19" node_number="823">Crossref</a></div><div title="valid: False, node: 824, tag: div, level: 18" node_number="824"><a title="valid: False, node: 825, tag: a, level: 19" node_number="825">PubMed</a></div><div title="valid: False, node: 826, tag: div, level: 18" node_number="826"><a title="valid: False, node: 827, tag: a, level: 19" node_number="827">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 828, tag: div, level: 14" node_number="828"><div title="valid: False, node: 829, tag: div, level: 15" node_number="829">30</div><div title="valid: False, node: 830, tag: div, level: 15" node_number="830"><div title="valid: False, node: 831, tag: div, level: 16" node_number="831"><div title="valid: False, node: 832, tag: div, level: 17" node_number="832">Y. Liu, J. Liu, H. Xia, X. Zhang, C. R. Fontes-Garfias, K. A. Swanson, H. Cai, R. Sarkar, W. Chen, M. Cutler, D. Cooper, S. C. Weaver, A. Muik, U. Sahin, K. U. Jansen, X. Xie, P. R. Dormitzer, P.-Y. Shi, Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. <b title="valid: False, node: 833, tag: b, level: 18" node_number="833">384</b>, 1466&#8211;1468 (2021).</div><div title="valid: False, node: 834, tag: div, level: 17" node_number="834"><div title="valid: False, node: 835, tag: div, level: 18" node_number="835"><a title="valid: False, node: 836, tag: a, level: 19" node_number="836">Crossref</a></div><div title="valid: False, node: 837, tag: div, level: 18" node_number="837"><a title="valid: False, node: 838, tag: a, level: 19" node_number="838">PubMed</a></div><div title="valid: False, node: 839, tag: div, level: 18" node_number="839"><a title="valid: False, node: 840, tag: a, level: 19" node_number="840">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 841, tag: div, level: 14" node_number="841"><div title="valid: False, node: 842, tag: div, level: 15" node_number="842">31</div><div title="valid: False, node: 843, tag: div, level: 15" node_number="843"><div title="valid: False, node: 844, tag: div, level: 16" node_number="844"><div title="valid: False, node: 845, tag: div, level: 17" node_number="845">X. Shen, H. Tang, C. McDanal, K. Wagh, W. Fischer, J. Theiler, H. Yoon, D. Li, B. F. Haynes, K. O. Sanders, S. Gnanakaran, N. Hengartner, R. Pajon, G. Smith, G. M. Glenn, B. Korber, D. C. Montefiori, SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe <b title="valid: False, node: 846, tag: b, level: 18" node_number="846">29</b>, 529&#8211;539.e3 (2021).</div><div title="valid: False, node: 847, tag: div, level: 17" node_number="847"><div title="valid: False, node: 848, tag: div, level: 18" node_number="848"><a title="valid: False, node: 849, tag: a, level: 19" node_number="849">Crossref</a></div><div title="valid: False, node: 850, tag: div, level: 18" node_number="850"><a title="valid: False, node: 851, tag: a, level: 19" node_number="851">PubMed</a></div><div title="valid: False, node: 852, tag: div, level: 18" node_number="852"><a title="valid: False, node: 853, tag: a, level: 19" node_number="853">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 854, tag: div, level: 14" node_number="854"><div title="valid: False, node: 855, tag: div, level: 15" node_number="855">32</div><div title="valid: False, node: 856, tag: div, level: 15" node_number="856"><div title="valid: False, node: 857, tag: div, level: 16" node_number="857"><div title="valid: False, node: 858, tag: div, level: 17" node_number="858">M. Voysey, A. J. Pollard, ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors&#8217; reply. Lancet <b title="valid: False, node: 859, tag: b, level: 18" node_number="859">396</b>, 1486&#8211;1487 (2020).</div><div title="valid: False, node: 860, tag: div, level: 17" node_number="860"><div title="valid: False, node: 861, tag: div, level: 18" node_number="861"><a title="valid: False, node: 862, tag: a, level: 19" node_number="862">Crossref</a></div><div title="valid: False, node: 863, tag: div, level: 18" node_number="863"><a title="valid: False, node: 864, tag: a, level: 19" node_number="864">PubMed</a></div><div title="valid: False, node: 865, tag: div, level: 18" node_number="865"><a title="valid: False, node: 866, tag: a, level: 19" node_number="866">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 867, tag: div, level: 14" node_number="867"><div title="valid: False, node: 868, tag: div, level: 15" node_number="868">33</div><div title="valid: False, node: 869, tag: div, level: 15" node_number="869"><div title="valid: False, node: 870, tag: div, level: 16" node_number="870"><div title="valid: False, node: 871, tag: div, level: 17" node_number="871">Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, M. Turroja, K. A. West, K. Gordon, K. G. Millard, V. Ramos, J. Da Silva, J. Xu, R. A. Colbert, R. Patel, J. Dizon, C. Unson-O&#8217;Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. J. Bjorkman, R. Casellas, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature <b title="valid: False, node: 872, tag: b, level: 18" node_number="872">592</b>, 616&#8211;622 (2021).</div><div title="valid: False, node: 873, tag: div, level: 17" node_number="873"><div title="valid: False, node: 874, tag: div, level: 18" node_number="874"><a title="valid: False, node: 875, tag: a, level: 19" node_number="875">Crossref</a></div><div title="valid: False, node: 876, tag: div, level: 18" node_number="876"><a title="valid: False, node: 877, tag: a, level: 19" node_number="877">PubMed</a></div><div title="valid: False, node: 878, tag: div, level: 18" node_number="878"><a title="valid: False, node: 879, tag: a, level: 19" node_number="879">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 880, tag: div, level: 14" node_number="880"><div title="valid: False, node: 881, tag: div, level: 15" node_number="881">34</div><div title="valid: False, node: 882, tag: div, level: 15" node_number="882"><div title="valid: False, node: 883, tag: div, level: 16" node_number="883"><div title="valid: False, node: 884, tag: div, level: 17" node_number="884">K. S. Corbett, B. Flynn, K. E. Foulds, J. R. Francica, S. Boyoglu-Barnum, A. P. Werner, B. Flach, S. O&#8217;Connell, K. W. Bock, M. Minai, B. M. Nagata, H. Andersen, D. R. Martinez, A. T. Noe, N. Douek, M. M. Donaldson, N. N. Nji, G. S. Alvarado, D. K. Edwards, D. R. Flebbe, E. Lamb, N. A. Doria-Rose, B. C. Lin, M. K. Louder, S. O&#8217;Dell, S. D. Schmidt, E. Phung, L. A. Chang, C. Yap, J. M. Todd, L. Pessaint, A. Van Ry, S. Browne, J. Greenhouse, T. Putman-Taylor, A. Strasbaugh, T.-A. Campbell, A. Cook, A. Dodson, K. Steingrebe, W. Shi, Y. Zhang, O. M. Abiona, L. Wang, A. Pegu, E. S. Yang, K. Leung, T. Zhou, I.-T. Teng, A. Widge, I. Gordon, L. Novik, R. A. Gillespie, R. J. Loomis, J. I. Moliva, G. Stewart-Jones, S. Himansu, W.-P. Kong, M. C. Nason, K. M. Morabito, T. J. Ruckwardt, J. E. Ledgerwood, M. R. Gaudinski, P. D. Kwong, J. R. Mascola, A. Carfi, M. G. Lewis, R. S. Baric, A. McDermott, I. N. Moore, N. J. Sullivan, M. Roederer, R. A. Seder, B. S. Graham, Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. <b title="valid: False, node: 885, tag: b, level: 18" node_number="885">383</b>, 1544&#8211;1555 (2020).</div><div title="valid: False, node: 886, tag: div, level: 17" node_number="886"><div title="valid: False, node: 887, tag: div, level: 18" node_number="887"><a title="valid: False, node: 888, tag: a, level: 19" node_number="888">Crossref</a></div><div title="valid: False, node: 889, tag: div, level: 18" node_number="889"><a title="valid: False, node: 890, tag: a, level: 19" node_number="890">PubMed</a></div><div title="valid: False, node: 891, tag: div, level: 18" node_number="891"><a title="valid: False, node: 892, tag: a, level: 19" node_number="892">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 893, tag: div, level: 14" node_number="893"><div title="valid: False, node: 894, tag: div, level: 15" node_number="894">35</div><div title="valid: False, node: 895, tag: div, level: 15" node_number="895"><div title="valid: False, node: 896, tag: div, level: 16" node_number="896"><div title="valid: False, node: 897, tag: div, level: 17" node_number="897">M. Guebre-Xabier, N. Patel, J.-H. Tian, B. Zhou, S. Maciejewski, K. Lam, A. D. Portnoff, M. J. Massare, M. B. Frieman, P. A. Piedra, L. Ellingsworth, G. Glenn, G. Smith, NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine <b title="valid: False, node: 898, tag: b, level: 18" node_number="898">38</b>, 7892&#8211;7896 (2020).</div><div title="valid: False, node: 899, tag: div, level: 17" node_number="899"><div title="valid: False, node: 900, tag: div, level: 18" node_number="900"><a title="valid: False, node: 901, tag: a, level: 19" node_number="901">Crossref</a></div><div title="valid: False, node: 902, tag: div, level: 18" node_number="902"><a title="valid: False, node: 903, tag: a, level: 19" node_number="903">PubMed</a></div><div title="valid: False, node: 904, tag: div, level: 18" node_number="904"><a title="valid: False, node: 905, tag: a, level: 19" node_number="905">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 906, tag: div, level: 14" node_number="906"><div title="valid: False, node: 907, tag: div, level: 15" node_number="907">36</div><div title="valid: False, node: 908, tag: div, level: 15" node_number="908"><div title="valid: False, node: 909, tag: div, level: 16" node_number="909"><div title="valid: False, node: 910, tag: div, level: 17" node_number="910">H. Wang, Y. Zhang, B. Huang, W. Deng, Y. Quan, W. Wang, W. Xu, Y. Zhao, N. Li, J. Zhang, H. Liang, L. Bao, Y. Xu, L. Ding, W. Zhou, H. Gao, J. Liu, P. Niu, L. Zhao, W. Zhen, H. Fu, S. Yu, Z. Zhang, G. Xu, C. Li, Z. Lou, M. Xu, C. Qin, G. Wu, G. F. Gao, W. Tan, X. Yang, Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell <b title="valid: False, node: 911, tag: b, level: 18" node_number="911">182</b>, 713&#8211;721.e9 (2020).</div><div title="valid: False, node: 912, tag: div, level: 17" node_number="912"><div title="valid: False, node: 913, tag: div, level: 18" node_number="913"><a title="valid: False, node: 914, tag: a, level: 19" node_number="914">Crossref</a></div><div title="valid: False, node: 915, tag: div, level: 18" node_number="915"><a title="valid: False, node: 916, tag: a, level: 19" node_number="916">PubMed</a></div><div title="valid: False, node: 917, tag: div, level: 18" node_number="917"><a title="valid: False, node: 918, tag: a, level: 19" node_number="918">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 919, tag: div, level: 14" node_number="919"><div title="valid: False, node: 920, tag: div, level: 15" node_number="920">37</div><div title="valid: False, node: 921, tag: div, level: 15" node_number="921"><div title="valid: False, node: 922, tag: div, level: 16" node_number="922"><div title="valid: False, node: 923, tag: div, level: 17" node_number="923">N. van Doremalen, T. Lambe, A. Spencer, S. Belij-Rammerstorfer, J. N. Purushotham, J. R. Port, V. A. Avanzato, T. Bushmaker, A. Flaxman, M. Ulaszewska, F. Feldmann, E. R. Allen, H. Sharpe, J. Schulz, M. Holbrook, A. Okumura, K. Meade-White, L. P&#233;rez-P&#233;rez, N. J. Edwards, D. Wright, C. Bissett, C. Gilbride, B. N. Williamson, R. Rosenke, D. Long, A. Ishwarbhai, R. Kailath, L. Rose, S. Morris, C. Powers, J. Lovaglio, P. W. Hanley, D. Scott, G. Saturday, E. de Wit, S. C. Gilbert, V. J. Munster, ChAdOx1&#160;nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature <b title="valid: False, node: 924, tag: b, level: 18" node_number="924">586</b>, 578&#8211;582 (2020).</div><div title="valid: False, node: 925, tag: div, level: 17" node_number="925"><div title="valid: False, node: 926, tag: div, level: 18" node_number="926"><a title="valid: False, node: 927, tag: a, level: 19" node_number="927">Crossref</a></div><div title="valid: False, node: 928, tag: div, level: 18" node_number="928"><a title="valid: False, node: 929, tag: a, level: 19" node_number="929">PubMed</a></div><div title="valid: False, node: 930, tag: div, level: 18" node_number="930"><a title="valid: False, node: 931, tag: a, level: 19" node_number="931">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 932, tag: div, level: 14" node_number="932"><div title="valid: False, node: 933, tag: div, level: 15" node_number="933">38</div><div title="valid: False, node: 934, tag: div, level: 15" node_number="934"><div title="valid: False, node: 935, tag: div, level: 16" node_number="935"><div title="valid: False, node: 936, tag: div, level: 17" node_number="936">A. B. Vogel, I. Kanevsky, Y. Che, K. A. Swanson, A. Muik, M. Vormehr, L. M. Kranz, K. C. Walzer, S. Hein, A. G&#252;ler, J. Loschko, M. S. Maddur, A. Ota-Setlik, K. Tompkins, J. Cole, B. G. Lui, T. Ziegenhals, A. Plaschke, D. Eisel, S. C. Dany, S. Fesser, S. Erbar, F. Bates, D. Schneider, B. Jesionek, B. S&#228;nger, A.-K. Wallisch, Y. Feuchter, H. Junginger, S. A. Krumm, A. P. Heinen, P. Adams-Quack, J. Schlereth, S. Schille, C. Kr&#246;ner, R. de la Caridad G&#252;imil Garcia, T. Hiller, L. Fischer, R. S. Sellers, S. Choudhary, O. Gonzalez, F. Vascotto, M. R. Gutman, J. A. Fontenot, S. Hall-Ursone, K. Brasky, M. C. Griffor, S. Han, A. A. H. Su, J. A. Lees, N. L. Nedoma, E. H. Mashalidis, P. V. Sahasrabudhe, C. Y. Tan, D. Pavliakova, G. Singh, C. Fontes-Garfias, M. Pride, I. L. Scully, T. Ciolino, J. Obregon, M. Gazi, R. Carrion Jr., K. J. Alfson, W. V. Kalina, D. Kaushal, P.-Y. Shi, T. Klamp, C. Rosenbaum, A. N. Kuhn, &#214;. T&#252;reci, P. R. Dormitzer, K. U. Jansen, U. Sahin, BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature <b title="valid: False, node: 937, tag: b, level: 18" node_number="937">592</b>, 283&#8211;289 (2021).</div><div title="valid: False, node: 938, tag: div, level: 17" node_number="938"><div title="valid: False, node: 939, tag: div, level: 18" node_number="939"><a title="valid: False, node: 940, tag: a, level: 19" node_number="940">Crossref</a></div><div title="valid: False, node: 941, tag: div, level: 18" node_number="941"><a title="valid: False, node: 942, tag: a, level: 19" node_number="942">PubMed</a></div><div title="valid: False, node: 943, tag: div, level: 18" node_number="943"><a title="valid: False, node: 944, tag: a, level: 19" node_number="944">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 945, tag: div, level: 14" node_number="945"><div title="valid: False, node: 946, tag: div, level: 15" node_number="946">39</div><div title="valid: False, node: 947, tag: div, level: 15" node_number="947"><div title="valid: False, node: 948, tag: div, level: 16" node_number="948"><div title="valid: False, node: 949, tag: div, level: 17" node_number="949">J. Verma, N. Subbarao, A comparative study of human betacoronavirus spike proteins: Structure, function and therapeutics. Arch. Virol. <b title="valid: False, node: 950, tag: b, level: 18" node_number="950">166</b>, 697&#8211;714 (2021).</div><div title="valid: False, node: 951, tag: div, level: 17" node_number="951"><div title="valid: False, node: 952, tag: div, level: 18" node_number="952"><a title="valid: False, node: 953, tag: a, level: 19" node_number="953">Crossref</a></div><div title="valid: False, node: 954, tag: div, level: 18" node_number="954"><a title="valid: False, node: 955, tag: a, level: 19" node_number="955">PubMed</a></div><div title="valid: False, node: 956, tag: div, level: 18" node_number="956"><a title="valid: False, node: 957, tag: a, level: 19" node_number="957">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 958, tag: div, level: 14" node_number="958"><div title="valid: False, node: 959, tag: div, level: 15" node_number="959">40</div><div title="valid: False, node: 960, tag: div, level: 15" node_number="960"><div title="valid: False, node: 961, tag: div, level: 16" node_number="961"><div title="valid: False, node: 962, tag: div, level: 17" node_number="962">J. Li, L. Ulitzky, E. Silberstein, D. R. Taylor, R. Viscidi, Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral Immunol. <b title="valid: False, node: 963, tag: b, level: 18" node_number="963">26</b>, 126&#8211;132 (2013).</div><div title="valid: False, node: 964, tag: div, level: 17" node_number="964"><div title="valid: False, node: 965, tag: div, level: 18" node_number="965"><a title="valid: False, node: 966, tag: a, level: 19" node_number="966">Crossref</a></div><div title="valid: False, node: 967, tag: div, level: 18" node_number="967"><a title="valid: False, node: 968, tag: a, level: 19" node_number="968">PubMed</a></div><div title="valid: False, node: 969, tag: div, level: 18" node_number="969"><a title="valid: False, node: 970, tag: a, level: 19" node_number="970">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 971, tag: div, level: 14" node_number="971"><div title="valid: False, node: 972, tag: div, level: 15" node_number="972">41</div><div title="valid: False, node: 973, tag: div, level: 15" node_number="973"><div title="valid: False, node: 974, tag: div, level: 16" node_number="974"><div title="valid: False, node: 975, tag: div, level: 17" node_number="975">R. L. Roper, K. E. Rehm, SARS vaccines: Where are we? Expert Rev. Vaccines <b title="valid: False, node: 976, tag: b, level: 18" node_number="976">8</b>, 887&#8211;898 (2009).</div><div title="valid: False, node: 977, tag: div, level: 17" node_number="977"><div title="valid: False, node: 978, tag: div, level: 18" node_number="978"><a title="valid: False, node: 979, tag: a, level: 19" node_number="979">Crossref</a></div><div title="valid: False, node: 980, tag: div, level: 18" node_number="980"><a title="valid: False, node: 981, tag: a, level: 19" node_number="981">PubMed</a></div><div title="valid: False, node: 982, tag: div, level: 18" node_number="982"><a title="valid: False, node: 983, tag: a, level: 19" node_number="983">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 984, tag: div, level: 14" node_number="984"><div title="valid: False, node: 985, tag: div, level: 15" node_number="985">42</div><div title="valid: False, node: 986, tag: div, level: 15" node_number="986"><div title="valid: False, node: 987, tag: div, level: 16" node_number="987"><div title="valid: False, node: 988, tag: div, level: 17" node_number="988">A. M. Sholukh, A. Fiore-Gartland, E. S. Ford, M. D. Miner, Y. J. Hou, L. V. Tse, H. Kaiser, H. Zhu, J. Lu, B. Madarampalli, A. Park, F. A. Lempp, R. St Germain, E. L. Bossard, J. J. Kee, K. Diem, A. B. Stuart, P. B. Rupert, C. Brock, M. Buerger, M. K. Doll, A. K. Randhawa, L. Stamatatos, R. K. Strong, C. McLaughlin, M. L. Huang, K. R. Jerome, R. S. Baric, D. Montefiori, L. Corey, Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. J. Clin. Microbiol. <b title="valid: False, node: 989, tag: b, level: 18" node_number="989">59</b>, e0052721 (2021).</div><div title="valid: False, node: 990, tag: div, level: 17" node_number="990"><div title="valid: False, node: 991, tag: div, level: 18" node_number="991"><a title="valid: False, node: 992, tag: a, level: 19" node_number="992">Crossref</a></div><div title="valid: False, node: 993, tag: div, level: 18" node_number="993"><a title="valid: False, node: 994, tag: a, level: 19" node_number="994">PubMed</a></div><div title="valid: False, node: 995, tag: div, level: 18" node_number="995"><a title="valid: False, node: 996, tag: a, level: 19" node_number="996">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 997, tag: div, level: 14" node_number="997"><div title="valid: False, node: 998, tag: div, level: 15" node_number="998">43</div><div title="valid: False, node: 999, tag: div, level: 15" node_number="999"><div title="valid: False, node: 1000, tag: div, level: 16" node_number="1000"><div title="valid: False, node: 1001, tag: div, level: 17" node_number="1001">M. Voysey, S. A. C. Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley, B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. M. Collins, R. Colin-Jones, C. L. Cutland, T. C. Darton, K. Dheda, C. J. A. Duncan, K. R. W. Emary, K. J. Ewer, L. Fairlie, S. N. Faust, S. Feng, D. M. Ferreira, A. Finn, A. L. Goodman, C. M. Green, C. A. Green, P. T. Heath, C. Hill, H. Hill, I. Hirsch, S. H. C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. M. Lawrie, A. Lelliott, V. Libri, P. J. Lillie, R. Mallory, A. V. A. Mendes, E. P. Milan, A. M. Minassian, A. McGregor, H. Morrison, Y. F. Mujadidi, A. Nana, P. J. O&#8217;Reilly, S. D. Padayachee, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy, S. Rhead, A. V. Schwarzbold, N. Singh, A. Smith, R. Song, M. D. Snape, E. Sprinz, R. K. Sutherland, R. Tarrant, E. C. Thomson, M. E. T&#246;r&#246;k, M. Toshner, D. P. J. Turner, J. Vekemans, T. L. Villafana, M. E. E. Watson, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, A. J. Pollard; Oxford COVID Vaccine Trial Group, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet <b title="valid: False, node: 1002, tag: b, level: 18" node_number="1002">397</b>, 99&#8211;111 (2021).</div><div title="valid: False, node: 1003, tag: div, level: 17" node_number="1003"><div title="valid: False, node: 1004, tag: div, level: 18" node_number="1004"><a title="valid: False, node: 1005, tag: a, level: 19" node_number="1005">Crossref</a></div><div title="valid: False, node: 1006, tag: div, level: 18" node_number="1006"><a title="valid: False, node: 1007, tag: a, level: 19" node_number="1007">PubMed</a></div><div title="valid: False, node: 1008, tag: div, level: 18" node_number="1008"><a title="valid: False, node: 1009, tag: a, level: 19" node_number="1009">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1010, tag: div, level: 14" node_number="1010"><div title="valid: False, node: 1011, tag: div, level: 15" node_number="1011">44</div><div title="valid: False, node: 1012, tag: div, level: 15" node_number="1012"><div title="valid: False, node: 1013, tag: div, level: 16" node_number="1013"><div title="valid: False, node: 1014, tag: div, level: 17" node_number="1014">J. E. Staples, A. D. T. Barrett, A. Wilder-Smith, J. Hombach, Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. NPJ Vaccines <b title="valid: False, node: 1015, tag: b, level: 18" node_number="1015">5</b>, 54 (2020).</div><div title="valid: False, node: 1016, tag: div, level: 17" node_number="1016"><div title="valid: False, node: 1017, tag: div, level: 18" node_number="1017"><a title="valid: False, node: 1018, tag: a, level: 19" node_number="1018">Crossref</a></div><div title="valid: False, node: 1019, tag: div, level: 18" node_number="1019"><a title="valid: False, node: 1020, tag: a, level: 19" node_number="1020">PubMed</a></div><div title="valid: False, node: 1021, tag: div, level: 18" node_number="1021"><a title="valid: False, node: 1022, tag: a, level: 19" node_number="1022">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1023, tag: div, level: 14" node_number="1023"><div title="valid: False, node: 1024, tag: div, level: 15" node_number="1024">45</div><div title="valid: False, node: 1025, tag: div, level: 15" node_number="1025"><div title="valid: False, node: 1026, tag: div, level: 16" node_number="1026"><div title="valid: False, node: 1027, tag: div, level: 17" node_number="1027">S. N. Crooke, M. M. Riggenbach, I. G. Ovsyannikova, N. D. Warner, M.-H. Chen, L. Hao, J. P. Icenogle, G. A. Poland, R. B. Kennedy, Durability of humoral immune responses to rubella following MMR vaccination. Vaccine <b title="valid: False, node: 1028, tag: b, level: 18" node_number="1028">38</b>, 8185&#8211;8193 (2020).</div><div title="valid: False, node: 1029, tag: div, level: 17" node_number="1029"><div title="valid: False, node: 1030, tag: div, level: 18" node_number="1030"><a title="valid: False, node: 1031, tag: a, level: 19" node_number="1031">Crossref</a></div><div title="valid: False, node: 1032, tag: div, level: 18" node_number="1032"><a title="valid: False, node: 1033, tag: a, level: 19" node_number="1033">PubMed</a></div><div title="valid: False, node: 1034, tag: div, level: 18" node_number="1034"><a title="valid: False, node: 1035, tag: a, level: 19" node_number="1035">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1036, tag: div, level: 14" node_number="1036"><div title="valid: False, node: 1037, tag: div, level: 15" node_number="1037">46</div><div title="valid: False, node: 1038, tag: div, level: 15" node_number="1038"><div title="valid: False, node: 1039, tag: div, level: 16" node_number="1039"><div title="valid: False, node: 1040, tag: div, level: 17" node_number="1040">H. Theeten, K. Van Herck, O. Van Der Meeren, P. Crasta, P. Van Damme, N. Hens, Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine <b title="valid: False, node: 1041, tag: b, level: 18" node_number="1041">33</b>, 5723&#8211;5727 (2015).</div><div title="valid: False, node: 1042, tag: div, level: 17" node_number="1042"><div title="valid: False, node: 1043, tag: div, level: 18" node_number="1043"><a title="valid: False, node: 1044, tag: a, level: 19" node_number="1044">Crossref</a></div><div title="valid: False, node: 1045, tag: div, level: 18" node_number="1045"><a title="valid: False, node: 1046, tag: a, level: 19" node_number="1046">PubMed</a></div><div title="valid: False, node: 1047, tag: div, level: 18" node_number="1047"><a title="valid: False, node: 1048, tag: a, level: 19" node_number="1048">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1049, tag: div, level: 14" node_number="1049"><div title="valid: False, node: 1050, tag: div, level: 15" node_number="1050">47</div><div title="valid: False, node: 1051, tag: div, level: 15" node_number="1051"><div title="valid: False, node: 1052, tag: div, level: 16" node_number="1052"><div title="valid: False, node: 1053, tag: div, level: 17" node_number="1053">A. A. Cohen, P. N. P. Gnanapragasam, Y. E. Lee, P. R. Hoffman, S. Ou, L. M. Kakutani, J. R. Keeffe, H.-J. Wu, M. Howarth, A. P. West, C. O. Barnes, M. C. Nussenzweig, P. J. Bjorkman, Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science <b title="valid: False, node: 1054, tag: b, level: 18" node_number="1054">371</b>, 735&#8211;741 (2021).</div><div title="valid: False, node: 1055, tag: div, level: 17" node_number="1055"><div title="valid: False, node: 1056, tag: div, level: 18" node_number="1056"><a title="valid: False, node: 1057, tag: a, level: 19" node_number="1057">Crossref</a></div><div title="valid: False, node: 1058, tag: div, level: 18" node_number="1058"><a title="valid: False, node: 1059, tag: a, level: 19" node_number="1059">PubMed</a></div><div title="valid: False, node: 1060, tag: div, level: 18" node_number="1060"><a title="valid: False, node: 1061, tag: a, level: 19" node_number="1061">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1062, tag: div, level: 14" node_number="1062"><div title="valid: False, node: 1063, tag: div, level: 15" node_number="1063">48</div><div title="valid: False, node: 1064, tag: div, level: 15" node_number="1064"><div title="valid: False, node: 1065, tag: div, level: 16" node_number="1065"><div title="valid: False, node: 1066, tag: div, level: 17" node_number="1066">A. E. Powell, K. Zhang, M. Sanyal, S. Tang, P. A. Weidenbacher, S. Li, T. D. Pham, J. E. Pak, W. Chiu, P. S. Kim, A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Cent. Sci. <b title="valid: False, node: 1067, tag: b, level: 18" node_number="1067">7</b>, 183&#8211;199 (2021).</div><div title="valid: False, node: 1068, tag: div, level: 17" node_number="1068"><div title="valid: False, node: 1069, tag: div, level: 18" node_number="1069"><a title="valid: False, node: 1070, tag: a, level: 19" node_number="1070">Crossref</a></div><div title="valid: False, node: 1071, tag: div, level: 18" node_number="1071"><a title="valid: False, node: 1072, tag: a, level: 19" node_number="1072">PubMed</a></div><div title="valid: False, node: 1073, tag: div, level: 18" node_number="1073"><a title="valid: False, node: 1074, tag: a, level: 19" node_number="1074">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1075, tag: div, level: 14" node_number="1075"><div title="valid: False, node: 1076, tag: div, level: 15" node_number="1076">49</div><div title="valid: False, node: 1077, tag: div, level: 15" node_number="1077"><div title="valid: False, node: 1078, tag: div, level: 16" node_number="1078"><div title="valid: False, node: 1079, tag: div, level: 17" node_number="1079">K. O. Saunders, E. Lee, R. Parks, D. R. Martinez, D. Li, H. Chen, R. J. Edwards, S. Gobeil, M. Barr, K. Mansouri, S. M. Alam, L. L. Sutherland, F. Cai, A. M. Sanzone, M. Berry, K. Manne, K. W. Bock, M. Minai, B. M. Nagata, A. B. Kapingidza, M. Azoitei, L. V. Tse, T. D. Scobey, R. L. Spreng, R. W. Rountree, C. T. DeMarco, T. N. Denny, C. W. Woods, E. W. Petzold, J. Tang, T. H. Oguin 3rd, G. D. Sempowski, M. Gagne, D. C. Douek, M. A. Tomai, C. B. Fox, R. Seder, K. Wiehe, D. Weissman, N. Pardi, H. Golding, S. Khurana, P. Acharya, H. Andersen, M. G. Lewis, I. N. Moore, D. C. Montefiori, R. S. Baric, B. F. Haynes, Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature <b title="valid: False, node: 1080, tag: b, level: 18" node_number="1080">594</b>, 553&#8211;559 (2021).</div><div title="valid: False, node: 1081, tag: div, level: 17" node_number="1081"><div title="valid: False, node: 1082, tag: div, level: 18" node_number="1082"><a title="valid: False, node: 1083, tag: a, level: 19" node_number="1083">Crossref</a></div><div title="valid: False, node: 1084, tag: div, level: 18" node_number="1084"><a title="valid: False, node: 1085, tag: a, level: 19" node_number="1085">PubMed</a></div><div title="valid: False, node: 1086, tag: div, level: 18" node_number="1086"><a title="valid: False, node: 1087, tag: a, level: 19" node_number="1087">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1088, tag: div, level: 14" node_number="1088"><div title="valid: False, node: 1089, tag: div, level: 15" node_number="1089">50</div><div title="valid: False, node: 1090, tag: div, level: 15" node_number="1090"><div title="valid: False, node: 1091, tag: div, level: 16" node_number="1091"><div title="valid: False, node: 1092, tag: div, level: 17" node_number="1092">C. J. Genito, Z. Beck, T. W. Phares, F. Kalle, K. J. Limbach, M. E. Stefaniak, N. B. Patterson, E. S. Bergmann-Leitner, N. C. Waters, G. R. Matyas, C. R. Alving, S. Dutta, Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine <b title="valid: False, node: 1093, tag: b, level: 18" node_number="1093">35</b>, 3865&#8211;3874 (2017).</div><div title="valid: False, node: 1094, tag: div, level: 17" node_number="1094"><div title="valid: False, node: 1095, tag: div, level: 18" node_number="1095"><a title="valid: False, node: 1096, tag: a, level: 19" node_number="1096">Crossref</a></div><div title="valid: False, node: 1097, tag: div, level: 18" node_number="1097"><a title="valid: False, node: 1098, tag: a, level: 19" node_number="1098">PubMed</a></div><div title="valid: False, node: 1099, tag: div, level: 18" node_number="1099"><a title="valid: False, node: 1100, tag: a, level: 19" node_number="1100">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1101, tag: div, level: 14" node_number="1101"><div title="valid: False, node: 1102, tag: div, level: 15" node_number="1102">51</div><div title="valid: False, node: 1103, tag: div, level: 15" node_number="1103"><div title="valid: False, node: 1104, tag: div, level: 16" node_number="1104"><div title="valid: False, node: 1105, tag: div, level: 17" node_number="1105">A. Ramakrishnan, N. M. Schumack, C. L. Gariepy, H. Eggleston, G. Nunez, N. Espinoza, M. Nieto, R. Castillo, J. Rojas, A. J. McCoy, Z. Beck, G. R. Matyas, C. R. Alving, P. Guerry, F. Poly, R. M. Laird, Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21. MSphere <b title="valid: False, node: 1106, tag: b, level: 18" node_number="1106">4</b> (2019).</div><div title="valid: False, node: 1107, tag: div, level: 17" node_number="1107"><div title="valid: False, node: 1108, tag: div, level: 18" node_number="1108"><a title="valid: False, node: 1109, tag: a, level: 19" node_number="1109">Crossref</a></div><div title="valid: False, node: 1110, tag: div, level: 18" node_number="1110"><a title="valid: False, node: 1111, tag: a, level: 19" node_number="1111">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1112, tag: div, level: 14" node_number="1112"><div title="valid: False, node: 1113, tag: div, level: 15" node_number="1113">52</div><div title="valid: False, node: 1114, tag: div, level: 15" node_number="1114"><div title="valid: False, node: 1115, tag: div, level: 16" node_number="1115"><div title="valid: False, node: 1116, tag: div, level: 17" node_number="1116">K. M. Wuertz, E. K. Barkei, W.-H. Chen, E. J. Martinez, I. Lakhal-Naouar, L. L. Jagodzinski, D. Paquin-Proulx, G. D. Gromowski, I. Swafford, A. Ganesh, M. Dong, X. Zeng, P. V. Thomas, R. S. Sankhala, A. Hajduczki, C. E. Peterson, C. Kuklis, S. Soman, L. Wieczorek, M. Zemil, A. Anderson, J. Darden, H. Hernandez, H. Grove, V. Dussupt, H. Hack, R. de la Barrera, S. Zarling, J. F. Wood, J. W. Froude, M. Gagne, A. R. Henry, E. B. Mokhtari, P. Mudvari, S. J. Krebs, A. S. Pekosz, J. R. Currier, S. Kar, M. Porto, A. Winn, K. Radzyminski, M. G. Lewis, S. Vasan, M. Suthar, V. R. Polonis, G. R. Matyas, E. A. Boritz, D. C. Douek, R. A. Seder, S. P. Daye, M. Rao, S. A. Peel, M. G. Joyce, D. L. Bolton, N. L. Michael, K. Modjarrad, A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines <b title="valid: False, node: 1117, tag: b, level: 18" node_number="1117">6</b>, 129 (2021).</div><div title="valid: False, node: 1118, tag: div, level: 17" node_number="1118"><div title="valid: False, node: 1119, tag: div, level: 18" node_number="1119"><a title="valid: False, node: 1120, tag: a, level: 19" node_number="1120">Crossref</a></div><div title="valid: False, node: 1121, tag: div, level: 18" node_number="1121"><a title="valid: False, node: 1122, tag: a, level: 19" node_number="1122">PubMed</a></div><div title="valid: False, node: 1123, tag: div, level: 18" node_number="1123"><a title="valid: False, node: 1124, tag: a, level: 19" node_number="1124">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1125, tag: div, level: 14" node_number="1125"><div title="valid: False, node: 1126, tag: div, level: 15" node_number="1126">53</div><div title="valid: False, node: 1127, tag: div, level: 15" node_number="1127"><div title="valid: False, node: 1128, tag: div, level: 16" node_number="1128"><div title="valid: False, node: 1129, tag: div, level: 17" node_number="1129">clinicaltrials.gov, (<a title="valid: False, node: 1130, tag: a, level: 18" node_number="1130">https://clinicaltrials.gov/ct2/show/NCT04784767?term=paul+scottdraw=2rank=1</a>, 2021).</div><div title="valid: False, node: 1131, tag: div, level: 17" node_number="1131"><div title="valid: False, node: 1132, tag: div, level: 18" node_number="1132"><a title="valid: False, node: 1133, tag: a, level: 19" node_number="1133">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1134, tag: div, level: 14" node_number="1134"><div title="valid: False, node: 1135, tag: div, level: 15" node_number="1135">54</div><div title="valid: False, node: 1136, tag: div, level: 15" node_number="1136"><div title="valid: False, node: 1137, tag: div, level: 16" node_number="1137"><div title="valid: False, node: 1138, tag: div, level: 17" node_number="1138">P. Singh, Z. Beck, G. R. Matyas, C. R. Alving, Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. J. Liposome Res. <b title="valid: False, node: 1139, tag: b, level: 18" node_number="1139">29</b>, 247&#8211;250 (2019).</div><div title="valid: False, node: 1140, tag: div, level: 17" node_number="1140"><div title="valid: False, node: 1141, tag: div, level: 18" node_number="1141"><a title="valid: False, node: 1142, tag: a, level: 19" node_number="1142">Crossref</a></div><div title="valid: False, node: 1143, tag: div, level: 18" node_number="1143"><a title="valid: False, node: 1144, tag: a, level: 19" node_number="1144">PubMed</a></div><div title="valid: False, node: 1145, tag: div, level: 18" node_number="1145"><a title="valid: False, node: 1146, tag: a, level: 19" node_number="1146">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1147, tag: div, level: 14" node_number="1147"><div title="valid: False, node: 1148, tag: div, level: 15" node_number="1148">55</div><div title="valid: False, node: 1149, tag: div, level: 15" node_number="1149"><div title="valid: False, node: 1150, tag: div, level: 16" node_number="1150"><div title="valid: False, node: 1151, tag: div, level: 17" node_number="1151">E. K. Nelson, B. Piehler, J. Eckels, A. Rauch, M. Bellew, P. Hussey, S. Ramsay, C. Nathe, K. Lum, K. Krouse, D. Stearns, B. Connolly, T. Skillman, M. Igra, LabKey Server: An open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics <b title="valid: False, node: 1152, tag: b, level: 18" node_number="1152">12</b>, 71 (2011).</div><div title="valid: False, node: 1153, tag: div, level: 17" node_number="1153"><div title="valid: False, node: 1154, tag: div, level: 18" node_number="1154"><a title="valid: False, node: 1155, tag: a, level: 19" node_number="1155">Crossref</a></div><div title="valid: False, node: 1156, tag: div, level: 18" node_number="1156"><a title="valid: False, node: 1157, tag: a, level: 19" node_number="1157">PubMed</a></div><div title="valid: False, node: 1158, tag: div, level: 18" node_number="1158"><a title="valid: False, node: 1159, tag: a, level: 19" node_number="1159">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1160, tag: div, level: 14" node_number="1160"><div title="valid: False, node: 1161, tag: div, level: 15" node_number="1161">56</div><div title="valid: False, node: 1162, tag: div, level: 15" node_number="1162"><div title="valid: False, node: 1163, tag: div, level: 16" node_number="1163"><div title="valid: False, node: 1164, tag: div, level: 17" node_number="1164">L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F.-W. Chan, V. Sahi, A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P. D. Kwong, J. G. Sodroski, M. T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D. D. Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature <b title="valid: False, node: 1165, tag: b, level: 18" node_number="1165">584</b>, 450&#8211;456 (2020).</div><div title="valid: False, node: 1166, tag: div, level: 17" node_number="1166"><div title="valid: False, node: 1167, tag: div, level: 18" node_number="1167"><a title="valid: False, node: 1168, tag: a, level: 19" node_number="1168">Crossref</a></div><div title="valid: False, node: 1169, tag: div, level: 18" node_number="1169"><a title="valid: False, node: 1170, tag: a, level: 19" node_number="1170">PubMed</a></div><div title="valid: False, node: 1171, tag: div, level: 18" node_number="1171"><a title="valid: False, node: 1172, tag: a, level: 19" node_number="1172">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1173, tag: div, level: 14" node_number="1173"><div title="valid: False, node: 1174, tag: div, level: 15" node_number="1174">57</div><div title="valid: False, node: 1175, tag: div, level: 15" node_number="1175"><div title="valid: False, node: 1176, tag: div, level: 16" node_number="1176"><div title="valid: False, node: 1177, tag: div, level: 17" node_number="1177">P. Wang, L. Liu, M. S. Nair, M. T. Yin, Y. Luo, Q. Wang, T. Yuan, K. Mori, A. G. Solis, M. Yamashita, A. Garg, L. J. Purpura, J. C. Laracy, J. Yu, L. Joshua-Tor, J. Sodroski, Y. Huang, D. D. Ho, SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg. Microbes Infect. <b title="valid: False, node: 1178, tag: b, level: 18" node_number="1178">9</b>, 2091&#8211;2093 (2020).</div><div title="valid: False, node: 1179, tag: div, level: 17" node_number="1179"><div title="valid: False, node: 1180, tag: div, level: 18" node_number="1180"><a title="valid: False, node: 1181, tag: a, level: 19" node_number="1181">Crossref</a></div><div title="valid: False, node: 1182, tag: div, level: 18" node_number="1182"><a title="valid: False, node: 1183, tag: a, level: 19" node_number="1183">PubMed</a></div><div title="valid: False, node: 1184, tag: div, level: 18" node_number="1184"><a title="valid: False, node: 1185, tag: a, level: 19" node_number="1185">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1186, tag: div, level: 14" node_number="1186"><div title="valid: False, node: 1187, tag: div, level: 15" node_number="1187">58</div><div title="valid: False, node: 1188, tag: div, level: 15" node_number="1188"><div title="valid: False, node: 1189, tag: div, level: 16" node_number="1189"><div title="valid: False, node: 1190, tag: div, level: 17" node_number="1190">K. T. Abe, Z. Li, R. Samson, P. Samavarchi-Tehrani, E. J. Valcourt, H. Wood, P. Budylowski, A. P. Dupuis 2nd, R. C. Girardin, B. Rathod, J. H. Wang, M. Barrios-Rodiles, K. Colwill, A. J. McGeer, S. Mubareka, J. L. Gommerman, Y. Durocher, M. Ostrowski, K. A. McDonough, M. A. Drebot, S. J. Drews, J. M. Rini, A.-C. Gingras, A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight <b title="valid: False, node: 1191, tag: b, level: 18" node_number="1191">5</b>, e142362 (2020).</div><div title="valid: False, node: 1192, tag: div, level: 17" node_number="1192"><div title="valid: False, node: 1193, tag: div, level: 18" node_number="1193"><a title="valid: False, node: 1194, tag: a, level: 19" node_number="1194">Crossref</a></div><div title="valid: False, node: 1195, tag: div, level: 18" node_number="1195"><a title="valid: False, node: 1196, tag: a, level: 19" node_number="1196">PubMed</a></div><div title="valid: False, node: 1197, tag: div, level: 18" node_number="1197"><a title="valid: False, node: 1198, tag: a, level: 19" node_number="1198">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1199, tag: div, level: 14" node_number="1199"><div title="valid: False, node: 1200, tag: div, level: 15" node_number="1200">59</div><div title="valid: False, node: 1201, tag: div, level: 15" node_number="1201"><div title="valid: False, node: 1202, tag: div, level: 16" node_number="1202"><div title="valid: False, node: 1203, tag: div, level: 17" node_number="1203">S. Fischinger, J. K. Fallon, A. R. Michell, T. Broge, T. J. Suscovich, H. Streeck, G. Alter, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods <b title="valid: False, node: 1204, tag: b, level: 18" node_number="1204">473</b>, 112630 (2019).</div><div title="valid: False, node: 1205, tag: div, level: 17" node_number="1205"><div title="valid: False, node: 1206, tag: div, level: 18" node_number="1206"><a title="valid: False, node: 1207, tag: a, level: 19" node_number="1207">Crossref</a></div><div title="valid: False, node: 1208, tag: div, level: 18" node_number="1208"><a title="valid: False, node: 1209, tag: a, level: 19" node_number="1209">PubMed</a></div><div title="valid: False, node: 1210, tag: div, level: 18" node_number="1210"><a title="valid: False, node: 1211, tag: a, level: 19" node_number="1211">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1212, tag: div, level: 14" node_number="1212"><div title="valid: False, node: 1213, tag: div, level: 15" node_number="1213">60</div><div title="valid: False, node: 1214, tag: div, level: 15" node_number="1214"><div title="valid: False, node: 1215, tag: div, level: 16" node_number="1215"><div title="valid: False, node: 1216, tag: div, level: 17" node_number="1216">L. Ninove, A. Nougairede, C. Gazin, L. Thirion, I. Delogu, C. Zandotti, R. N. Charrel, X. De Lamballerie, RNA and DNA bacteriophages as molecular diagnosis controls in clinical virology: A comprehensive study of more than 45,000 routine PCR tests. PLOS ONE <b title="valid: False, node: 1217, tag: b, level: 18" node_number="1217">6</b>, e16142 (2011).</div><div title="valid: False, node: 1218, tag: div, level: 17" node_number="1218"><div title="valid: False, node: 1219, tag: div, level: 18" node_number="1219"><a title="valid: False, node: 1220, tag: a, level: 19" node_number="1220">Crossref</a></div><div title="valid: False, node: 1221, tag: div, level: 18" node_number="1221"><a title="valid: False, node: 1222, tag: a, level: 19" node_number="1222">PubMed</a></div><div title="valid: False, node: 1223, tag: div, level: 18" node_number="1223"><a title="valid: False, node: 1224, tag: a, level: 19" node_number="1224">Google Scholar</a></div></div></div></div></div></section></div></section><div class="valid" valid="valid" title="valid: True, node: 1225, tag: div, level: 11" node_number="1225"><div class="valid" valid="valid" title="valid: True, node: 1226, tag: div, level: 12" node_number="1226"><header class="valid" valid="valid" title="valid: True, node: 1227, tag: header, level: 13" node_number="1227"><h2 class="valid" valid="valid" title="valid: True, node: 1228, tag: h2, level: 14" node_number="1228">Information Authors</h2></header><section class="valid" valid="valid" title="valid: True, node: 1229, tag: section, level: 13" node_number="1229"><h3 class="valid" valid="valid" title="valid: True, node: 1230, tag: h3, level: 14" node_number="1230">Information</h3><section class="valid" valid="valid" title="valid: True, node: 1231, tag: section, level: 14" node_number="1231"><h4 title="valid: False, node: 1232, tag: h4, level: 15" node_number="1232">Published In</h4><div title="valid: False, node: 1233, tag: div, level: 15" node_number="1233"> <div title="valid: False, node: 1234, tag: div, level: 16" node_number="1234"><div title="valid: False, node: 1235, tag: div, level: 17" node_number="1235">Science Translational Medicine</div><div title="valid: False, node: 1236, tag: div, level: 17" node_number="1236">First Release</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1237, tag: section, level: 14" node_number="1237"><h4 title="valid: False, node: 1238, tag: h4, level: 15" node_number="1238">Copyright</h4><div title="valid: False, node: 1239, tag: div, level: 15" node_number="1239">Copyright &#169; 2021, American Association for the Advancement of Science.</div><div title="valid: False, node: 1240, tag: div, level: 15" node_number="1240">https://creativecommons.org/licenses/by/4.0/ </div><div title="valid: False, node: 1241, tag: div, level: 15" node_number="1241">This is an open-access article distributed under the terms of the <a title="valid: False, node: 1242, tag: a, level: 16" node_number="1242">Creative Commons Attribution license</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></section><section class="valid" valid="valid" title="valid: True, node: 1243, tag: section, level: 14" node_number="1243"><h4 title="valid: False, node: 1244, tag: h4, level: 15" node_number="1244">Submission history</h4><div title="valid: False, node: 1245, tag: div, level: 15" node_number="1245"><b title="valid: False, node: 1246, tag: b, level: 16" node_number="1246">Received</b>: 17 March 2021</div><div title="valid: False, node: 1247, tag: div, level: 15" node_number="1247"><b title="valid: False, node: 1248, tag: b, level: 16" node_number="1248">Accepted</b>: 8 December 2021</div></section><section class="valid" valid="valid" title="valid: True, node: 1249, tag: section, level: 14" node_number="1249"><h4 title="valid: False, node: 1250, tag: h4, level: 15" node_number="1250">Permissions</h4><div title="valid: False, node: 1251, tag: div, level: 15" node_number="1251">Request permissions for this article.</div><div title="valid: False, node: 1252, tag: div, level: 15" node_number="1252"><a title="valid: False, node: 1253, tag: a, level: 16" node_number="1253">Request Permissions</a></div></section><section class="valid" valid="valid" title="valid: True, node: 1254, tag: section, level: 14" node_number="1254"><h4 title="valid: False, node: 1255, tag: h4, level: 15" node_number="1255">Acknowledgments</h4><div title="valid: False, node: 1256, tag: div, level: 15" node_number="1256"><b title="valid: False, node: 1257, tag: b, level: 16" node_number="1257">ACKNOWLEDGMENTS</b></div><div title="valid: False, node: 1258, tag: div, level: 15" node_number="1258">We thank J. Lay, E. Zografos, J. Lynch, L. Mendez-Rivera, N. Jackson, B. Slike, U. Tran, S. Peters, J. Bolton, T. Robinson, E. Duncan, H. Siegfried, R.J. O&#8217;Connell, Z. Beck and C. Alving for technical support, assistance, and advice.</div><div title="valid: False, node: 1259, tag: div, level: 15" node_number="1259"><b title="valid: False, node: 1260, tag: b, level: 16" node_number="1260">Funding:</b> We acknowledge support from the U.S. Department of Defense, Defense Health Agency (Restoral FY20 to KM). This work was partially executed through a cooperative agreement between the U.S. Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.</div><div title="valid: False, node: 1261, tag: div, level: 15" node_number="1261"><b title="valid: False, node: 1262, tag: b, level: 16" node_number="1262">Author contributions:</b> K.M. and M.G.J designed the study. I.E.N, A.A., K.K.P., C.M.C., C.S., R.E.C, J.B.C., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., M.C., C.S., P.J.L., A.A., K.M.W., M.S.N., H.M.S., N.dV., M.D., I.S., J.R.C., K.G.L, V.D., S.M., K.A., R.C., S.J.K. D.P.P., N.K., V.R.P., Y.H., L.L.J., G.D.G. performed immunologic and virologic assays. H.A.E, A.C., M.G.L. led the clinical care of the animals. S.P.D., X.Z., E.K.D performed histopathology. K.M., M.G.J., P.V.T., W-H.C., R.S.S., A.H., E.J.M., C.E.P., W.C.C., and M.C. designed the immunogens. M.R., G.R.M., and A.A. designed and provided the adjuvant. M.G.J., H.A.D.K. J.A.H., S.P.D., M.F.A., S.V., P.T.S., D.D.H., M.S.D., M.G.L., M.R., G.D.G., S.A.P., N.L.M. D.L.B. and K.M. analyzed and interpreted the data. K.M. wrote the paper with assistance from all coauthors.</div><div title="valid: False, node: 1263, tag: div, level: 15" node_number="1263"><b title="valid: False, node: 1264, tag: b, level: 16" node_number="1264">Competing interests:</b> K.M. and M.G.J. are primary co-inventors on related vaccine patents (U.S. Provisional Application 62/986,522 filed March 6, 2020, and to U.S. Provisional Application 63/038,600 filed June 12, 2020). M.S.D. is a consultant for Inbios, Vir Biotechnology, Fortress Biotech, and Carnival Corporation. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. M.S.D. is on the Scientific Advisory Boards of Moderna and Immunome. The other authors declare no competing interests.</div><div title="valid: False, node: 1265, tag: div, level: 15" node_number="1265"><b title="valid: False, node: 1266, tag: b, level: 16" node_number="1266">Data and materials availability:</b> All data are available in the manuscript or the supplementary materials. The vaccine and adjuvant used in this study will be made available to the scientific community by contacting Kayvon Modjarrad and completion of a materials transfer agreement.</div><div title="valid: False, node: 1267, tag: div, level: 15" node_number="1267">This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 1268, tag: a, level: 16" node_number="1268">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using this material.</div></section></section><section class="valid" valid="valid" title="valid: True, node: 1269, tag: section, level: 13" node_number="1269"><h3 class="valid" valid="valid" title="valid: True, node: 1270, tag: h3, level: 14" node_number="1270">Authors</h3><section class="valid" valid="valid" title="valid: True, node: 1271, tag: section, level: 14" node_number="1271"><h4 title="valid: False, node: 1272, tag: h4, level: 15" node_number="1272">Affiliations</h4><div title="valid: False, node: 1273, tag: div, level: 15" node_number="1273"><div title="valid: False, node: 1274, tag: div, level: 16" node_number="1274">M. Gordon Joyce<sup title="valid: False, node: 1275, tag: sup, level: 17" node_number="1275">*</sup> <a title="valid: False, node: 1276, tag: a, level: 17" node_number="1276">[email&#160;protected]</a></div><div title="valid: False, node: 1277, tag: div, level: 16" node_number="1277"><div title="valid: False, node: 1278, tag: div, level: 17" node_number="1278"><div title="valid: False, node: 1279, tag: div, level: 18" node_number="1279">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1280, tag: div, level: 18" node_number="1280">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1281, tag: div, level: 17" node_number="1281">View all articles by this author</div></div></div><div title="valid: False, node: 1282, tag: div, level: 15" node_number="1282"><div title="valid: False, node: 1283, tag: div, level: 16" node_number="1283">Hannah A. D. King</div><div title="valid: False, node: 1284, tag: div, level: 16" node_number="1284"><div title="valid: False, node: 1285, tag: div, level: 17" node_number="1285"><div title="valid: False, node: 1286, tag: div, level: 18" node_number="1286">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1287, tag: div, level: 18" node_number="1287">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1288, tag: div, level: 18" node_number="1288">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1289, tag: div, level: 17" node_number="1289">View all articles by this author</div></div></div><div title="valid: False, node: 1290, tag: div, level: 15" node_number="1290"><div title="valid: False, node: 1291, tag: div, level: 16" node_number="1291">Ines Elakhal-Naouar</div><div title="valid: False, node: 1292, tag: div, level: 16" node_number="1292"><div title="valid: False, node: 1293, tag: div, level: 17" node_number="1293"><div title="valid: False, node: 1294, tag: div, level: 18" node_number="1294">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1295, tag: div, level: 18" node_number="1295">Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1296, tag: div, level: 17" node_number="1296">View all articles by this author</div></div></div><div title="valid: False, node: 1297, tag: div, level: 15" node_number="1297"><div title="valid: False, node: 1298, tag: div, level: 16" node_number="1298">Aslaa Ahmed</div><div title="valid: False, node: 1299, tag: div, level: 16" node_number="1299"><div title="valid: False, node: 1300, tag: div, level: 17" node_number="1300"><div title="valid: False, node: 1301, tag: div, level: 18" node_number="1301">Viral Diseases Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1302, tag: div, level: 17" node_number="1302">View all articles by this author</div></div></div><div title="valid: False, node: 1303, tag: div, level: 15" node_number="1303"><div title="valid: False, node: 1304, tag: div, level: 16" node_number="1304">Kristina K. Peachman</div><div title="valid: False, node: 1305, tag: div, level: 16" node_number="1305"><div title="valid: False, node: 1306, tag: div, level: 17" node_number="1306"><div title="valid: False, node: 1307, tag: div, level: 18" node_number="1307">Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1308, tag: div, level: 17" node_number="1308">View all articles by this author</div></div></div><div title="valid: False, node: 1309, tag: div, level: 15" node_number="1309"><div title="valid: False, node: 1310, tag: div, level: 16" node_number="1310">Camila Macedo Cincotta</div><div title="valid: False, node: 1311, tag: div, level: 16" node_number="1311"><div title="valid: False, node: 1312, tag: div, level: 17" node_number="1312"><div title="valid: False, node: 1313, tag: div, level: 18" node_number="1313">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1314, tag: div, level: 18" node_number="1314">Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1315, tag: div, level: 17" node_number="1315">View all articles by this author</div></div></div><div title="valid: False, node: 1316, tag: div, level: 15" node_number="1316"><div title="valid: False, node: 1317, tag: div, level: 16" node_number="1317">Caroline Subra</div><div title="valid: False, node: 1318, tag: div, level: 16" node_number="1318"><div title="valid: False, node: 1319, tag: div, level: 17" node_number="1319"><div title="valid: False, node: 1320, tag: div, level: 18" node_number="1320">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1321, tag: div, level: 18" node_number="1321">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1322, tag: div, level: 18" node_number="1322">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1323, tag: div, level: 17" node_number="1323">View all articles by this author</div></div></div><div title="valid: False, node: 1324, tag: div, level: 15" node_number="1324"><div title="valid: False, node: 1325, tag: div, level: 16" node_number="1325">Rita E. Chen</div><div title="valid: False, node: 1326, tag: div, level: 16" node_number="1326"><div title="valid: False, node: 1327, tag: div, level: 17" node_number="1327"><div title="valid: False, node: 1328, tag: div, level: 18" node_number="1328">Department of Medicine, Washington University, St. Louis, MO 63130, USA.</div><div title="valid: False, node: 1329, tag: div, level: 18" node_number="1329">Department of Pathology Immunology, Washington University, St. Louis, MO 63130, USA.</div></div><div title="valid: False, node: 1330, tag: div, level: 17" node_number="1330">View all articles by this author</div></div></div><div title="valid: False, node: 1331, tag: div, level: 15" node_number="1331"><div title="valid: False, node: 1332, tag: div, level: 16" node_number="1332">Paul V. Thomas</div><div title="valid: False, node: 1333, tag: div, level: 16" node_number="1333"><div title="valid: False, node: 1334, tag: div, level: 17" node_number="1334"><div title="valid: False, node: 1335, tag: div, level: 18" node_number="1335">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1336, tag: div, level: 18" node_number="1336">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1337, tag: div, level: 17" node_number="1337">View all articles by this author</div></div></div><div title="valid: False, node: 1338, tag: div, level: 15" node_number="1338"><div title="valid: False, node: 1339, tag: div, level: 16" node_number="1339">Wei-Hung Chen</div><div title="valid: False, node: 1340, tag: div, level: 16" node_number="1340"><div title="valid: False, node: 1341, tag: div, level: 17" node_number="1341"><div title="valid: False, node: 1342, tag: div, level: 18" node_number="1342">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1343, tag: div, level: 18" node_number="1343">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1344, tag: div, level: 17" node_number="1344">View all articles by this author</div></div></div><div title="valid: False, node: 1345, tag: div, level: 15" node_number="1345"><div title="valid: False, node: 1346, tag: div, level: 16" node_number="1346">Rajeshwer S. Sankhala</div><div title="valid: False, node: 1347, tag: div, level: 16" node_number="1347"><div title="valid: False, node: 1348, tag: div, level: 17" node_number="1348"><div title="valid: False, node: 1349, tag: div, level: 18" node_number="1349">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1350, tag: div, level: 18" node_number="1350">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1351, tag: div, level: 17" node_number="1351">View all articles by this author</div></div></div><div title="valid: False, node: 1352, tag: div, level: 15" node_number="1352"><div title="valid: False, node: 1353, tag: div, level: 16" node_number="1353">Agnes Hajduczki</div><div title="valid: False, node: 1354, tag: div, level: 16" node_number="1354"><div title="valid: False, node: 1355, tag: div, level: 17" node_number="1355"><div title="valid: False, node: 1356, tag: div, level: 18" node_number="1356">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1357, tag: div, level: 18" node_number="1357">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1358, tag: div, level: 17" node_number="1358">View all articles by this author</div></div></div><div title="valid: False, node: 1359, tag: div, level: 15" node_number="1359"><div title="valid: False, node: 1360, tag: div, level: 16" node_number="1360">Elizabeth J. Martinez</div><div title="valid: False, node: 1361, tag: div, level: 16" node_number="1361"><div title="valid: False, node: 1362, tag: div, level: 17" node_number="1362"><div title="valid: False, node: 1363, tag: div, level: 18" node_number="1363">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1364, tag: div, level: 18" node_number="1364">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1365, tag: div, level: 17" node_number="1365">View all articles by this author</div></div></div><div title="valid: False, node: 1366, tag: div, level: 15" node_number="1366"><div title="valid: False, node: 1367, tag: div, level: 16" node_number="1367">Caroline E. Peterson</div><div title="valid: False, node: 1368, tag: div, level: 16" node_number="1368"><div title="valid: False, node: 1369, tag: div, level: 17" node_number="1369"><div title="valid: False, node: 1370, tag: div, level: 18" node_number="1370">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1371, tag: div, level: 18" node_number="1371">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1372, tag: div, level: 17" node_number="1372">View all articles by this author</div></div></div><div title="valid: False, node: 1373, tag: div, level: 15" node_number="1373"><div title="valid: False, node: 1374, tag: div, level: 16" node_number="1374">William C. Chang</div><div title="valid: False, node: 1375, tag: div, level: 16" node_number="1375"><div title="valid: False, node: 1376, tag: div, level: 17" node_number="1376"><div title="valid: False, node: 1377, tag: div, level: 18" node_number="1377">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1378, tag: div, level: 18" node_number="1378">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1379, tag: div, level: 17" node_number="1379">View all articles by this author</div></div></div><div title="valid: False, node: 1380, tag: div, level: 15" node_number="1380"><div title="valid: False, node: 1381, tag: div, level: 16" node_number="1381">Misook Choe</div><div title="valid: False, node: 1382, tag: div, level: 16" node_number="1382"><div title="valid: False, node: 1383, tag: div, level: 17" node_number="1383"><div title="valid: False, node: 1384, tag: div, level: 18" node_number="1384">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1385, tag: div, level: 18" node_number="1385">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1386, tag: div, level: 17" node_number="1386">View all articles by this author</div></div></div><div title="valid: False, node: 1387, tag: div, level: 15" node_number="1387"><div title="valid: False, node: 1388, tag: div, level: 16" node_number="1388">Clayton Smith</div><div title="valid: False, node: 1389, tag: div, level: 16" node_number="1389"><div title="valid: False, node: 1390, tag: div, level: 17" node_number="1390"><div title="valid: False, node: 1391, tag: div, level: 18" node_number="1391">Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</div></div><div title="valid: False, node: 1392, tag: div, level: 17" node_number="1392">View all articles by this author</div></div></div><div title="valid: False, node: 1393, tag: div, level: 15" node_number="1393"><div title="valid: False, node: 1394, tag: div, level: 16" node_number="1394">Parker J. Lee</div><div title="valid: False, node: 1395, tag: div, level: 16" node_number="1395"><div title="valid: False, node: 1396, tag: div, level: 17" node_number="1396"><div title="valid: False, node: 1397, tag: div, level: 18" node_number="1397">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1398, tag: div, level: 18" node_number="1398">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1399, tag: div, level: 17" node_number="1399">View all articles by this author</div></div></div><div title="valid: False, node: 1400, tag: div, level: 15" node_number="1400"><div title="valid: False, node: 1401, tag: div, level: 16" node_number="1401">Jarrett A. Headley</div><div title="valid: False, node: 1402, tag: div, level: 16" node_number="1402"><div title="valid: False, node: 1403, tag: div, level: 17" node_number="1403"><div title="valid: False, node: 1404, tag: div, level: 18" node_number="1404">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1405, tag: div, level: 18" node_number="1405">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1406, tag: div, level: 17" node_number="1406">View all articles by this author</div></div></div><div title="valid: False, node: 1407, tag: div, level: 15" node_number="1407"><div title="valid: False, node: 1408, tag: div, level: 16" node_number="1408">Mekdi G. Taddese</div><div title="valid: False, node: 1409, tag: div, level: 16" node_number="1409"><div title="valid: False, node: 1410, tag: div, level: 17" node_number="1410"><div title="valid: False, node: 1411, tag: div, level: 18" node_number="1411">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1412, tag: div, level: 18" node_number="1412">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1413, tag: div, level: 17" node_number="1413">View all articles by this author</div></div></div><div title="valid: False, node: 1414, tag: div, level: 15" node_number="1414"><div title="valid: False, node: 1415, tag: div, level: 16" node_number="1415">Hanne A. Elyard</div><div title="valid: False, node: 1416, tag: div, level: 16" node_number="1416"><div title="valid: False, node: 1417, tag: div, level: 17" node_number="1417"><div title="valid: False, node: 1418, tag: div, level: 18" node_number="1418">Bioqual, Rockville, MD 20850, USA.</div></div><div title="valid: False, node: 1419, tag: div, level: 17" node_number="1419">View all articles by this author</div></div></div><div title="valid: False, node: 1420, tag: div, level: 15" node_number="1420"><div title="valid: False, node: 1421, tag: div, level: 16" node_number="1421">Anthony Cook</div><div title="valid: False, node: 1422, tag: div, level: 16" node_number="1422"><div title="valid: False, node: 1423, tag: div, level: 17" node_number="1423"><div title="valid: False, node: 1424, tag: div, level: 18" node_number="1424">Bioqual, Rockville, MD 20850, USA.</div></div><div title="valid: False, node: 1425, tag: div, level: 17" node_number="1425">View all articles by this author</div></div></div><div title="valid: False, node: 1426, tag: div, level: 15" node_number="1426"><div title="valid: False, node: 1427, tag: div, level: 16" node_number="1427">Alexander Anderson</div><div title="valid: False, node: 1428, tag: div, level: 16" node_number="1428"><div title="valid: False, node: 1429, tag: div, level: 17" node_number="1429"><div title="valid: False, node: 1430, tag: div, level: 18" node_number="1430">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1431, tag: div, level: 18" node_number="1431">Oak Ridge Institute of Science and Education, Oak Ridge, TN 37830, USA.</div></div><div title="valid: False, node: 1432, tag: div, level: 17" node_number="1432">View all articles by this author</div></div></div><div title="valid: False, node: 1433, tag: div, level: 15" node_number="1433"><div title="valid: False, node: 1434, tag: div, level: 16" node_number="1434">Kathryn McGuckin Wuertz</div><div title="valid: False, node: 1435, tag: div, level: 16" node_number="1435"><div title="valid: False, node: 1436, tag: div, level: 17" node_number="1436"><div title="valid: False, node: 1437, tag: div, level: 18" node_number="1437">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1438, tag: div, level: 17" node_number="1438">View all articles by this author</div></div></div><div title="valid: False, node: 1439, tag: div, level: 15" node_number="1439"><div title="valid: False, node: 1440, tag: div, level: 16" node_number="1440">Ming Dong</div><div title="valid: False, node: 1441, tag: div, level: 16" node_number="1441"><div title="valid: False, node: 1442, tag: div, level: 17" node_number="1442"><div title="valid: False, node: 1443, tag: div, level: 18" node_number="1443">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1444, tag: div, level: 18" node_number="1444">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1445, tag: div, level: 18" node_number="1445">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1446, tag: div, level: 17" node_number="1446">View all articles by this author</div></div></div><div title="valid: False, node: 1447, tag: div, level: 15" node_number="1447"><div title="valid: False, node: 1448, tag: div, level: 16" node_number="1448">Isabella Swafford</div><div title="valid: False, node: 1449, tag: div, level: 16" node_number="1449"><div title="valid: False, node: 1450, tag: div, level: 17" node_number="1450"><div title="valid: False, node: 1451, tag: div, level: 18" node_number="1451">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1452, tag: div, level: 18" node_number="1452">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1453, tag: div, level: 18" node_number="1453">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1454, tag: div, level: 17" node_number="1454">View all articles by this author</div></div></div><div title="valid: False, node: 1455, tag: div, level: 15" node_number="1455"><div title="valid: False, node: 1456, tag: div, level: 16" node_number="1456">James Brett Case</div><div title="valid: False, node: 1457, tag: div, level: 16" node_number="1457"><div title="valid: False, node: 1458, tag: div, level: 17" node_number="1458"><div title="valid: False, node: 1459, tag: div, level: 18" node_number="1459">Department of Medicine, Washington University, St. Louis, MO 63130, USA.</div></div><div title="valid: False, node: 1460, tag: div, level: 17" node_number="1460">View all articles by this author</div></div></div><div title="valid: False, node: 1461, tag: div, level: 15" node_number="1461"><div title="valid: False, node: 1462, tag: div, level: 16" node_number="1462">Jeffrey R. Currier</div><div title="valid: False, node: 1463, tag: div, level: 16" node_number="1463"><div title="valid: False, node: 1464, tag: div, level: 17" node_number="1464"><div title="valid: False, node: 1465, tag: div, level: 18" node_number="1465">Viral Diseases Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1466, tag: div, level: 17" node_number="1466">View all articles by this author</div></div></div><div title="valid: False, node: 1467, tag: div, level: 15" node_number="1467"><div title="valid: False, node: 1468, tag: div, level: 16" node_number="1468">Kerri G. Lal</div><div title="valid: False, node: 1469, tag: div, level: 16" node_number="1469"><div title="valid: False, node: 1470, tag: div, level: 17" node_number="1470"><div title="valid: False, node: 1471, tag: div, level: 18" node_number="1471">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1472, tag: div, level: 18" node_number="1472">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1473, tag: div, level: 18" node_number="1473">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1474, tag: div, level: 17" node_number="1474">View all articles by this author</div></div></div><div title="valid: False, node: 1475, tag: div, level: 15" node_number="1475"><div title="valid: False, node: 1476, tag: div, level: 16" node_number="1476">Sebastian Molnar</div><div title="valid: False, node: 1477, tag: div, level: 16" node_number="1477"><div title="valid: False, node: 1478, tag: div, level: 17" node_number="1478"><div title="valid: False, node: 1479, tag: div, level: 18" node_number="1479">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1480, tag: div, level: 18" node_number="1480">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1481, tag: div, level: 18" node_number="1481">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1482, tag: div, level: 17" node_number="1482">View all articles by this author</div></div></div><div title="valid: False, node: 1483, tag: div, level: 15" node_number="1483"><div title="valid: False, node: 1484, tag: div, level: 16" node_number="1484">Manoj S. Nair</div><div title="valid: False, node: 1485, tag: div, level: 16" node_number="1485"><div title="valid: False, node: 1486, tag: div, level: 17" node_number="1486"><div title="valid: False, node: 1487, tag: div, level: 18" node_number="1487">Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</div></div><div title="valid: False, node: 1488, tag: div, level: 17" node_number="1488">View all articles by this author</div></div></div><div title="valid: False, node: 1489, tag: div, level: 15" node_number="1489"><div title="valid: False, node: 1490, tag: div, level: 16" node_number="1490">Vincent Dussupt</div><div title="valid: False, node: 1491, tag: div, level: 16" node_number="1491"><div title="valid: False, node: 1492, tag: div, level: 17" node_number="1492"><div title="valid: False, node: 1493, tag: div, level: 18" node_number="1493">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1494, tag: div, level: 18" node_number="1494">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1495, tag: div, level: 18" node_number="1495">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1496, tag: div, level: 17" node_number="1496">View all articles by this author</div></div></div><div title="valid: False, node: 1497, tag: div, level: 15" node_number="1497"><div title="valid: False, node: 1498, tag: div, level: 16" node_number="1498">Sharon P. Daye</div><div title="valid: False, node: 1499, tag: div, level: 16" node_number="1499"><div title="valid: False, node: 1500, tag: div, level: 17" node_number="1500"><div title="valid: False, node: 1501, tag: div, level: 18" node_number="1501">Center for Infectious Diseases Research, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1502, tag: div, level: 17" node_number="1502">View all articles by this author</div></div></div><div title="valid: False, node: 1503, tag: div, level: 15" node_number="1503"><div title="valid: False, node: 1504, tag: div, level: 16" node_number="1504">Xiankun Zeng</div><div title="valid: False, node: 1505, tag: div, level: 16" node_number="1505"><div title="valid: False, node: 1506, tag: div, level: 17" node_number="1506"><div title="valid: False, node: 1507, tag: div, level: 18" node_number="1507">Division of Pathology, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.</div></div><div title="valid: False, node: 1508, tag: div, level: 17" node_number="1508">View all articles by this author</div></div></div><div title="valid: False, node: 1509, tag: div, level: 15" node_number="1509"><div title="valid: False, node: 1510, tag: div, level: 16" node_number="1510">Erica K. Barkei</div><div title="valid: False, node: 1511, tag: div, level: 16" node_number="1511"><div title="valid: False, node: 1512, tag: div, level: 17" node_number="1512"><div title="valid: False, node: 1513, tag: div, level: 18" node_number="1513">Veterinary Medicine Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1514, tag: div, level: 17" node_number="1514">View all articles by this author</div></div></div><div title="valid: False, node: 1515, tag: div, level: 15" node_number="1515"><div title="valid: False, node: 1516, tag: div, level: 16" node_number="1516">Hilary M. Staples</div><div title="valid: False, node: 1517, tag: div, level: 16" node_number="1517"><div title="valid: False, node: 1518, tag: div, level: 17" node_number="1518"><div title="valid: False, node: 1519, tag: div, level: 18" node_number="1519">Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio TX 78227, USA.</div></div><div title="valid: False, node: 1520, tag: div, level: 17" node_number="1520">View all articles by this author</div></div></div><div title="valid: False, node: 1521, tag: div, level: 15" node_number="1521"><div title="valid: False, node: 1522, tag: div, level: 16" node_number="1522">Kendra Alfson</div><div title="valid: False, node: 1523, tag: div, level: 16" node_number="1523"><div title="valid: False, node: 1524, tag: div, level: 17" node_number="1524"><div title="valid: False, node: 1525, tag: div, level: 18" node_number="1525">Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio TX 78227, USA.</div></div><div title="valid: False, node: 1526, tag: div, level: 17" node_number="1526">View all articles by this author</div></div></div><div title="valid: False, node: 1527, tag: div, level: 15" node_number="1527"><div title="valid: False, node: 1528, tag: div, level: 16" node_number="1528">Ricardo Carrion</div><div title="valid: False, node: 1529, tag: div, level: 16" node_number="1529"><div title="valid: False, node: 1530, tag: div, level: 17" node_number="1530"><div title="valid: False, node: 1531, tag: div, level: 18" node_number="1531">Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio TX 78227, USA.</div></div><div title="valid: False, node: 1532, tag: div, level: 17" node_number="1532">View all articles by this author</div></div></div><div title="valid: False, node: 1533, tag: div, level: 15" node_number="1533"><div title="valid: False, node: 1534, tag: div, level: 16" node_number="1534">Shelly J. Krebs</div><div title="valid: False, node: 1535, tag: div, level: 16" node_number="1535"><div title="valid: False, node: 1536, tag: div, level: 17" node_number="1536"><div title="valid: False, node: 1537, tag: div, level: 18" node_number="1537">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1538, tag: div, level: 18" node_number="1538">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1539, tag: div, level: 18" node_number="1539">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1540, tag: div, level: 17" node_number="1540">View all articles by this author</div></div></div><div title="valid: False, node: 1541, tag: div, level: 15" node_number="1541"><div title="valid: False, node: 1542, tag: div, level: 16" node_number="1542">Dominic Paquin-Proulx</div><div title="valid: False, node: 1543, tag: div, level: 16" node_number="1543"><div title="valid: False, node: 1544, tag: div, level: 17" node_number="1544"><div title="valid: False, node: 1545, tag: div, level: 18" node_number="1545">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1546, tag: div, level: 18" node_number="1546">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1547, tag: div, level: 18" node_number="1547">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1548, tag: div, level: 17" node_number="1548">View all articles by this author</div></div></div><div title="valid: False, node: 1549, tag: div, level: 15" node_number="1549"><div title="valid: False, node: 1550, tag: div, level: 16" node_number="1550">Nicos Karasavva</div><div title="valid: False, node: 1551, tag: div, level: 16" node_number="1551"><div title="valid: False, node: 1552, tag: div, level: 17" node_number="1552"><div title="valid: False, node: 1553, tag: div, level: 18" node_number="1553">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1554, tag: div, level: 18" node_number="1554">Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1555, tag: div, level: 17" node_number="1555">View all articles by this author</div></div></div><div title="valid: False, node: 1556, tag: div, level: 15" node_number="1556"><div title="valid: False, node: 1557, tag: div, level: 16" node_number="1557">Victoria R. Polonis</div><div title="valid: False, node: 1558, tag: div, level: 16" node_number="1558"><div title="valid: False, node: 1559, tag: div, level: 17" node_number="1559"><div title="valid: False, node: 1560, tag: div, level: 18" node_number="1560">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1561, tag: div, level: 17" node_number="1561">View all articles by this author</div></div></div><div title="valid: False, node: 1562, tag: div, level: 15" node_number="1562"><div title="valid: False, node: 1563, tag: div, level: 16" node_number="1563">Linda L. Jagodzinski</div><div title="valid: False, node: 1564, tag: div, level: 16" node_number="1564"><div title="valid: False, node: 1565, tag: div, level: 17" node_number="1565"><div title="valid: False, node: 1566, tag: div, level: 18" node_number="1566">Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1567, tag: div, level: 17" node_number="1567">View all articles by this author</div></div></div><div title="valid: False, node: 1568, tag: div, level: 15" node_number="1568"><div title="valid: False, node: 1569, tag: div, level: 16" node_number="1569">Mihret F. Amare</div><div title="valid: False, node: 1570, tag: div, level: 16" node_number="1570"><div title="valid: False, node: 1571, tag: div, level: 17" node_number="1571"><div title="valid: False, node: 1572, tag: div, level: 18" node_number="1572">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1573, tag: div, level: 18" node_number="1573">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div></div><div title="valid: False, node: 1574, tag: div, level: 17" node_number="1574">View all articles by this author</div></div></div><div title="valid: False, node: 1575, tag: div, level: 15" node_number="1575"><div title="valid: False, node: 1576, tag: div, level: 16" node_number="1576">Sandhya Vasan</div><div title="valid: False, node: 1577, tag: div, level: 16" node_number="1577"><div title="valid: False, node: 1578, tag: div, level: 17" node_number="1578"><div title="valid: False, node: 1579, tag: div, level: 18" node_number="1579">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1580, tag: div, level: 18" node_number="1580">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1581, tag: div, level: 18" node_number="1581">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1582, tag: div, level: 17" node_number="1582">View all articles by this author</div></div></div><div title="valid: False, node: 1583, tag: div, level: 15" node_number="1583"><div title="valid: False, node: 1584, tag: div, level: 16" node_number="1584">Paul T. Scott</div><div title="valid: False, node: 1585, tag: div, level: 16" node_number="1585"><div title="valid: False, node: 1586, tag: div, level: 17" node_number="1586"><div title="valid: False, node: 1587, tag: div, level: 18" node_number="1587">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1588, tag: div, level: 17" node_number="1588">View all articles by this author</div></div></div><div title="valid: False, node: 1589, tag: div, level: 15" node_number="1589"><div title="valid: False, node: 1590, tag: div, level: 16" node_number="1590">Yaoxing Huang</div><div title="valid: False, node: 1591, tag: div, level: 16" node_number="1591"><div title="valid: False, node: 1592, tag: div, level: 17" node_number="1592"><div title="valid: False, node: 1593, tag: div, level: 18" node_number="1593">Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</div></div><div title="valid: False, node: 1594, tag: div, level: 17" node_number="1594">View all articles by this author</div></div></div><div title="valid: False, node: 1595, tag: div, level: 15" node_number="1595"><div title="valid: False, node: 1596, tag: div, level: 16" node_number="1596">David D. Ho</div><div title="valid: False, node: 1597, tag: div, level: 16" node_number="1597"><div title="valid: False, node: 1598, tag: div, level: 17" node_number="1598"><div title="valid: False, node: 1599, tag: div, level: 18" node_number="1599">Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.</div></div><div title="valid: False, node: 1600, tag: div, level: 17" node_number="1600">View all articles by this author</div></div></div><div title="valid: False, node: 1601, tag: div, level: 15" node_number="1601"><div title="valid: False, node: 1602, tag: div, level: 16" node_number="1602">Natalia de Val</div><div title="valid: False, node: 1603, tag: div, level: 16" node_number="1603"><div title="valid: False, node: 1604, tag: div, level: 17" node_number="1604"><div title="valid: False, node: 1605, tag: div, level: 18" node_number="1605">Center for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.</div></div><div title="valid: False, node: 1606, tag: div, level: 17" node_number="1606">View all articles by this author</div></div></div><div title="valid: False, node: 1607, tag: div, level: 15" node_number="1607"><div title="valid: False, node: 1608, tag: div, level: 16" node_number="1608">Michael S. Diamond</div><div title="valid: False, node: 1609, tag: div, level: 16" node_number="1609"><div title="valid: False, node: 1610, tag: div, level: 17" node_number="1610"><div title="valid: False, node: 1611, tag: div, level: 18" node_number="1611">Department of Medicine, Washington University, St. Louis, MO 63130, USA.</div><div title="valid: False, node: 1612, tag: div, level: 18" node_number="1612">Department of Pathology Immunology, Washington University, St. Louis, MO 63130, USA.</div><div title="valid: False, node: 1613, tag: div, level: 18" node_number="1613">Department of Molecular Microbiology, Washington University, St. Louis, MO 63130, USA.</div></div><div title="valid: False, node: 1614, tag: div, level: 17" node_number="1614">View all articles by this author</div></div></div><div title="valid: False, node: 1615, tag: div, level: 15" node_number="1615"><div title="valid: False, node: 1616, tag: div, level: 16" node_number="1616">Mark G. Lewis</div><div title="valid: False, node: 1617, tag: div, level: 16" node_number="1617"><div title="valid: False, node: 1618, tag: div, level: 17" node_number="1618"><div title="valid: False, node: 1619, tag: div, level: 18" node_number="1619">Bioqual, Rockville, MD 20850, USA.</div></div><div title="valid: False, node: 1620, tag: div, level: 17" node_number="1620">View all articles by this author</div></div></div><div title="valid: False, node: 1621, tag: div, level: 15" node_number="1621"><div title="valid: False, node: 1622, tag: div, level: 16" node_number="1622">Mangala Rao</div><div title="valid: False, node: 1623, tag: div, level: 16" node_number="1623"><div title="valid: False, node: 1624, tag: div, level: 17" node_number="1624"><div title="valid: False, node: 1625, tag: div, level: 18" node_number="1625">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1626, tag: div, level: 17" node_number="1626">View all articles by this author</div></div></div><div title="valid: False, node: 1627, tag: div, level: 15" node_number="1627"><div title="valid: False, node: 1628, tag: div, level: 16" node_number="1628">Gary R. Matyas</div><div title="valid: False, node: 1629, tag: div, level: 16" node_number="1629"><div title="valid: False, node: 1630, tag: div, level: 17" node_number="1630"><div title="valid: False, node: 1631, tag: div, level: 18" node_number="1631">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1632, tag: div, level: 17" node_number="1632">View all articles by this author</div></div></div><div title="valid: False, node: 1633, tag: div, level: 15" node_number="1633"><div title="valid: False, node: 1634, tag: div, level: 16" node_number="1634">Gregory D. Gromowski</div><div title="valid: False, node: 1635, tag: div, level: 16" node_number="1635"><div title="valid: False, node: 1636, tag: div, level: 17" node_number="1636"><div title="valid: False, node: 1637, tag: div, level: 18" node_number="1637">Viral Diseases Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1638, tag: div, level: 17" node_number="1638">View all articles by this author</div></div></div><div title="valid: False, node: 1639, tag: div, level: 15" node_number="1639"><div title="valid: False, node: 1640, tag: div, level: 16" node_number="1640">Sheila A. Peel</div><div title="valid: False, node: 1641, tag: div, level: 16" node_number="1641"><div title="valid: False, node: 1642, tag: div, level: 17" node_number="1642"><div title="valid: False, node: 1643, tag: div, level: 18" node_number="1643">Diagnostics and Countermeasures Branch, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1644, tag: div, level: 17" node_number="1644">View all articles by this author</div></div></div><div title="valid: False, node: 1645, tag: div, level: 15" node_number="1645"><div title="valid: False, node: 1646, tag: div, level: 16" node_number="1646">Nelson L. Michael</div><div title="valid: False, node: 1647, tag: div, level: 16" node_number="1647"><div title="valid: False, node: 1648, tag: div, level: 17" node_number="1648"><div title="valid: False, node: 1649, tag: div, level: 18" node_number="1649">Center for Infectious Diseases Research, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1650, tag: div, level: 17" node_number="1650">View all articles by this author</div></div></div><div title="valid: False, node: 1651, tag: div, level: 15" node_number="1651"><div title="valid: False, node: 1652, tag: div, level: 16" node_number="1652">Diane L. Bolton</div><div title="valid: False, node: 1653, tag: div, level: 16" node_number="1653"><div title="valid: False, node: 1654, tag: div, level: 17" node_number="1654"><div title="valid: False, node: 1655, tag: div, level: 18" node_number="1655">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div><div title="valid: False, node: 1656, tag: div, level: 18" node_number="1656">Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda MD 20817, USA.</div><div title="valid: False, node: 1657, tag: div, level: 18" node_number="1657">US Military HIV Research Program, WRAIR, Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1658, tag: div, level: 17" node_number="1658">View all articles by this author</div></div></div><div title="valid: False, node: 1659, tag: div, level: 15" node_number="1659"><div title="valid: False, node: 1660, tag: div, level: 16" node_number="1660">Kayvon Modjarrad<sup title="valid: False, node: 1661, tag: sup, level: 17" node_number="1661">*</sup> [email&#160;protected]</div><div title="valid: False, node: 1662, tag: div, level: 16" node_number="1662"><div title="valid: False, node: 1663, tag: div, level: 17" node_number="1663"><div title="valid: False, node: 1664, tag: div, level: 18" node_number="1664">Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research (WRAIR), Silver Spring MD 20910, USA.</div></div><div title="valid: False, node: 1665, tag: div, level: 17" node_number="1665">View all articles by this author</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1666, tag: section, level: 14" node_number="1666"><h4 title="valid: False, node: 1667, tag: h4, level: 15" node_number="1667">Funding Information</h4><div title="valid: False, node: 1668, tag: div, level: 15" node_number="1668">U.S. Department of Defensehttp://dx.doi.org/10.13039/100000005: </div></section><section class="valid" valid="valid" title="valid: True, node: 1669, tag: section, level: 14" node_number="1669"><h4 title="valid: False, node: 1670, tag: h4, level: 15" node_number="1670">Notes</h4><div title="valid: False, node: 1671, tag: div, level: 15" node_number="1671">*Corresponding authors. Email: [email&#160;protected]; [email&#160;protected]</div></section></section></div><div class="valid" valid="valid" title="valid: True, node: 1672, tag: div, level: 12" node_number="1672"><header class="valid" valid="valid" title="valid: True, node: 1673, tag: header, level: 13" node_number="1673"><h2 class="valid" valid="valid" title="valid: True, node: 1674, tag: h2, level: 14" node_number="1674">Metrics Citations</h2></header><section class="valid" valid="valid" title="valid: True, node: 1675, tag: section, level: 13" node_number="1675"><h3 class="valid" valid="valid" title="valid: True, node: 1676, tag: h3, level: 14" node_number="1676">Metrics</h3><section class="valid" valid="valid" title="valid: True, node: 1677, tag: section, level: 14" node_number="1677"> <h5 title="valid: False, node: 1678, tag: h5, level: 15" node_number="1678"> Article Usage </h5> </section><section class="valid" valid="valid" title="valid: True, node: 1679, tag: section, level: 14" node_number="1679"> <h5 title="valid: False, node: 1680, tag: h5, level: 15" node_number="1680"> Altmetrics </h5> </section></section><section class="valid" valid="valid" title="valid: True, node: 1681, tag: section, level: 13" node_number="1681"><h3 class="valid" valid="valid" title="valid: True, node: 1682, tag: h3, level: 14" node_number="1682">Citations</h3><section class="valid" valid="valid" title="valid: True, node: 1683, tag: section, level: 14" node_number="1683"> <div title="valid: False, node: 1684, tag: div, level: 15" node_number="1684"> <h5 title="valid: False, node: 1685, tag: h5, level: 16" node_number="1685">Export citation</h5> <p title="valid: False, node: 1686, tag: p, level: 16" node_number="1686">Select the format you want to export the citation of this publication.</p> </div> </section></section></div><div class="valid" valid="valid" title="valid: True, node: 1687, tag: div, level: 12" node_number="1687"><header class="valid" valid="valid" title="valid: True, node: 1688, tag: header, level: 13" node_number="1688"><h2 class="valid" valid="valid" title="valid: True, node: 1689, tag: h2, level: 14" node_number="1689">View Options</h2></header><div class="valid" valid="valid" title="valid: True, node: 1690, tag: div, level: 13" node_number="1690"><h3 class="valid" valid="valid" title="valid: True, node: 1691, tag: h3, level: 14" node_number="1691">View options</h3><section class="valid" valid="valid" title="valid: True, node: 1692, tag: section, level: 14" node_number="1692"><h4 title="valid: False, node: 1693, tag: h4, level: 15" node_number="1693">PDF format</h4><p title="valid: False, node: 1694, tag: p, level: 15" node_number="1694">Download this article as a PDF file</p>Download PDF</section></div><div class="valid" valid="valid" title="valid: True, node: 1695, tag: div, level: 13" node_number="1695"><h3 class="valid" valid="valid" title="valid: True, node: 1696, tag: h3, level: 14" node_number="1696">Get Access</h3><section class="valid" valid="valid" title="valid: True, node: 1697, tag: section, level: 14" node_number="1697"> <div title="valid: False, node: 1698, tag: div, level: 15" node_number="1698"><h5 title="valid: False, node: 1699, tag: h5, level: 16" node_number="1699">Log in to view the full text</h5> <p title="valid: False, node: 1700, tag: p, level: 16" node_number="1700"><a title="valid: False, node: 1701, tag: a, level: 17" node_number="1701">AAAS Log in</a></p> <p title="valid: False, node: 1702, tag: p, level: 16" node_number="1702">AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul title="valid: False, node: 1703, tag: ul, level: 16" node_number="1703"> <li title="valid: False, node: 1704, tag: li, level: 17" node_number="1704">Become a AAAS Member</li> <li title="valid: False, node: 1705, tag: li, level: 17" node_number="1705"><a title="valid: False, node: 1706, tag: a, level: 18" node_number="1706">Activate your Account</a></li> <li title="valid: False, node: 1707, tag: li, level: 17" node_number="1707"><a title="valid: False, node: 1708, tag: a, level: 18" node_number="1708">Purchase Access to Other Journals in the Science Family</a></li> <li title="valid: False, node: 1709, tag: li, level: 17" node_number="1709"><a title="valid: False, node: 1710, tag: a, level: 18" node_number="1710">Account Help</a></li> </ul> <div title="valid: False, node: 1711, tag: div, level: 16" node_number="1711"> <div title="valid: False, node: 1712, tag: div, level: 17" node_number="1712">Log in via OpenAthens. <div title="valid: False, node: 1713, tag: div, level: 18" node_number="1713"><a title="valid: False, node: 1714, tag: a, level: 19" node_number="1714">via OpenAthens</a></div> </div> <div title="valid: False, node: 1715, tag: div, level: 17" node_number="1715">Log in via Shibboleth. <div title="valid: False, node: 1716, tag: div, level: 18" node_number="1716"><a title="valid: False, node: 1717, tag: a, level: 19" node_number="1717">via Shibboleth</a></div> </div> </div> </div> <div title="valid: False, node: 1718, tag: div, level: 15" node_number="1718"><h4 title="valid: False, node: 1719, tag: h4, level: 16" node_number="1719">More options</h4><p title="valid: False, node: 1720, tag: p, level: 16" node_number="1720"><a title="valid: False, node: 1721, tag: a, level: 17" node_number="1721">Purchase digital access to this article</a></p><p title="valid: False, node: 1722, tag: p, level: 16" node_number="1722">Download and print this article for your personal scholarly, research, and educational use.</p></div> </section></div></div><div class="valid" valid="valid" title="valid: True, node: 1723, tag: div, level: 12" node_number="1723"><header class="valid" valid="valid" title="valid: True, node: 1724, tag: header, level: 13" node_number="1724"><h2 class="valid" valid="valid" title="valid: True, node: 1725, tag: h2, level: 14" node_number="1725">Media</h2></header><section class="valid" valid="valid" title="valid: True, node: 1726, tag: section, level: 13" node_number="1726"><h3 class="valid" valid="valid" title="valid: True, node: 1727, tag: h3, level: 14" node_number="1727">Figures</h3></section><section class="valid" valid="valid" title="valid: True, node: 1728, tag: section, level: 13" node_number="1728"><h3 class="valid" valid="valid" title="valid: True, node: 1729, tag: h3, level: 14" node_number="1729">Multimedia</h3></section></div><div class="valid" valid="valid" title="valid: True, node: 1730, tag: div, level: 12" node_number="1730"><header class="valid" valid="valid" title="valid: True, node: 1731, tag: header, level: 13" node_number="1731"><h2 class="valid" valid="valid" title="valid: True, node: 1732, tag: h2, level: 14" node_number="1732">Tables</h2></header></div><div class="valid" valid="valid" title="valid: True, node: 1733, tag: div, level: 12" node_number="1733"><header class="valid" valid="valid" title="valid: True, node: 1734, tag: header, level: 13" node_number="1734"><h2 class="valid" valid="valid" title="valid: True, node: 1735, tag: h2, level: 14" node_number="1735">Share</h2></header><h3 class="valid" valid="valid" title="valid: True, node: 1736, tag: h3, level: 13" node_number="1736">Share</h3><div class="valid" valid="valid" title="valid: True, node: 1737, tag: div, level: 13" node_number="1737"><section class="valid" valid="valid" title="valid: True, node: 1738, tag: section, level: 14" node_number="1738"><h4 title="valid: False, node: 1739, tag: h4, level: 15" node_number="1739">Share article link</h4><div title="valid: False, node: 1740, tag: div, level: 15" node_number="1740"><a title="valid: False, node: 1741, tag: a, level: 16" node_number="1741">Copy Link</a><div title="valid: False, node: 1742, tag: div, level: 16" node_number="1742"><p title="valid: False, node: 1743, tag: p, level: 17" node_number="1743">Copied!</p><p title="valid: False, node: 1744, tag: p, level: 17" node_number="1744">Copying failed.</p></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1745, tag: section, level: 14" node_number="1745"><h4 title="valid: False, node: 1746, tag: h4, level: 15" node_number="1746">Share on social media</h4><div title="valid: False, node: 1747, tag: div, level: 15" node_number="1747">facebook<a title="valid: False, node: 1748, tag: a, level: 16" node_number="1748">twitter</a><a title="valid: False, node: 1749, tag: a, level: 16" node_number="1749">linkedin</a><a title="valid: False, node: 1750, tag: a, level: 16" node_number="1750">email</a></div></section></div></div></div></article><section class="valid" valid="valid" title="valid: True, node: 1751, tag: section, level: 10" node_number="1751"><div class="valid" valid="valid" title="valid: True, node: 1752, tag: div, level: 11" node_number="1752"><div class="valid" valid="valid" title="valid: True, node: 1753, tag: div, level: 12" node_number="1753"><div class="valid" valid="valid" title="valid: True, node: 1754, tag: div, level: 13" node_number="1754"><div class="valid" valid="valid" title="valid: True, node: 1755, tag: div, level: 14" node_number="1755"><h3 title="valid: False, node: 1756, tag: h3, level: 15" node_number="1756">Submit a Response to This Article</h3></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 1757, tag: div, level: 11" node_number="1757"> <div class="valid" valid="valid" title="valid: True, node: 1758, tag: div, level: 12" node_number="1758"> <h2 class="valid" valid="valid" title="valid: True, node: 1759, tag: h2, level: 13" node_number="1759">(0)eLetters</h2> </div> <p class="valid" valid="valid" title="valid: True, node: 1760, tag: p, level: 12" node_number="1760">eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> <a class="valid" valid="valid" title="valid: True, node: 1761, tag: a, level: 12" node_number="1761">Log In to Submit a Response</a> <p class="valid" valid="valid" title="valid: True, node: 1762, tag: p, level: 12" node_number="1762">No eLetters have been published for this article yet.</p> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 1763, tag: div, level: 10" node_number="1763"><a class="valid" valid="valid" title="valid: True, node: 1764, tag: a, level: 11" node_number="1764">View Full Text</a><a class="valid" valid="valid" title="valid: True, node: 1765, tag: a, level: 11" node_number="1765">Download PDF</a></div> </div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1766, tag: div, level: 6" node_number="1766"><div class="valid" valid="valid" title="valid: True, node: 1767, tag: div, level: 7" node_number="1767"><div class="valid" valid="valid" title="valid: True, node: 1768, tag: div, level: 8" node_number="1768"><div class="valid" valid="valid" title="valid: True, node: 1769, tag: div, level: 9" node_number="1769"><section class="valid" valid="valid" title="valid: True, node: 1770, tag: section, level: 10" node_number="1770"><div class="valid" valid="valid" title="valid: True, node: 1771, tag: div, level: 11" node_number="1771"><h4 class="valid" valid="valid" title="valid: True, node: 1772, tag: h4, level: 12" node_number="1772"> Current Issue </h4><div class="valid" valid="valid" title="valid: True, node: 1773, tag: div, level: 12" node_number="1773"><div class="valid" valid="valid" title="valid: True, node: 1774, tag: div, level: 13" node_number="1774"> <div class="valid" valid="valid" title="valid: True, node: 1775, tag: div, level: 14" node_number="1775"><div title="valid: False, node: 1776, tag: div, level: 15" node_number="1776"><article title="valid: False, node: 1777, tag: article, level: 16" node_number="1777"><div title="valid: False, node: 1778, tag: div, level: 17" node_number="1778"><div title="valid: False, node: 1779, tag: div, level: 18" node_number="1779"><h3 title="valid: False, node: 1780, tag: h3, level: 19" node_number="1780"><a title="valid: False, node: 1781, tag: a, level: 20" node_number="1781">Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics</a></h3><ul title="valid: False, node: 1782, tag: ul, level: 19" node_number="1782"><li title="valid: False, node: 1783, tag: li, level: 20" node_number="1783">By<ul title="valid: False, node: 1784, tag: ul, level: 21" node_number="1784"> <li title="valid: False, node: 1785, tag: li, level: 22" node_number="1785">Jay-Hyun Jo</li> <li title="valid: False, node: 1786, tag: li, level: 22" node_number="1786">Catriona P. Harkins</li> <li title="valid: False, node: 1787, tag: li, level: 22" node_number="1787">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1788, tag: article, level: 16" node_number="1788"><div title="valid: False, node: 1789, tag: div, level: 17" node_number="1789"><div title="valid: False, node: 1790, tag: div, level: 18" node_number="1790"><h3 title="valid: False, node: 1791, tag: h3, level: 19" node_number="1791">A human orthogonal IL-2 and IL-2R&#946; system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia</h3><ul title="valid: False, node: 1792, tag: ul, level: 19" node_number="1792"><li title="valid: False, node: 1793, tag: li, level: 20" node_number="1793">By<ul title="valid: False, node: 1794, tag: ul, level: 21" node_number="1794"> <li title="valid: False, node: 1795, tag: li, level: 22" node_number="1795">Qian Zhang</li> <li title="valid: False, node: 1796, tag: li, level: 22" node_number="1796">Morgan E. Hresko</li> <li title="valid: False, node: 1797, tag: li, level: 22" node_number="1797">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1798, tag: article, level: 16" node_number="1798"><div title="valid: False, node: 1799, tag: div, level: 17" node_number="1799"><div title="valid: False, node: 1800, tag: div, level: 18" node_number="1800"><h3 title="valid: False, node: 1801, tag: h3, level: 19" node_number="1801">An orthogonal IL-2 and IL-2R&#946; system drives persistence and activation of CAR T cells and clearance of bulky lymphoma</h3><ul title="valid: False, node: 1802, tag: ul, level: 19" node_number="1802"><li title="valid: False, node: 1803, tag: li, level: 20" node_number="1803">By<ul title="valid: False, node: 1804, tag: ul, level: 21" node_number="1804"> <li title="valid: False, node: 1805, tag: li, level: 22" node_number="1805">Paul-Joseph Aspuria</li> <li title="valid: False, node: 1806, tag: li, level: 22" node_number="1806">Sandro Vivona</li> <li title="valid: False, node: 1807, tag: li, level: 22" node_number="1807">et al.</li> </ul> </li></ul></div></div></article></div><div title="valid: False, node: 1808, tag: div, level: 15" node_number="1808">Table of Contents</div></div> </div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1809, tag: section, level: 10" node_number="1809"> <h4 class="valid" valid="valid" title="valid: True, node: 1810, tag: h4, level: 11" node_number="1810">LATEST NEWS</h4> <div class="valid" valid="valid" title="valid: True, node: 1811, tag: div, level: 11" node_number="1811"> <div class="valid" valid="valid" title="valid: True, node: 1812, tag: div, level: 12" node_number="1812"><div class="valid" valid="valid" title="valid: True, node: 1813, tag: div, level: 13" node_number="1813"> <article class="valid" valid="valid" title="valid: True, node: 1814, tag: article, level: 14" node_number="1814"> <div title="valid: False, node: 1815, tag: div, level: 15" node_number="1815"> <div title="valid: False, node: 1816, tag: div, level: 16" node_number="1816"> News<time title="valid: False, node: 1817, tag: time, level: 17" node_number="1817">30 Dec 2021</time> </div> <div title="valid: False, node: 1818, tag: div, level: 16" node_number="1818"> Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1819, tag: article, level: 14" node_number="1819"> <div title="valid: False, node: 1820, tag: div, level: 15" node_number="1820"> <div title="valid: False, node: 1821, tag: div, level: 16" node_number="1821"> ScienceInsider<time title="valid: False, node: 1822, tag: time, level: 17" node_number="1822">29 Dec 2021</time> </div> <div title="valid: False, node: 1823, tag: div, level: 16" node_number="1823"> <a title="valid: False, node: 1824, tag: a, level: 17" node_number="1824"> Once a &#8216;crazy idea,&#8217; patent-pooling nonprofit will help bring COVID-19 pills to world&#8217;s poor </a> </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1825, tag: article, level: 14" node_number="1825"> <div title="valid: False, node: 1826, tag: div, level: 15" node_number="1826"> <div title="valid: False, node: 1827, tag: div, level: 16" node_number="1827"> ScienceInsider<time title="valid: False, node: 1828, tag: time, level: 17" node_number="1828">28 Dec 2021</time> </div> <div title="valid: False, node: 1829, tag: div, level: 16" node_number="1829"> The natural world loses two of its biggest advocates </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1830, tag: article, level: 14" node_number="1830"> <div title="valid: False, node: 1831, tag: div, level: 15" node_number="1831"> <div title="valid: False, node: 1832, tag: div, level: 16" node_number="1832"> ScienceInsider<time title="valid: False, node: 1833, tag: time, level: 17" node_number="1833">28 Dec 2021</time> </div> <div title="valid: False, node: 1834, tag: div, level: 16" node_number="1834"> <a title="valid: False, node: 1835, tag: a, level: 17" node_number="1835"> What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1836, tag: article, level: 14" node_number="1836"> <div title="valid: False, node: 1837, tag: div, level: 15" node_number="1837"> <div title="valid: False, node: 1838, tag: div, level: 16" node_number="1838"> ScienceInsider<time title="valid: False, node: 1839, tag: time, level: 17" node_number="1839">25 Dec 2021</time> </div> <div title="valid: False, node: 1840, tag: div, level: 16" node_number="1840"> NASA&#8217;s Webb telescope takes flight&#8212;a Christmas gift to astronomers everywhere </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1841, tag: article, level: 14" node_number="1841"> <div title="valid: False, node: 1842, tag: div, level: 15" node_number="1842"> <div title="valid: False, node: 1843, tag: div, level: 16" node_number="1843"> News<time title="valid: False, node: 1844, tag: time, level: 17" node_number="1844">23 Dec 2021</time> </div> <div title="valid: False, node: 1845, tag: div, level: 16" node_number="1845"> <a title="valid: False, node: 1846, tag: a, level: 17" node_number="1846"> More than a virus: Science&#8217;s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>